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Sammenfatning 
Denne rapport præsenterer fysiologisk baserede toksikokinetiske (PBTK) modeller for tebuconazol 
og prochloraz.  Modellerne blev konstrueret med det formål at udvikle et PBTK 
modelleringsværktøj til brug i risikovurdering af individuelle kemikalier og binære blandinger. 
Eksponeringsscenarier konstrueret baseret på observationer af pesticidrester i fødevarer og 
vurdering af hudeksponering ved professionelt brug blev anvendt.  
 
Den videnskabelige litteratur blev gennemgået for at udvikle PBTK modeller for disse stoffer, og for 
at fastlægge parametrene, der indgår i modellerne.  Modellerne er derefter blevet udviklet og 
implementeret.  PBTK modeller er afhængige af, at der er tilgængelige parametre som beskriver 
arternes fysiologi samt kemikaliernes ADME karakteristika (absorption, distribution, metabolisme 
og elimination).  Modeller baseret på kvantitative struktur-aktivitets-relationer (QSAR) blev med 
succes anvendt til at forudsige to parametre, som ikke var tilgængelige for tebuconazole og 
prochloraz, men som var tilgængelige for strukturelt lignende stoffer. 
 
Dette pilotprojekt er tænkt som det første skridt på vej mod at udvikle en beregningsbaseret 
strategi, som skal hjælpe med at forbedre metoder til kumulativ risikovurdering af eksponering til 
blandinger af pesticider og biocider, samt risikovurdering af aggregat eksponering af forskellige 
veje. Vores mål er at, undersøge hvorvidt PBTK modellering kan bidrage til at forbedre kumulativ 
risikovurdering ved lave eksponeringsniveauer, og kan hjælpe med at identificere ved hvilke doser 
metaboliseringsvejene overbelastes.  PBTK modeller kan benyttes til at estimere koncentrationer 
(interne doser) af kemiske stoffer og deres metabolitter i udvalgte væv og organer.  Ved en 
tilstrækkeligt god beskrivelse af ADME for de individuelle stoffer og blandinger i organismer, kan 
interne doser estimeres for forskellige eksponeringsscenarier i såvel rotter som mennesker. 
 
Til validering af PBTK modellerne, anvendtes koncentrationer af tebuconazol i blod og væv målt i 
kanin og simple målinger af koncentrationen i blod for begge stoffer fra et blandingsstudie på 
rotter. Valideringer og analyser af tebuconazol i kanin indikerer at koncentrationsniveauet blev 
forudsagt inden for faktor på to i blod og i de fleste væv, men desværre ikke i leveren. Forskellen på 
QSAR forudsigelsen af fraktionen af ikke bundet prochloraz i plasma og en in vitro måling af den 
samme egenskab var 5%.  Disse observationer forventes undersøgt nærmere i det videre arbejde.     
 
Vores simulering for en binær blanding af tebuconazol og prochloraz indikerer at det ikke er 
nødvendigt at medtage inhibering af de metaboliske enzymer ved relativt lave eksponeringsniveauer 
som i de valgte scenarier. Simuleringerne viste at koncentrationsniveauer af det aktive stof i forhold 
til eksponering var omkring ti gange højere for dermal eksponering end ved eksponering via maden. 
Simuleringerne viste at det var vigtigt med dage uden eksponering for at kroppen kunne rense sig 
for de sidste rester af især de dannede metabolitter.  
 
Vi har udviklet en pilotversion af et værktøj til at beregne interne doser for to stoffer og en blanding 
af disse.  Fremgangsmådens styrker og begrænsninger er blevet evalueret og analyseret som en del 
af dette arbejde, anbefalinger til videre udvikling af værktøjerne er diskuteret.  På basis af vores 
undersøgelser, vurderer vi at de udviklede modeller kan bidrage med kvalitativ information til brug 
for risikovurdering ved de relevante eksponeringssituationer, som er langt under NOAEL 
(nuleffektniveauet).    
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Summary 
This report presents physiologically based toxicokinetic (PBTK) models for tebuconazole and 
prochloraz.  These models were constructed with the aim of developing a PBTK modelling tool for 
use in the risk assessment of individual chemicals and binary mixture of the compounds. Exposure 
scenarios were constructed based on findings of pesticide residues in food, and assessment of 
dermal exposure during professional use. 
 
The scientific literature has been investigated in order to develop PBTK models for these 
compounds and to determine parameters to be used in the models, the models have been developed 
and implemented. PBTK modeling relies on the availability of parameters describing species 
physiology and the ADME (absorption, distribution, metabolism and elimination) characteristics of 
the chemicals. Quantitative Structure-Activity Relationship (QSAR) models were successfully used 
to predict two parameters, where experimental data were not available for tebuconazole and 
prochloraz, but where the corresponding data were available for structurally similar compounds. 
 
This pilot project is intended as the first step in developing a computational strategy to assist in 
refining methods for cumulative risk assessment of exposure to mixture of pesticides and biocides, 
as well as risk assessment of aggregate exposure by different routes. The projects aim is to 
investigate, if PBTK modeling can contribute to improving the cumulative risk assessment in the 
low dose exposure range, and help to identify at which dose levels overload of metabolic pathways 
may occur. PBTK models can be used to estimate the concentrations (internal doses) of toxic 
substances and their metabolites in target organs. By adequately describing the ADME of individual 
compounds and mixtures in the organism, internal doses can be estimated at various exposure 
scenarios in both rats and humans.  
 
The PBTK models were validated on plasma and tissue concentration level data for tebuconazole in 
rabbit, and simple blood concentration measurements for both compounds from a mixture study in 
rat.  The validations and analysis of tebuconazole in rabbit indicate that the blood and tissue levels 
were generally predicted within a factor of two from the experimental data, but unfortunately not 
for the liver.  The difference between fraction unbound predicted for prochloraz by QSAR differed 
from an experimental value measured in vitro by 5%. These observations will be investigated 
further in future work. 
 
The simulations for a binary mixture of tebuconazole and prochloraz indicate that it is not 
necessary to include inhibition at low exposure levels like the exposure scenarios chosen in this 
project. The simulated internal dose levels of the active compound relative to exposure were ten 
times higher for exposure via the dermal route compared to the dietary one. The simulations 
indicated that it is important with exposure free day to clear the body for metabolites formed. 
 
We have developed a pilot version of a toolbox for calculating internal doses for two compounds 
and a mixture of those. The strengths and limitations of the approach are evaluated and analysed as 
a part of this work, and recommendations are given for the further development of these tools. We 
evaluate based on our studies that the models can in their present form provide qualitative input to 
assist in risk assessment at relevant exposure levels, which are well below the no observed adverse 
effect level (NOAEL).  
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Abbreviations and acronyms 
ADI  Acceptable Daily Intake 
ADME  Absorption, Distribution, Metabolism and Elimination 
BMD  Benchs Mark Dose 
CYP   Cytochrome P450 
CV  Cross-validation 
HI  Hazard Index 
LOO  Leave One Out (cross validation method in QSAR) 
NOAEL  No Adverse Effect Level 
PBTK  Physiologically Based Toxicokinetic 
PBPK  Physiologically Based Pharmacokinetic, same as PBTK in pharmacokinetics 
PLS  Partial Least Square regression 
RMSD  Root mean square deviation 
SVM  Support Vector Machine 
QSAR  Quantitative Structure-Activity Relationship 
 
The different variables and parameterise used in the PBTK models are explained in Appendix 5. 
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Introduction and background 
This report presents results from the project “Optimization of the cumulative risk assessment of 
pesticides and biocides using computational techniques: Pilot project”.  
 
Content of this report: The basic information on pesticidal action, absorption, distribution, 
metabolism and elimination (ADME) and toxicology of tebuconazole and prochloraz, as well as 
short introduction to the theory of PBTK and QSAR is found in chapter 2. The outline of the PBTK 
models and the parameters used in the models are presented in chapter 3, and detailed 
mathematical description of the developed models is given in Appendix 2-4. QSAR predictions and 
the QSAR models developed for predicting missing parameters for the PBTK simulation are 
presented in chapter 4. Results from the PBTK modelling, validation results for the developed 
models, simulations with single compound and binary models, including simulations for the chosen 
exposure scenarios, are shown in chapter 5. Discussion, conclusion and perspectives are written in 
chapters 6, 7 and 8 respectively. 
 
1.1 Main objectives 
 
The long term objective of this project is to integrate the computer modelling tools physiologically 
based toxicokinetic (PBTK) and quantitative structure-activity relationship (QSAR) modelling in the 
assessment of human health risks from exposure to active compounds in pesticides and biocides. 
The project is intended to provide methods that can contribute to the risk assessment of chronic 
effects in the liver caused by low dose exposures. Low dose exposures are defined as the quantities 
of pesticides and biocides ordinary citizens may be exposed to via the food, as well as via non-
occupational or occupational use, typically well below health based guidance values based on 
NOAELs (no observed adverse effect levels).   
 
We have developed a pilot version of a tool for PBTK simulations of a binary mixture, intended at a 
later stage to be further developed into a tool for PBTK based cumulative risk assessment of 
chemicals. For this purpose separate PBTK models were developed for two individual compounds, 
tebuconazole and prochloraz, as well as a model of a binary mixture of the two compounds. 
 
The concentration levels (internal doses) of toxic substances can be very different from the exposed 
dose, and a series of more or less toxic metabolites can be formed in the liver. PBTK modelling can 
help us to evaluate internal doses of toxicants and their metabolites in target organs, given that 
appropriate physiological, physico-chemical and toxicokinetic parameters are available. 
 
The PBTK based tool box was developed to calculate the internal doses of the active compounds 
(pesticides or biocides) and their relevant toxic metabolites in the blood, liver and other tissues. The 
tool box was designed to generate information to evaluate human health risks due to exposure to 
individual compounds, and particularly cumulative effects by binary mixtures of the compounds on 
rats and humans. The models cover both oral exposures (for pesticide residues in food) and dermal 
exposures (for biocides absorbed through the skin). The necessary parameters for the PBTK 
modeling were taken from the scientific literature and databases, predicted by QSAR models 
developed in this project, and adjusted to experimental elimination data.  
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We focus on exploring the effects in the low dose regime, where the exposed doses fed into the 
model are based on realistic exposure scenarios. By carrying out separate PBTK simulations at high 
exposed doses as well, modeling results are compared to available data from animal studies, when 
possible, and to explore at which doses overload in metabolic pathways are seen in rats and 
humans. 
 
1.2 Background 
 
At present, health risk assessments of pesticides and biocides, and subsequent establishment of 
reference values, are generally based upon data from studies on the individual compounds. 
However, during the last two decades increasing focus has been put on the fact that humans are 
concurrently exposed to a large number of chemicals via the food and the environment. These 
compounds may act additively or may interact and potentially cause higher (synergism), or in some 
cases lower (antagonism) toxic effect compared to the individual compounds.  
 
The current understanding is that chemicals that share similar mode of action or mechanisms of 
action typically act by dose addition. Whereas mode of action refers to functional or anatomic 
changes on a cellular level resulting from exposure to chemicals, mechanism of action refers to the 
specific biochemical interaction that leads to the chemically induced adverse effect. Recent works 
demonstrate that compounds that have the same adverse effect through dissimilar mode or 
mechanism of action can also be modelled by dose addition. Therefore, one of the present 
challenges is to adequately group such chemicals for evaluation of mixture effects (Nielsen et al., 
2012; Kortenkamp et al., 2012; EFSA Panel on Plant Protection Products and their Residues (PPR), 
2013; EFSA, 2013). 
 
In recent years, increased focus has been devoted to the use of PBTK methods in risk assessment 
(WHO, 2010d; EFSA, 2013; Reffstrup et al., 2010; Meek et al., 2013; U.S.EPA, 2012), as well as the 
development of methods for risk assessment of chemical mixtures (Hadrup et al., 2013). These 
papers and reports recommend the use of PBTK modelling for higher tier cumulative risk 
assessment of pesticides (EFSA, 2007; Kortenkamp et al., 2012), and a checklists and specifications 
for selecting PPTK models for risk assessment have been proposed (WHO, 2010c; Meek et al., 2013; 
Clewell and Clewell, III, 2008).  Another important area for the use of PBTK, is risk assessment 
aggregate exposure via different routes (Beamer et al., 2012). 
 
Several research groups work with methods for PBTK based risk assessment. Judson et al. (Judson 
et al., 2011) did propose an interesting high throughput approach, and the Acropolis EU project also 
work with research in this area. Probabilistic methods have also been used for cumulative risk 
assessments of chemicals in the food, for example as a part of the SafeFood EU project (Bos et al., 
2009; Muller et al., 2009).  
 
Much interest is presently devoted to PBTK modelling of mixtures of pesticides, and mixture 
models have been used extensively for example volatile compounds (Haddad et al., 2000; Price and 
Krishnan, 2011).  Also any model that includes both an active compound and an active metabolite 
can be considered as a mixture model. Several PBTK models for pesticides have been published 
during the last decade (for example (Crowell et al., 2011; Timchalk et al., 2002; Mirfazaelian et al., 
2006; Lowe et al., 2009; Poet et al., 2004; Pelekis and Emond, 2009; Tornero-Velez et al., 2012; 
Kim et al., 2008)), with only a few studies on cumulative effects (Timchalk and Poet, 2008; El-
Masri et al., 2004; Weijs et al., 2013).  PBTK has been used for many for the risk assessment of 
various types of organic chemicals and drugs (Clewell and Andersen, 2004c; Clewell and Clewell, 
III, 2008; Kirman et al., 2010; Sweeney et al., 2012; Sweeney et al., 2009; Sweeney et al., 2001; van 
den Berg et al., 2012). 
 
In a PBTK model the animal or human is described as a set of tissue compartments. The models 
seek to describe the relationship between exposure and the internal tissue dose (concentration) 
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level using a description of mammalian physiology and biochemistry, especially ADME, as realistic 
as possible (U.S.EPA, 2006; Clewell and Andersen, 2004b; Campbell, Jr. et al., 2012; Rietjens et al., 
2011; Reffstrup, 2012). The PBTK modeling can be made for relevant routes of exposure, i.e. 
dietary, inhalation and dermal, and for different species, for example rats and humans. It is also 
possible to do high-dose to low-dose extrapolations and to predict overload of toxicokinetic 
pathways which may lead to toxicity (Conolly, 2001; Klaassen, 1996; Krishnan et al., 1994).  
 
PBTK modelling can provide information not otherwise available by performing low-dose 
computational simulations in humans. Inter-species differences can be simulated by developing 
models for the same chemical in different spcecies and use inter-species extrapolation of 
parameters from one species to another when necessary and feasible (Campbell, Jr. et al., 2012). 
Simulations for different age group can be conducted, given that sufficient data are available 
(Clewell et al., 2007), and inter-individual variability can be incorporated by use of appropriate 
data, supplemented by probabilistic methods (Bois et al., 2010). Therefore, there is increased 
interest in using PBTK models as an assisting tool in risk assessment of pesticides and biocides.   
 
Exposure to multiple chemicals may cause alterations in the toxicokinetics of the individual 
chemicals resulting in a change in the predicted toxicity based on the summation of the effects of 
the individual compounds. Toxicokinetic interactions occur as a result of one compound altering 
the absorption, distribution, metabolism or elimination of other compounds, for example by 
competitive inhibition of metabolic pathways in the liver or induction of hepatic metabolism. Such 
interactions may affect the relationship between the exposed dose and the dose delivered to the 
target site (Krishnan et al., 1994; Krishnan et al., 2002). The PBTK model can be used to investigate 
interaction between chemicals and to define the doses at which interactions become significant (the 
interaction threshold) (ATSDR, 2001). 
  
In cases where no experimental data is available for specific physico-chemical and kinetic 
parameters for a compound, and the corresponding data for other structurally similar compounds 
are available, QSAR modeling can in some cases be used for predicting the missing parameters  
(Zvinavashe et al., 2008; Peyret and Krishnan, 2011). QSARs are correlative equations/ models that 
are developed by statistically adjusting a given property to structural features and properties of the 
molecules used to build the model. Subsequently, the model can be used to predict the same 
property for other compounds, given that they are sufficiently similar to the chemicals used to build 
the model.   
 
In this work we have developed QSAR models for predicting plasma protein binding (fraction 
unbound) and volume of distribution based on data for triazoles and imidazoles used as drugs, and 
used these models for predicting the corresponding parameters for tebuconazole and prochloraz. 
 
The QSAR group at National Food Institute, DTU has recently developed a new battery of QSAR 
models  that can predict if a compound acts as a substrate (undergoes metabolic reaction) or as an 
inhibitor (blocks metabolic enzymes and hinder them  in mediating metabolic reactions) to major 
Cytochrome P450 (CYP) metabolic enzymes (Jonsdottir et al., 2012; Ringsted et al., 2009).  These 
models are of particular relevance for identifying which CYP enzymes pesticides and biocides 
interact with, for example to explore which compounds are competing for the same enzymes, and 
can thereby potentially interact. We have used models for identifying substrates and inhibitors to 
CYP3A4, 2C9 and 2D6, based on human clinical data. These are all important CYPs for xenobiotic 
metabolism.  
 
Exposure data for pesticide residues in food are available via reports from the Danish monitoring 
programs (Petersen et al., 2013; Jensen et al., 2010; Jensen et al., 2011; Jensen et al., 2012), and 
corresponding data for Europe are available from EFSA and other monitoring programs. For 
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biocides, which we are primarily exposed to via the skin, dermal exposure, corresponding 
monitoring data are not available. 
 
1.3 Project Plan 
 
The PBTK modelling part of this project is focused on combined action of compounds with similar 
mode of action. The previously developed PBTK modelling tool for chlorpyrifos, was extended  to 
model two new individual compounds and generalized to be used for cumulative effects of binary 
mixtures of compounds. PBTK models were established for the individual compounds (oral and 
dermal exposure) and subsequently for a binary mixture of the same compounds.  
 
PBTK modeling requires much work with model architecture, analysis of available data for 
determining the compound specific parameters, and evaluation of the predictivity of the resulting 
models. Therefore, two compounds with similar mode of action were selected for the purpose of 
developing a pilot version PBTK based method for assessing cumulative effects. 
 
1.3.1 Selection of compounds for PBTK based cumulative risk assessment 
 
Criteria used for selecting pesticides / biocides for evaluation of cumulative effects based on PBTK 
modeling. 
1. The compounds are evaluated to have similar mode of action. 
2. The compounds have documented chronic adverse effects on the liver after repeated 
exposure. 
3. The compounds are approved for use as pesticides in EU. 
4. The compounds are preferably also used as biocides in EU. 
5. The compounds are found as pesticide residues in food by the Danish pesticide control 
(FVST, 2010).  
6. Information about active metabolites formed, and data for estimating the necessary 
parameters needed for the PBTK simulation are available. 
 
As mentioned above, scientific opinion from EFSAs PPR panel (Panel on Plant Protection Products 
and their Residues) (EFSA, 2009) has classified 11 triazoles as a CAG group of compounds with 
documented chronic liver toxic effects, also discussed in (EFSA, 2009). Two of these triazoles match 
the six above mentioned criteria, namely propiconazole and tebuconazole. Difenoconazole, 
epoxiconazole, myclobutanil and triadimenol met all the same but the fourth criteria, see Table 1.1. 
Some of these compounds have available data from high dose experiments in rats, which can 
provide help for testing the predictive performance of the PBTK models. The compounds are chosen 
irrespective of their residue levels in food.  
 
The PPR panel members supported the grouping of these 11 triazoles into a single CAG group by the 
following observations. The fungicidal activity of triazoles is associated with their direct inhibition 
of the CYP51 enzyme. Trizoles are also reported to inhibit several other CYP enzymes, and to act as 
ligands for nuclear receptors and thereby to induce the activity of a number of CYP enzymes. It was 
shown in a study for myclobutanil, propiconazole and triadimefon that altered metabolism in the 
liver was a common response to all three triazoles. The same three triazole fungicides and the drug 
fluconazole were found to increase liver weights and exhibit centrilobular hypertrophy in a repeated 
dose in vivo study. The four triazoles were seen to affect the expression of multiple CYP3A and 
CYP2C genes in rat liver, and to have similar toxicogenomic responses to CAR (Constitutive 
androstane receptor) / PXR (pregnane X receptor) regulated genes in rat liver. Furthermore, these 
triazoles affected the expression of gene involved in steroid hormone metabolism (EFSA, 2009) and 
references therein. 
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TABLE 1.1 
LIST OF TRIAZOLES SELECTED FOR A CAG FOR CHRONIC ASSESMENT OF HEPATOTOXIC EFFECTS AND THE 
IMIDAZOLE PROCHLORAS, WITH THEIR STATUS WITH REGARDS TO APPROVAL AND PESTICIDES AND BIOCIDES. 
   Approval as pesticides 
December 2011 
Approval as 
biocides 
 
CAG: chronic 
liver toxicitya 
Agreed 
referen
ce value 
ADI 
(mg/ kg 
bw/d) 
UF 100b 
Hepato-
toxic 
effect 
ADI 
(mg/ kg 
bw/d) 
UF 100a 
Appro
ved 
under 
Reg.  
(EC) 
No 
1107/2
009b 
Expi-
ration 
dateb 
Ap-
pro-
ved 
in 
DKc 
In-
clud-
ed in 
ap-
pen- 
dix 
Id 
Sub-
mit-
ted 
dos-
sierf 
Resi-
dues 
in 
food 
2009
g 
Bitertanol 0.003 0.01 No  Yes No  Yes 
Cyproconazol
e 
0.02 0.02 Yes 31-05-21 No No Yes No 
Difenoconazo
le 
0.01 0.01 Yes 31-12-18 Yes No  Yes 
Diniconazole  0.05 No  No No  No 
Epoxiconazol
e 
0.008 0.008 Yes 30-4-19 Yes No  Yes 
Flusilazole 0.002 0.005 Yes 30-08-08 No No  No 
Myclobutanyl 0.025 0.39 Yes 31-05-21 No No  Yes 
Propiconazol
e 
0.04 0.036 Yes 31-05-14 Yes Yese Yes Yes 
Tebuconazole 0.03 0.16 Yes 31-05-14 Yes Yese Yes Yes 
Triadimefon 0.03 0.16 No  No No  Yes 
Triademenol 0.05 0.05 Yes 31-08-19 No No  Yes 
Prochloraz 0.01 0.01h Yes 31-12-21 No No  Yes 
a EFSA Scientific Opinion (EFSA, 2009). 
b According to EU Pesticide Database, Active substance updated on 13/10/2011 
http://ec.europa.eu/sanco_pesticides/public/index.cfm 
c According to Danish EPA list over approved active substances in pesticides and biocides,. URLs 
http://www.mst.dk/Virksomhed_og_myndighed/Bekaempelsesmidler/TestBek%C3%A6mpelsesmidler/Regulering/Godkendte
bekaempelsesmidler.htm (last updated 29/06/2010d According list over active substances EU has included in appendix I  under 
the biocide directive URLs   
http://www.mst.dk/Virksomhed_og_myndighed/Bekaempelsesmidler/biocider/Hvornår+ansøger+du/aktivstoffer+og+ansøgn
ingsfrister/produkttype8.htm and (last updated 15/7/2011) and 
https://www.retsinformation.dk/Forms/R0710.aspx?id=135670#B14 
e Expiration of the right to import, sell, use or possess without approval according to the principles of the biocide directive is on 
31/3/2012 for these two active compounds.  
f According List of participants and of applicants having submitted a dossier in accordance with Article 5(3) of Regulation (EC) 
No 2032/2003 (by product-types). URL http://ec.europa.eu/environment/biocides/pdf/list_participants_applicants_prod.pdf 
(Updated 20/5/11) 
g Found as pesticide residues in food on the Danish market, results from the Danish pesticide control in 2009 (FVST, 2009).  
URL http://www.fodevarestyrelsen.dk/fdir/pub/2010003/rapport.pdf, h According to JMPR (JMPR, 2001). 
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Effects on sex and thyroid hormones for epoxiconazole, prochloraz, propiconazole and tebuconazole 
were investigated by in vitro and in vivo methods. Generally these four compounds showed similar 
effects, indicating that the imidazole prochloraz also can be considered to have similar mode of 
action as the 11 triazoles. Dose-response effect on liver weight was measured for two of the 
compounds, propiconazole and tebuconazole, showing increase in liver weights in both cases 
(Kjaerstad et al., 2007).  These results add further support to the grouping made by the PPR panel. 
After consulting with the Danish EPA, tebuconazole and prochloraz were selected for the PBTK 
work. Prochloraz meets five of required criteria listed above, and tebuconazole is also used as 
biocide and meets all six criteria.  
 
1.3.2 Literature search and data analysis for determining parameters for the 
PBTK modeling 
 
A PBTK model uses many physiological, physico-chemical and toxicokinetic parameters. The 
parameters are used in this project are listed in Table 3.1 in section 3. 
 
Good estimates for the physiological parameters for both rats and humans, respectively, are 
generally available in the literature. The different tissue:blood partition coefficients can be 
estimated based on the octanol-water partition coefficient (lipophilicity) for each compound. 
Fractional intestinal absorption is also generally available for pesticides. 
 
QSAR models for predicting parameters needed for the PBTK modeling were developed in our 
licensed QSAR modeling software. Due to the lack of experimental data for tebuconazole and 
prochoraz, we have developed new QSAR models for three properties, namely plasma protein 
binding (fraction unbound in plasma), volume of distribution and percent renal clearance.  We 
developed so-called local QSAR models, i.e. models that are based on experimental data for 
structurally similar compounds, in this case, azoles and related compounds. We have chosen this 
approach to be able to predict as accurate parameters as possible for these compounds. A 
preliminary literature search revealed that for this compound class sufficient amount of 
experimental data are available in the scientific literature and in the freely available PK/DB 
database of Pharmacokinetic Properties that contains experimental data for around 1400 
compounds (http://miro.ifsc.usp.br/pkdb) (Moda et al., 2008).  Such QSAR models can be used to 
predict the same parameters for other similar compounds, and the developed models can thus be 
applicable for providing parameters for PBTK modelling outside this project. Information on which 
metabolites can be formed, are generally available for pesticides.  
 
However, a limiting factor in PBTK modelling is the lack of experimental data on metabolic enzyme 
kinetics, which is necessary for determining the internal dose of the parent compound and any 
critical metabolite (Peyret and Krishnan, 2011). These parameters can in some cases be derived 
from in vivo or in vitro data, and as a first attempt we search for the availability of such data. 
In cases where experimental data on metabolic constants (Michaelis-Menten constants and 
maximum velocities of metabolic reactions) are not available for a given compound, a viable option 
is to adapt corresponding constants for similar compounds that undergo comparable metabolic 
reactions (reduction, oxidation, etc.) from the literature. We used our battery of QSAR models to 
identify to which CYPs a given compound is a substrate, and adapt metabolic constants for other 
substrate compounds metabolized by the same CYPs. We used our models to identify substrates and 
inhibitors to three major enzymes for xenobiotic metabolism, CYP3A4, CYP2D6 and CYP2C9 (6 
models based on human clinical data), as supporting evidence in the read-a-cross work. 
 
1.3.3 PBTK modeling 
 
In order to develop a PBTK model for a binary mixture of chemicals, PBTK models for the 
individual compounds have to be developed and validated first. Development of a PBTK model is 
comprised of several steps.  
1. Design of appropriate model architecture for the problem studied (which compartments 
are relevant to include in the model, which routes of exposures are needed). 
2. Find or estimate appropriate parameters, as described above.  
3. Develop the model and write the model code.   
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4. Carrying out simulations and validate the model by comparing with experimental in vivo 
and in vitro data, when possible.   
5. Carry out the PBTK simulations in accordance with the chosen exposure criteria.  In this 
project we consider both oral and dermal exposure, thus we develop an oral exposure 
model first and add the dermal part afterwards. 
 
Individual PBTK models were developed for each of the model compounds, tebuconazole and 
prochloraz, as described above. Simulations were carried out for both rats and humans, using the 
chosen exposure criteria. When the PBTK models for the individual compounds had been 
appropriately tested and validated, a binary PBTK model was developed for tebuconazole and 
prochloraz according to the steps described above.  
In order to optimally evaluate the impact of PBTK modeling on risk assessment, the PBTK 
simulation has to be made for several theoretical examples of exposure scenarios. The project is 
primarily focused on low-dose exposures based on realistic exposure scenarios.  
1. A set of realistic exposure levels were estimated from values for pesticide residues from 
food according to the pesticide monitoring program. 
2. Similarly, dermal exposure levels were estimated from available data. 
 
Before carrying out the low-dose simulations, high-dose simulations were be made in order to 
validate the models against experimental data from studies in rats, when possible, and to explore 
overload in metabolic pathways in both humans and rats. Although, humans are normally exposed 
to relatively low doses of individual pesticides and biocides, overload of specific CYPs may occur 
due to combined exposure to similar compounds, potentially leading to toxic effects. It was 
investigated if and when such effects are seen in the PBTK modelling for the binary mixture.  
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2. Materials and Methods 
2.1 Pesticidal action, ADME and toxicology of tebuconazole and 
prochloraz  
 
2.1.1 Tebuconazole 
 
2.1.1.1 Pesticidal action 
 
Tebuconazole ((RS)-1-p-chlorophenyl-4,4-dimethyl-3-(1H-1,2,4-triazol-1-ylmethyl)pentan-3-ol) (as 
well as other triazoles) acts by binding to the haeme iron in the cytochrome P450 CYP51 and 
thereby inhibiting its activity (inhibiting lanosterol-alpha-demethylase activity of CYP51) which is 
damaging to fungal growth (EFSA, 2009). Lanosterol-alpha-demethylase acitivty is the enzyme that 
converts lanosterol to cholesterol. 
 
2.1.1.2  ADME 
 
Tebuconazole is rapidly and almost completely absorbed from the gastrointestinal tract (GIT) in 
rats and rapidly distributed (within 1 hour) in the body (EFSA, 2008; JMPR, 2010). Tebuconazole-
derived radioactivity was measured in almost all tissues and organs (except compact bone 
substance) one hour after administration. Very high concentrations were found in the contents of 
the stomach and some portions of the small intestine, in the preputial gland, areas of the mucosa of 
nose and tongue and epithelium of the oesophagus. High concentrations were detected in the liver, 
the cortex of the adrenal gland, the infraorbital gland and the hair follicles of the dorsal skin (JMPR, 
2010). 
 
Less than 1 % of the administered dose was recovered in tissues and organs 72 hr after exposure, 
indicating that no accumulation occurs.  The terminal half-lives were calculated to 31.9-52.5 hr 
(JMPR, 2010). 
 
In rats tebuconazole is oxidized to simple oxidation products such as tebuconazole-1-hydroxy (M 
03) and betuconazole-carboxyl acid (M 06) which are the major metabolites accounting for 15.7-
28.2 % and 14.1-36.2 %, respectively, see Figure 2.1. These products can be conjugated to 
glucuronide and sulphate. Only minor cleavage of the triazole moiety occurs. In males 5.4 % of the 
administered dose of tebuconazole were metabolised to the free triazole and 1.5 % in that of females 
(JMPR, 2010). 
 
It has been reported that in male rats the primary oxidation products can be further oxidized to triol 
(M 04) and keto acid (M 07) derivatives and that cleavage for triazole occurred to a higher extent. 
But these metabolites accounted for less than 10 % of the total 14C in the excreta (JMPR, 2010). 
 
Tebuconazole-1-hydroxy (M 03) and its conjugated product (M 11) are also the primary metabolites 
in lactating goats. In laying hens the primary metabolites are the same as in rats, namely M 03 and 
M 06 (FAO, 1994). As the same metabolic reactions occur in different animals for which studies are 
available, it is assumed that tebuconazole undergoes similar metabolic reactions in humans. 
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Between 72 and 82 % of the administered dose was excreted via faeces in males and about 62 % in 
female rats 72 hour after oral administration of tebuconazole ([phenyl-UL-14C]-tebuconazole). 
Urinary excretion was 14-17 % in males and about 29-33 % in females. Male rats with biliary fistulae 
(bile duct-cannulated) excreted about 91 % of the recovered radioactivity with the bile, about 7 % in 
urine and 1.5 % in the faeces within 48 hr. The large quantities in the faeces of the intact rats 
compared to the bile duct-cannulated rats indicate that radioactivity is excreted into the intestinal 
lumen with the bile under normal circumstances. Within 48 hours after administration the animals 
with biliary fistulae excreted about half of the quantity of tebuconazole-derived radioactivity in the 
urine (e.g. 7.4 % at 2 mg/kg BW), compared with the corresponding males of the intact rats (14-15 
% at 2 mg/kg BW), which indicate an enterohepatic recirculation of the radioactivity. Further, a 
high biliary excretion combined with a long-lasting enterohepatic circulation and a relatively low 
renal elimination rate was also shown by autoradiography (JMPR, 2010). 
 
 
FIGURE 2.1 METABOLISM OF TEBUCONAZOLE IN RATS. FIGURE FROM (JMPR, 2010).  
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2.1.1.3  Toxicology 
 
Target organs in rats are liver, adrenals and blood system. In dogs the target organs are 
adrenals/hypertrophy of zona fasciculate cells (JMPR, 2010). An overview of the studies JMPR 
(JMPR, 2010) used for their toxicological evaluation is given in Appendix 1.  An ADI of 0.03 mg/kg 
BW/day was established based on a NOAEL of 2.9 mg/kg BW/day for histopathological alterations 
in the adrenal gland in two 52 week toxicity studies in dogs. 
 
Tebuconazole is non-irritating to eyes and skin in rabbits and was not found to be a skin sensitizer 
in guinea-pigs. The lowest relevant dermal NOAEL was 1000 mg/kg BW/day in rabbits (JMPR, 
2010). Several endocrine disrupting properties are associated tebuconazole, and have been studied 
extensively by colleges in our department, among others (Taxvig et al., 2007; Kjaerstad et al., 2010; 
Kjaerstad et al., 2007; Dreisig et al., 2013; Kongsbak et al., 2013).  
 
1,2,4-triazole is a minor metabolite of tebuconazole. It is well known that some triazoles including 
1,2,4-triazole can cause specific cranio-facial malformations. However these malformations for 
1,2,4-triazole were found at doses higher than those of the parent compounds (EFSA, 2009). 
Tebuconazole is, however, not found to cause cranio-facial malformations (JMPR, 2010). As 
mentioned before only 1.5 % of the administered dose of tebuconazole is metabolized to 1,2,4-
triazole in females and 5.4 % in males. Due to the small amount formed in females and the fact that 
this endpoint is not relevant for males it is concluded, that it is not necessary to describe the risk for 
these malformations in the PBTK model. 
 
 
2.1.2 Prochloraz  
 
2.1.2.1 Pesticidal action 
 
Prochloraz acts by blocking the fungi ergosterole-biosynthesis by inhibition of steroid 
demethylation (C14-demethylation). 
(http://planteapp.dlbr.dk/middeldatabasen/Chemical.asp?ChemicalID=1073#Virkningsmekanism
e). 
 
2.1.2.2 ADME 
Prochloraz is rapidly absorbed from the gastrointestinal tract and rapidly distributed in the body. It 
is excreted within 72 hr as metabolites and there is no evidence of accumulation. Faecal excretion is 
predominating in females (70% in females and 59% in males at low dose) whereas urinary excretion 
is predominating in males (65% in males, 41% in females at high dose) (JMPR, 2001).  
A study with bile duct-cannulated rats showed that [14C]prochloraz was well absorbed, a mean of 
74% of the dose (range, 60–96%) being detected in bile, urine, cage washings and carcass. The 
major route of elimination was biliary excretion (JMPR, 2001). Poor dermal absorption is reported: 
<2% in pigs.  
The biotransformation of prochloraz was studied by giving [14C-phenyl-U]prochloraz 
(radiochemical purity, > 99%) at a single oral dose of 5 or 100 mg /kg BW” to male and female rats. 
Prochloraz was seen to be extensively metabolized in rats, where no unchanged compound was 
detectable in the urine. The main metabolites found were 2,4,6-trichlorophenoxyacetic acid 
(metabolite 3) and 2-(2,4,6-trichlorophenoxy)ethanol glucuronide conjugate (metabolite 7). These 
two metabolites accounted for up to 80% of the urinary radiolabel (JMPR, 2001).  
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The proposed main metabolic pathway (Figure 2.2) involves opening of the imidazole ring and 
initial loss of small fragments (JMPR, 2001; Needham and Challis, 1991; Needham et al., 1992; 
Laignelet et al., 1992). The above metabolites, and a considerable quantity of unchanged prochloraz, 
were found in faeces. Metabolites 2 and 3 do not form directly from prochloraz, but metabolite 1 
needs to be formed before, as an intermediate. Metabolite 4, which was mainly excreted in faeces, 
can be further metabolized to metabolite 2 and then metabolite 3 as well (JMPR, 2001) 
 
In addition to the experiments for male and female rats, radio-labeled studies were reported for 
mice, dogs and female goats. No significant qualitative differences are seen between the metabolic 
profiles of prochloraz in the urine of all these species. However, the metabolism did differ 
quantitatively according to sex, female rats did excrete more of the most polar metabolites 
compared to males, but no new metabolites were seen (JMPR, 2001).  Similarly, the metabolic 
profile of prochloraz in bovine tissues and milk was very similar to the one in rats, and no additional 
metabolites were found  (JMPR, 2001). As tebuconazole is metabolized in a similar way in many 
species and the metabolic reactions are common for such type of compounds, we assume that the 
same metabolites are formed in humans as well.  
 
 
FIGURE 2.2  
METABOLITES OF PRCHLORAZ EXCRETED IN THE URINE OF RATS. FIGURE FROM JMPR 2001 HAS BEEN MODIFIED 
TO ILLUSTRATE THAT METABOLITES 2 AND 3 FORM FROM METABOLITE 1, AND NOT BY A DIRECT REACTION. 
 
2.1.2.3 Toxicology 
 
The principal target organ is liver (increased weight in rats, mice and dogs; hepatocyte enlargement 
in rats and mice, periportal fat infiltration and glycogen loss in mice) and prostate and testis 
(decreased weight in dogs) (JMPR, 2001; EFSA, 2011).  An ADI of 0.01 mg/kg BW/day was 
established based on a NOAEL of 0.9 mg/kg BW/day for increased liver weitght and histopathology 
found in a 2-year dog study (EFSA, 2011). 
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Prochloraz is known to have a wide range of toxicological problems, including endocrine disrupting 
properties (Kjaerstad et al., 2010; Kjaerstad et al., 2007).  Fetal toxicity was seen at doses higher 
than for maternal toxicity. Prochloraz is carcinogenic in mice but not in rats, and EFSA has 
categorised it as “limited evidence of a cancinogenic effect”. ” It was also concluded that prochloraz 
is unlikely to be genotoxic (JMPR, 2001).  Prochloraz was not seen to affect plasma or erythrocyte 
cholinesterase activity in rats or dogs (JMPR, 2001; EFSA, 2011).  
 
We investigated if some serious toxicological problems were associated with the formed 
metabolites, especially the 2,4,6-trichlorophenoxyacetic acid (metabolite 3), as it is one of the two 
metabolites formed in significant quantities. The other metabolites are either formed in relatively 
small quantities or have conjugated to form a glucoronide or a sulphate, indicating less toxicity. 
 
No toxicological information on metabolite 3 was available to us. Toxicological evaluations have 
been published on the related compounds 2,4-dichlorophenoxyacetic acid (JMPR, 1996) and 2.4,5-
trichlorophenoxyacetic acid (JMPR, 1979). Despite that the chlorophenoxyacetic acids has been 
associated with toxicological problems, mainly due to trace contamination with polychlorinated 
dibenzo-p-dioxins, this type of compounds are by themselves not generally associated with serious 
toxicological issues with respect to the liver. Thus, to best of our ability, we do not have evidence for 
toxicological concerns with respect to metabolite 3, although those can’t be ruled out." 
 
Prochloraz is a potent inducer of the hepatic microsomal mixed-function oxidase system, at dose of 
100 mg/kg bw and higher. Marginal effect was seen at 10 mg/kg bw. In studies on prochloraz in 
mice and rats a post-mitochondiral supernatant containing microsomal enzymes was isolated from 
each liver and analysed for protein and cytochromes P450 and b5 content. Cytochrome P450 
enzymes will absorb light at wavelengths of 450 nm which is called the Soret peak. The Soret peak 
of cytochrome P450 difference spectrum in the present studies was 450 nm. That is, the spectrum 
of induction was similar to that caused by phenobarbital with an increased content and activity of 
cytochrome P450 enzymes (JMPR, 2001).  
 
Prochloraz is considered as mixed inducer of hepatic CYPs, especially CYP 1A (Rudzok et al., 2009; 
Laignelet et al., 1989). Prochloraz has been identified as a potent aryl hydrocarbon receptor (AhR) 
agonist in a human, rat and mouse receptor gene assays (Takeuchi et al., 2008; Kojima et al., 2010; 
Long et al., 2003), and as pregnane X receptor (PXR) agonist in both mouse and human in vitro 
receptor gene assays  (Kojima et al., 2011; Kojima et al., 2010). Both these receptors are known to 
induce CYP activity upon activation, PXR induces CYP 3A and CYP 2C (Chen and Nie, 2009; 
Dvorak, 2011) and AhR is linked to CYP 1A induction (Ma, 2001).  Week induction of CYP 2E1 has 
been reported as well (JMPR, 2001). 
 
 
2.2 Computational techniques 
 
2.2.1 Physiologically based toxicokinetic (PBTK) modelling, basic concepts 
 
PBTK modelling is as a technique for calculating the internal doses (tissue and blood 
concentrations) after exposure to one or more chemical compounds. This technique, which has 
found extensive uses in pharmacology, toxicology and for studying volatile organic substances, 
divides the body into so-called tissue compartment for different part of the body. The underlying 
biological processes are described by a mathematical description (differential equations) that 
describe the absorption, distribution, metabolism and elimination (ADME) process the compound 
undergoes in the human or the animal body. A set a parameters need to be provided to the model, 
both species specific physiological parameters like tissue weights and blood flows, and a variety of 
compound specific parameters.  
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Conceptual representation of a PBTK models in shown in Figures 2.3 and 2.4, which also illustrate 
that the same model architecture can in principle be used to represent both human and rat. The 
mathematical formulation would often be the same or similar, but the parameters would differ.   
 
 
FIGURE 2.3  
CONCEPTUAL REPRESENTATION OF A PBTK MODEL WITH BOTH DERMAL AND ORAL EXPOSURE ROUTES FOR A 
HUMAN. IN THIS MODEL, LIVER, SKIN AND FAT ARE TREATED AS SEPARATE COMPARTMENT, AND THE REMAINING 
TISSUE AND ORGANS ARE LUMPES TOGETHER IN TWO COMPARTMENTS, NAMELY TISSUES WITH SLOW BLOOD 
PERFUSIONS (MUSCLE AND BONE), AND TISSUES WITH RAPID BLOOD PERFUSION (KIDNY, BRAIN, LUNGS, HEART 
AND SIMILAR).  
 
FIGURE 2.4  
CONCEPTUAL REPRESENTATION OF A PBTK MODEL WITH BOTH DERMAL AND ORAL EXPOSURE ROUTES FOR A 
RAT. THIS MODEL CORRESPONDS TO THE HUMAN MODEL (FIGURE 2.3, WHERE DIFFERENT SET OF PARAMETERS 
NEEDS TO BE USED. 
 
2.2.1.1 Basic mathematical description 
 
Basically, each compartment is described by a set of differential equations. For compartments like 
fat, rapidly and slowly perfused tissues in the example in Figures 2.3 and 2.4, a simple equation for 
the change in tissue concentration over time (dCt/dt) is used. It is calculated as the difference 
between the free concentration in the arterial blood entering the tissue (CA) and the free 
concentration in venous blood leaving the tissue (CV.t), multiplied by the blood flow rate in the 
tissue (Qt) and divided by the tissue volume (Vt) (Figure 2.5). The free concentration in the venous 
blood leaving the tissue is calculated as the ratio between the free tissue concentration (Ct) and the 
blood:tissue partition coefficient (Pt). Simply speaking, the difference between the mass of the 
compound entering and leaving the tissue is left in the tissue, so mass is preserved. 
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Figure 2.5  
REPRESENTATION OF INPUT AND OUTPUT TO A SIMPLE TISSUE COMPARTMENT, WHERE THE COMPOUND IS 
DISTRIBUTED VIA THE BLOOD FLOW. 
 
It is a flow based, well-strirred, model assuming that the distribution to the differently tissue 
compartments occours as an instant equilibrium between the tissue and the blood compartments. 
The equilibrium above occurs between the unbound (free) blood and tissue concentrations of the 
compounds, and not between the parts bound to plasma or tissue proteins. This is illustrated in 
Figure 2.6.  
 
 
 
FIGURE 2.6 
ILLUSTRATION OF EQUILIBRIUM BETWEEN UNBOUND AND BOUND CHEMICAL IN BLOOD AND TISSUE. 
 
 
 
FIGURE 2.7.  
REPRESENTATION OF INPUT AND OUTPUT TO THE LIVER (T=LIVER) COMPARTMENT, WHERE INPUT FROM THE GIT 
AND OUTPUT DUE TO METABOLISM NEED TO BE CONSIDERED IN ADDITION TO THE BLOOD FLOWS. 
 
The description of c0mpartments like the liver, where input to the body is provided from the GIT 
via the portal vein and a part of the compound is removed by metabolism, becomes more 
complicated (Figure 2.7).  The input due to single or repeated oral bolus dose (-dAOL/dt) is often 
delivered to the liver by a pulse function representing the absorption rate, but the dietary input 
(A’Dietexp) is normally approximated by a continuous input over a period of time.  
 
𝑑𝐶𝑡
𝑑𝑡
=  𝑄𝑡
𝑉𝑡
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The metabolism rate (-dAML/dt) is generally described by Michaelis-Menten kintetics, see the 
mathematical equation below. Vmax is the maximum velocity of the metabolic reaction, KM  is the 
Michaelis-Menten constant and [S] is the substrate concentration.  
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𝑑𝐴𝑀𝐿
𝑑𝑡
= 𝑉max  [S]
𝐾𝑀 +  [𝑆] 
 
In some cases first and second order kinetics can be used instead. For example when information 
on the metabolic stability (intrinsic clearance, CLint) of the parent compound is available, the 
following first order equation can be used at low substrate concentrations. This simple equation 
does, however, not render accurate results at higher concentrations when the Michaelis-Menten 
curve becomes non-linear, and especially when saturation of the metabolic enzymes is reached. 
 
𝑑𝐴𝑀𝐿
𝑑𝑡
=  𝐶𝐿𝑖𝑛𝑡  [S] 
 
In cases where reversible competitive inhibition occurs, the Michaelis-Menten is modified as 
follows, where [I] is the inhibitor concentration and KI is the inhibition constant. (Non-competitive 
and uncompetitive inhibition is not relevant in this report, and thus not presented here.)  
 
𝑑𝐴𝑀𝐿
𝑑𝑡
= 𝑉max  [S]
𝐾𝑀 �1 + [𝐼]𝐾𝐼� + [𝑆] 
 
As liver is in most cases the main metabolic organ, it is the basic concept in PBTK modelling that all 
metabolism occurs there. In fact metabolism can occur in other compartments too, and metabolism 
in other organs would only be implemented in cases where it is substantial and of importance to the 
problem at hand. Induction can also be included in PBTK models, given that sufficient data are 
available. 
 
Similarly, the concentration changes in the skin compartment (t=skin) is described by, 
 
𝑑𝐶𝑡
𝑑𝑡
=  𝑄𝑡
𝑉𝑡
� 𝐶𝐴 −  𝐶𝑉,𝑡� + 1𝑉𝑡  𝑑𝐴𝐷𝑆𝑑𝑡    
 
where dADS/dt  is the amount of compound that is absorbed from the skin surface to the skin at 
each time point, i.e. the rate of dermal absorption. ADS is the total dermally absorbed dose.  
 
Excretion is normally treated by a first order kinetics reaction. The excretion covers both the part of 
the dose that is not absorbed and is excreted in the faeces and the part of the dose that is absorbed 
from the GIT.  The absorbed dose can both be excreted as mother compound and/or as metabolites 
in the urine and in some cases also in the faeces via the bile as a result of enterohepatic 
recirculation.  
 
For the compounds studied in this work, the part that enters systemic circulation is practically fully 
metabolised. The elimination rate (dAE/dt) the sum of all metabolites is described with the 
following differential equation, which in each specific case can be divided into subparts for urinary 
and faceal excretion for the metabolites.  
 
𝑑𝐴𝐸
𝑑𝑡
= 𝐴𝑀𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒𝑠 𝑘𝑒 
 
AMetabolites, is the total amount metabolites in the body at each time point and ke is the elimination 
rate constant. 
 
This is described in greater detailed in the mathematical description of the individual models, 
including equations for the blood compartment in Appendix 2 -4. 
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The mathematical description above is valid for flow based models, that assumes that the 
compound is distributed and eliminated rapidly, and it does not accumulate in tissue. In cases 
where accumulation occurs, for example in adipose tissue or liver, it can be necessary to include a 
deep compartment (a reservoir) in the model (Campbell, Jr. et al., 2012). 
 
2.2.1.2 Modeling tool 
 
The PBTK models were developed in a tool called Berkeley Madonna 
(http://www.berkeleymadonna.com/), which is a flexible and computationally robust differential 
equation solver for dynamic modelling of biological systems. This software is widely used, and is 
provided with a graphical interface that makes it easy to visualize and analyse results from PBTK 
models. Exposure data and parameters can be changed in a specific window, the simulation results 
and experimental data can be visualized in a flexible graphical window, and it is possible to overlay 
several simulations on top of one another. The program has a curve fitting option for adjusting 
parameters to experimental data, and many more options. 
 
The PBTK models were developed by listing parameters and writing the collection of equations in 
the format required by Berkeley Madonna, see detailed description of the developed models in 
Appendix 2-5. We used Rosenbrock (stiff) algorithm for all the dynamic simulations presented in 
this report. 
 
 
2.2.2 Quantitative Structure-Activity Relationships (QSARs) 
 
2.2.2.1 Basic information on QSAR 
 
A QSAR model links information on the chemical structure of compounds with a specific property, 
and can subsequently be used for predicting the same property for structurally similar compounds, 
that have not available experimental data for the same properties. This is done by calculating so-
called descriptors based on the compounds molecular structure, and then use a statistical method to 
find correlations between the structural descriptors and the property to be modelled (the target 
variable). The QSAR model is the mathematical equation resulting from this analysis. 
 
There are many types of descriptors used in QSAR. In this work we use generic descriptors, which is 
a mixture of indices describing connectivity of the atoms and electronic topology of the molecules, 
as well as a range of molecular property descriptors. The latter are properties like molecular weight, 
number of hydrogen bond donor or acceptor atoms in the molecule, and the calculated octanol-
water partition coefficient (logPow), among others. 
 
To measure the quality of the model, we use the correlation coefficient (r2) and the root mean 
square deviation (rmsd) between the experimental and the calculated target variables in the data 
set. This is called training performance, and is a measure of how well the regression equation fits 
the data used to train/ develop the model. In addition we have calculated the performance of the 
model by using the leave one out (LOO) cross-validation method. In the LOO method, a series of 
models are developed for all but one molecule in the data set, and the model is then used to predict 
the target variable for the compound left out. This is done for every compound in the data set, and 
the cross-validated (CV) correlation coefficient (r2CV) is then calculated between the observed and 
predicted target variables, the cross validated rmsdCV is calculated as well.  
 
In addition, we have left a few data points out and not included them in the model development. 
These data points are used for so-called external validation, which test how well a model predicts 
the property for at prediction set not used to develop the model. When the model has been 
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developed and adequately validated, it can be used for predicting the property for tebuconazole, 
prochloraz and other similar compounds. 
 
2.2.2.2 Modelling method, Technical Description  
 
The experimental data, compound name and identifier, as well as the molecular structures in 
SMILES (Simplified Molecular-Input Line-Entry System) format, were retrieved from the PK/DB 
database (Moda et al., 2008) (http://www.pkdb.ifsc.usp.br/pkdb/). In addition we searched for 
other available data sets in the scientific literature by the use of literature search engines like ISIS 
Web of Science and SciFinder (chemical abstracts). 
 
The data set (id, compound name, SMILES code for the molecular structure and the target variable 
(the property to be modelled) for each chemical was imported into the SciQSAR software (version 
2.3.0.0.12, SciMatics, Inc., http://www.scimatics.com), a set of 208 descriptors were generated, and 
exported with the rest of the data set to a sdf-file (a file format used to host both molecular 
structures and data). The sdf-file was imported into the Molegro Data Modeller (MDM) software 
(version 2.6.0, CLC bio, http://www.clcbio.com/products/molegro/) and the QSAR models were 
developed and validated. 
 
SciQSAR uses generic descriptors like molecular connectivity indices, electrotopological (E-state 
and HE-state) indices and molecular properties, among others (Contrera et al., 2005). Two 
additional descriptors were calculated with ACD-labs logD tool-box in ACD/ToxSuite (version 2.95, 
ACD/Labs, http://www.acdlabs.com/products/pc_admet/tox/tox/). These tw0 descriptors, namely 
the distribution coefficients (logD) at pH=7.0 and pH=7.4 (pH of blood), were added to the 
descriptor matrix (table) in MDM, together with the descriptors generated by SciQSAR. logD has 
been reported as a descriptor that correlates well with properties like VdSS, and therefore we added 
it to the pool of descriptors used for the QSAR modeling. The calculated logD values are listed in 
Table 3.4 and Appendix 7. 
 
Before developing a QSAR model, a correlation matrix, listing the correlation coefficients between 
the different descriptors in the given data set was calculated. For descriptors with 95% internal 
correlation or higher, only one of the descriptors were kept and the others were removed from the 
data set. In such a way, redundancy and interdependency between the descriptors is largely 
reduced. Also descriptors with no variance in the given data set (descriptors with identical values 
for all data points) were removed.     
 
Two different statistical methods (Partial Least Square (PLS) regression (Hasegawa and Funatsu, 
2010; Stanton, 2012) and Support Machine Vector (SVM) regression)  (Byvatov and Schneider, 
2003) were used for the model development.  
 
The volume of distribution and renal clearance QSARs were developed using PLS. In each case the 
best descriptors were selected by a forward selection (heuristic) method. This was done by 
minimizing the rmsd between the predicted and the experimental values, while training the model 
in a 10-fold cross-validation. In each case the number of PLS-factors (latent variables) and 
descriptors was varied and optimized by developing a series of QSAR models. The criteria was to 
use as few PLS-factors and descriptors as possible, to ensure good predictivity of the model and to 
avoid over-fitting. PLS, like other linear regression methods, is sensitive to the number of variables 
used in the model.   
 
The protein plasma binding QSAR was developed with the SVM method. Simply speaking, this 
method transforms data (target variables) which are non-linear with respect to the descriptors used, 
by so-called kernel function, such that a linear relationship can be obtained between the descriptors 
and the target variable. The SVM method requires optimization of some model specific constants. 
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The two most important constants are the γ parameter of the radial distribution function, which we 
use as a kernel, and the cost function, which is simply speaking a tolerance for the fit.  
The resulting QSAR model were validated on data not used in the given model and finally used for 
predicting the same property for tebuconazole, prochloraz, and in some cases for their most 
important metabolites as well.  
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3. The developed PBTK 
models 
PBTK models were developed for tebuconazole and prochloraz as single compounds. Discussion on 
the choice of compartments and detailed mathematical formulation of the model is given below, as 
well as the selection of parameters for both models. Finally, the binary model for these two 
compounds is described, along with the additional parameters needed for the binary model. 
Overview of PBTK models developed in this project is given in Figure 3.1. (An additional binary 
model was developed, where the two enantiomers of tebuconazole, R- and S-, were treated as 
separate compounds.) 
 
 
 
FIGURE 3.1.   
OVERVIEW OF PBTK MODELS DEVELOPED IN THIS PILOT PROJECT. EXTRA MODELS FOR RHESUS MONKEY AND 
RABBIT WERE DEVELOPED FOR TEBUCONAZOLE, AS THESE WERE NEEDED FOR MODEL VALIDATION PURPOSES.  
 
We set up a simple modular approach to ease the development of binary models from the single 
compound models, and it is intended to be extended to multi-component mixtures at a later stage. 
It was also used for developing new single compound models by using features from other models 
(Figure 3.2). The Berkeley Madonna model code was divided into three sections:  
1. List of species specific physiological parameters for each species (rat and human). 
2. List of chemical and species specific parameters for each compound.  
3. The equation section for specific sub-models for the specific compounds (list of equations). 
Also the equation part was divided into subsections associated with each tissue/ organ.  
 
In addition, a name system was defined, ensuring that each compound is assigned a unique name, 
and that all the parameters and variables for this compound are labelled with this name. 
1. In a single compound model the mother compound is labelled C1M0 (compound 1, 
metabolite 0) and the metabolites are labelled C1M1 (compound 1, metabolite 1). (If more 
than one metabolite is considered separately in the model, the different metabolites are 
assigned running numbers). 
2. When a binary model is constructed, all parameters and variables for one of the 
compounds assigned a new name, C2M0 for the mother compound, and C2M1 for the 
metabolites, by word replacement. 
It should be mentioned that a PBTK model for each individual compound is always unique, and that 
a number of compound specific issues have to be considered. This is especially important in the case 
of the metabolism, where the set of equations is specific for the metabolic pathway of the compound 
considered, and for the elimination as well. Thus in our approach we use a collection of basic 
equations similar to many compounds and equations tailored to specific compounds. The modular 
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approach should thus be suitable to accommodate a broad variety of compounds, and also to 
accommodate PBTK simulations of other biological processes than those included in the present 
PBTK models.  
 
 
 
FIGURE 3.2.   
SCHEMATIC VIEW OF THE MODULAR APPROACH USED FOR COMBINING SINGLE COMPOUND MODELS TO MODELS 
FOR BINARY MIXTURES IN BERKELEY MADONNA. 
 
 
3.1 The PBTK model for tebuconazole 
 
3.1.1 Choice of compartments for the Tebuconazole Model 
 
In a PBTK model target organs have to be described as separate compartments. The target organs 
for tebuconazole are liver, adrenals and blood. As liver is the main target of interest to this project, 
and due to lack of data on adrenals (e.g. on the tissue composition of neutral and phospholipids 
necessary for calculating the adrenal:blood partition coefficient), it was decided not to make a 
specific adrenal compartment in the model. In the PBTK model for tebuconazole we also want to 
simulate dermal exposure and therefore, a skin compartment is also included. 
 
The rest of the body is described by two compartments: rapidly perfused and slowly perfused 
tissues. The rapidly perfused tissue includes tissues like kidney, brain, heart, lung, thyroid, testis 
and hepatoportal system, and the slowly perfused tissues includes muscle, skin, adipose (fat) 
(Brown et al., 1997; Renwick, 2001). Excretion of tebuconazole metabolites, both in faeces via the 
bile and in the urine, is described by a separate excretion compartment. This is a commonly used 
method in PBTK modelling, to avoid developing complicated models. A schematic presentation of 
the PBTK model for tebuconazole is shown in Figure 3.3. 
 
As described earlier, tebuconazole administered orally is rapidly absorbed and excreted within 72 
hr. Therefore in the model a 100 % instant absorption (Fa=1) and 100 % excretion within 72 hr is 
assumed. The molecular weight (MW) of tebuconazole is 0.3078 mg/µmol. 
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FIGURE 3.3.  
PBTK MODEL FOR TEBUCONAZOLE. THE BLACK PART IS INPUT TO THE MODEL, THE GREEN PART DESCRIBES THE 
DISTRIBUTION IN THE COMPARTMENTS AND METABOLISM (IN LIVER) AND THE BLUE PART DESCRIBES THE 
EXCRETION OF METABOLITES IN EITHER URINE OR FAECES. 
 
The ADME studies described in a previous section indicated an enterohepatic recirculation. In 
general higher molecular weight compounds can be found in the bile. They enter the intestine after 
storage in the gallbladder and they may be reabsorbed in the intestine to complete an enterohepatic 
cycle, see Figure 3.4 (Tozer et al., 2006). 
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FIGURE 3.4  
WHEN A CHEMICAL IS EXCRETED FROM THE LIVER INTO THE BILE IT IS STORED IN THE GALLBLADDER. WHEN 
THE GALLBLADDER IS EMPTYING (ESPECIALLY WHEN INDUCED BY FOOD) THE CHEMICAL ALSO PASSES INTO THE 
LUMEN OF THE SMALL INTESTINE. IF IT AFTERWARDS IS ABSORBED FROM THE SMALL OR LARGE INTESTINE INTO 
THE PORTAL BLOOD SYSTEM AND TRANSPORTED INTO THE LIVER, IT IS SAID TO HAVE COMPLETED THE 
ENTEROHEPATIC CYCLE, SHOWN AS DASHED LINES IN THE FIGURE. FIGURE IS FROM (TOZER ET AL., 2006).  
 
It was considered whether the enterohepatic recirculation should be included in the present model 
or not. Enterohepatic recirculation is relevant in rats for anionic compounds with a molecular 
weight above 325 +/- 50 g/mol and for humans at 500 +/- 50 g/mol (Millburn et al., 1967; Yang et 
al., 2009). Above this threshold it is expected that the compound will undergo substantial biliary 
excretion (Yang et al., 2009). 
 
The molecular weight of tebuconazole is 307.8 g/mol and that of glucoronide (M11 in Figure 1) is 
497.9 g/mol. The molecular weight for tebuconazole is below the threshold for enterohepatic 
recirculation in humans but for the glucoronide metabolite it is within the range. In rats it may be 
relevant especially for the glucoronide. However, it was decided to omit a description of 
enterohepatic recirculation in the model due to lack of parameters to describe this. 
 
It is important to keep a PBTK model as simple as possible but still biological plausible. For every 
new compartment or feature, additional parameters are needed, and thus more data are needed for 
determining the parameters. Such increased complexity is not necessarily equal to accuracy and 
usefulness of the model but may instead create greater uncertainty in the model description. By 
using a technical excretion compartment, we can develop a relatively simple PBTK model that is 
focused on the main target organ of the studied compounds, namely the liver. 
 
 
3.2 PBTK model for prochloraz 
 
3.2.1  Choice of compartments for the Prochloraz Model 
 
The PBTK model for prochloraz is similar to the model for tebuconazole, with the change that the 
skin compartment is omitted, see Figure 3.5. Prochloraz is only used as pesticide and not as a 
biocide. Dermal exposure has not been included in the prochloraz model, and therefore there is no 
need for a skin compartment. Instead the skin is included in slowly perfused tissue compartment 
together with muscle and bone. A special compartment was made for adipose tissue, due to the 
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special properties of fat, and the rapidly perfused compartment for prochloraz consists of the same 
tissue as the corresponding compartment for tebuconazole (Figure 3.5). (It is easy add a skin 
compartment and dermal exposure to the model if need arises). 
 
Liver is a separate compartment, as the main target organ and the main site of metabolism. The 
main focus of this project is the toxicity in the liver, and since we do not have sufficient parameters 
to describe the other target organs, prostate and testis, these are not included in the model as 
separate compartments.   
 
As described earlier, on average 74% of prochloraz administered orally is rapidly absorbed, and the 
remaining prochloraz is excreted in faeces. The fraction of prochloraz that is absorbed into the 
blood stream is fully metabolised and excreted. In the model 74 % instant absorption (Fa=0.74) 
and 100 % excretion within 72 hr is assumed. The molecular weight (MW) of prochloraz is 0.3767 
mg/µmol. 
 
 
 
FIGURE 3.5.  
PBTK MODEL FOR PROCHLORAZ. THE BLACK PART IS INPUT TO THE MODEL, THE GREEN PART DESCRIBES THE 
DISTRIBUTION IN THE COMPARTMENTS AND METABOLISM (IN LIVER) AND THE BLUE PART DESCRIBES THE 
EXCRETION OF METABOLITES IN EITHER URINE OR FAECES. 
 
 
3.3  Parameters for the PBTK Models 
 
A PBTK model is a set of differential equations that model the absorption, distribution, metabolism 
and elimination (ADME) processes of a compound in the in body. They are used to calculate 
concentrations of compounds, for example environmental contaminants, in the blood, tissues and 
organs up on exposure. The model relays on a good mathematical description of these processes, 
and good parameters that describe the physiology of the species and properties of the chemical 
substances. The parameters needed for the models developed in this project are listed in Table 3.1. 
The different parameters are discussed in this section, with the exception of parameters determined 
on the basis of quantitative structure-activity relationships (QSARs),  presented in section 3.2.1. 
 
3.3.1 Physiological parameters 
 
No international accepted set of reference values of physiological parameters have been compiled. 
Several groups of scientists have created compendia of reference values of physiological parameters 
for adult as well as for young animals and humans for use in PBTK modelling e.g. (Brown et al., 
1997; Davies and Morris, 1993; Thompson et al., 2009; U.S.EPA, 2009; U.S.EPA, 1988). It was 
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decided to use the very comprehensive paper from Brown and co-workers (Brown et al., 1997). This 
paper provides a valuable overview of the physiological parameters for both rats and humans to be 
used in PBTK models and it has previously been used in several PBTK models (e.g. (Belfiore et al., 
2007; Brightman et al., 2006; Chan et al., 2006; Chen et al., 2009; Clewell, III et al., 2001; 
Dennison et al., 2004; Fisher et al., 2004; Godin et al., 2010; Jonsson and Johanson, 2002; Kim et 
al., 2007; Lee et al., 2002; Lowe et al., 2009; McMullin et al., 2003; Mirfazaelian et al., 2006; Nong 
et al., 2008; Poet et al., 2004; Reddy et al., 2003; Timchalk and Poet, 2008; Zhang et al., 2007)). 
Volumes of arterial and venous blood were taken from Igari et al. (Igari et al., 1983), see Table 3.2. 
Table 3.3 shows the physiological parameters to be used in the PBTK models in this project.  
 
 
TABLE 3.1. 
PHYSIOLOGICAL, PHYSICO-CHEMICAL AND TOXICOKINETIC PARAMETERS USED FOR THE PBTK MODELS.  THE 
SECTIONS, WHERE THE DIFFERENT PARAMETERS ARE DISCUSSED, ARE LISTED IN PARENTHESIS. 
 
Physiological parameters 
(species specific) 
Physico-chemical & toxicokinetic parameters 
(compound and species specific) 
• Body weight (BW)  
(section 3.3.1.1 ) 
• Tissue volumes (Vt)  
(section 3.3.1.1) 
• Cardiac output (QC)  
(section 3.3.1.2) 
• Blood flow rate in tissues (Qt)  
(section  3.3.1.2) 
• Surface area of skin (SA)  
(section  3.3.3.1) 
• Molecular weight (MW) 
 (sections 3.1.1, 3.2.1) 
• Fractional intestinal absorption (Fa)  
(sections 3.1.1, 3.2.1) 
Tissue:blood partition coefficients (Pt)  
(section 3.3.2.1) 
• Michaelis-Menten constant ( KM)   
(section 3.3.2.2 ) 
• Maximum velocity of metabolic reaction (Vmax)  
(section 3.3.2.2) 
• First order elimination rate constants (ke) 
(section 3.3.2.3 ) 
• Volume of distribution (VdSS)  
(section 4.1.2.1) 
• % Plasma-protein binding (%PPB)  
(section 4.1.2.2) 
• Skin:surface partion coefficient (Pskin:surface)  
(sections 3.3.2.1, 3.3.3.2 ) 
• Skin permeability (Kp)  
(sections  3.3.3.2 ) 
 
3.3.1.1 Body weight (BW) and Tissue volumes as percentage of BW 
 
The values for tissue volumes as percentage of BW in Table 3.3 is summed up to 86.1 % for rat and 
up to 86.6 % for human. The tissue volumes as percentage of body weight is supposed to sum up to 
100 %, however this will seldom be fulfilled. For practical reasons, the gastrointestinal tract (2.7 % 
in rat and 1.7 % in human) was excluded from the model, and the bone marrow (2.3 % in rat and 7.2 
% in human) was not considered relevant. Another reason for not summing up to 100 % is that the 
values are means derived from multiple studies (Brown et al., 1997). The volume of arterial and 
venous blood was calculated from data in (Igari et al., 1983).  Tissue volumes (Vt)  in [l] were 
calculated by (Vt = BW Vp,t/100), where Vp,t are the tissue volumes as percent of BW.  
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TABLE 3.2 
MEAN VALUES FOR BLOOD VOLUME AND % OF BW OF 0.25 KG RAT AND 70 KG HUMAN (BROWN ET AL., 1997). 
 
 Volume [ml] from 
 (Igari et al., 1983) 
% of BW 
Blood Rat  Human  Rat (0.250 kg) Human (70 kg)  
Artery  6.8 1800 2.72 2.57 
Vein  13.6 3600 5.44 5.14 
Artery+vein - - 8.16 7.71 
 
3.3.1.2 Cardiac output, Organ blood flows as percentage of cardiac output 
 
The cardiac output were found in unanesthetized rats and humans to be 110.4 ml/min and 5200 
ml/min (Brown et al., 1997). These values are recalculated to the unit l/hr:  
 
𝑄𝑐(𝑟𝑎𝑡) =  110.4 𝑚𝑙/𝑚𝑖𝑛 60 𝑚𝑖𝑛/ℎ𝑟1000 𝑚𝑙/𝑙 = 6.6 𝑙/ℎ 
 
𝑄𝑐(𝑟𝑎𝑡) =  5200 𝑚𝑙/𝑚𝑖𝑛 60 𝑚𝑖𝑛/ℎ𝑟1000 𝑚𝑙/𝑙 = 312 𝑙/ℎ 
 
Andersen and co-workers (Andersen et al., 1987) have calculated the cardiac output (QC) by the 
following equation: 
 
𝑄𝑐(𝑟𝑎𝑡) =  15 𝑙ℎ𝑟 𝑘𝑔0.74 𝐵𝑊0.74 = 15 𝑙ℎ𝑟 𝑘𝑔0.74 (0.25 𝑘𝑔)0.74 = 5.4 𝑙ℎ𝑟 
𝑄𝑐(𝑟𝑎𝑡) =  15 𝑙ℎ𝑟 𝑘𝑔0.74 𝐵𝑊0.74 = 15 𝑙ℎ𝑟 𝑘𝑔0.74 (70 𝑘𝑔)0.74 = 310 𝑙ℎ𝑟 
 
There is good agreement between the measured values of cardiac output and the calculated values. 
The values for organ blood flows as percentage of cardiac output for rat in Table 3.3 are summed up 
to 94.7 % and for human 92.7 %. Organ blood flows (Qt in [l/hr]) were calculated by (Qt = QC 
Qp,t/100), where Cp,t are the tissue volumes as percent of QC. 
 
 
3.3.2 Compound specific parameters 
 
3.3.2.1 Partition Coefficients 
 
The tissue.blood partition coefficients were determined based on the volume fractional content of 
water (Fw), neutral lipids (Fnl) and phospholipids (Fph) in wet tissue and the compounds 
octanol:water partition coefficient (Pow).  For orally administrated compounds, the tissue:blood 
partition coefficient (Ptb  also labelled Pt) is calculated as the ratio between the solubility of the 
compound in tissue and blood (Pt:b), respectively, multiplied the ratio between fraction of unbound 
compound in blood (fu,b also labelled fu) and tissue (fu,t). 
 
𝑃𝑡 = 𝑃𝑡𝑏 = 𝑃𝑡:𝑏  ×  𝑓𝑢,𝑏𝑓𝑢,𝑡 = �𝑃𝑜𝑤 �𝐹𝑛𝑙,𝑡 + 0.3 𝐹𝑝ℎ,𝑡� + �𝐹𝑤,𝑡 + 0.7𝐹𝑝ℎ,𝑡���𝑃𝑜𝑤 �𝐹𝑛𝑙,𝑏 + 0.3 𝐹𝑝ℎ,𝑏� + �𝐹𝑤,𝑏 + 0.7𝐹𝑝ℎ,𝑏��  × 𝑓𝑢,𝑏𝑓𝑢,𝑡  
 
The volume fractional contents for the majority of tissue were taken from the paper by Poulin and 
Theil (Poulin and Theil, 2002) , who have made a comprehensive analysis and a revised list of 
values based available handbooks and scientific papers. Values for human whole blood and rat 
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erythrocytes were taken from Poulin and Krishnan (Poulin and Krishnan, 1996; Poulin and 
Krishnan, 2001) . There are some differences are among volume fractional contents used in 
different studies (Rodgers et al., 2005; Rodgers and Rowland, 2006; Peyret et al., 2010; Fenneteau 
et al., 2010), and the work by Poulin and Theil (Poulin and Theil, 2002) was the most 
comprehensive and up to date work. (Pt:p is calculated in the same way, where blood values are 
replaced by the corresponding volume fractional contents for plasma.) 
 
As tebuconazole undergoes relatively fast excretion from the body we find it unlikely that it binds to 
proteins in tissue interstitial space, thus we have set fu,t=1. Thus we consider that tebuconazole only 
binds to plasma proteins. The fraction unbound in blood (plasma) has been predicted by QSAR, 
based on corresponding values for similar compounds, see below. 
 
TABLE 3.3.  
PHYSIOLOGICAL PARAMETERS FOR THE PBTK MODELS. DATA FROM (BROWN ET AL., 1997) IF NOT OTHERWISE 
STATED.  
Parameter Rat Human  Rabbit  
BW (kg) 0.250 70 2.12 (mean 
value from (Zhu 
et al., 2007)) 
Tissue volume as percentage of body weight [l/kg BW] 
Vp,liver 3.66 (± 0.65) 2.57 2.87 
Vp,skin 19.0 (± 2.62) 3.71  
Vp,rperfused 
 (=brain+heart+kidney+lung+pancreas+ 
spleen+thyroid+adrenal) 
0.57+0.33+0.73+ 
0.50+0.32+0.20+ 
0.005+0.019=2.67 
2.0+0.47+0.44+ 
0.76+0.14+0.26+ 
0.03+0.02=4.12 
 
Vp,sperfused  (=muscle+bone) 40.43+5.0+= 45.43 40.00+7.1= 47.1  
Vp,fat  (=adipose) 7.21 21.42  
Vp,venous (Igari et al., 1983) 5.44 5.14  
Vp,arterial (Igari et al., 1983) 2.72 2.57  
Vp_blood (venous+arterial) 8.16 7.71  
Cardiac output [l/hr] 
QC  6.6 312 33 (calculated 
from rat value) 
Organ blood flows as percentage of cardiac output  
Qp,liver 18.3  22.7  
Qp,skin 5.8 5.8  
Qp,rperfused  
(=brain+heart+kidney+lung+adrenal) 
2.0+5.1+14.1+2.1+0.3
=23.6 
11.4+4.0+17.5+2.5+0.3
=35.7 
 (bronchial flow for 
lungs, rat values for 
adrenals) 
 
Qp,sperfused  (=muscle+bone) 27.8+12.2=40.0 19.1+4.2+=23.3  
Qp,fat  (=adipose) 7.0 5.2  
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Experimentally determined Pow values at 25ºC were used for the two compounds: logPow for  
tebuconazole is 3.7 (Chimuka et al., 2009; Baugros et al., 2009; Coscolla et al., 2009) The 
corresponding value for prochloraz is 4.10-4.12 (Giordano et al., 2009; Coscolla et al., 2009). 
logPow=4.12 was used.  
 
Due to the special properties of adipose tissue (fat), which is particularly rich in neutral lipids, it is 
recommend to use the vegetable oil water partition coefficient (logPwow) rather than logPow for 
evaluating Pt.  Pwow was calculated with the following correlation from (Poulin and Haddad, 2012). 
 
𝑙𝑜𝑔𝑃𝑤𝑜𝑤 = 1.099 𝑙𝑜𝑔𝑃𝑜𝑤 −  1.31 
 
 Table 3.4 shows the used composition of blood and tissue, and the estimated partition coefficients 
are listed in Table 3.5. 
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TABLE 3.4.  
THE COMPOSITION OF BLOOD AND TISSUE. VALUES FOR RAPIDLY AND SLOWLY PERFUSED TISSUE WERE 
CALCULATED FROM THE COMPOSITION OF THE INDIVIDUAL TISSUES (POULIN AND THEIL, 2002; POULIN AND 
KRISHNAN, 1996), WEIGHTED BY THE FRACTION OF BW (BROWN ET AL., 1997; POULIN AND THEIL, 2002). 
 
  Tissue volume                               Tissue composition     
  (Fraction of BW)            (Volume fractional content of wet tissue weight) 
  [l/kg])         
           Water (Fw) Neutral lipids (Fnl) Phospholipids (Fph) 
  Rat Human Rat Human Rat Human Rat  Human 
Adipose 0.072 0.214 0.120 0.180 0.853 0.790 0.0020 0.0020 
Bone 0.050 0.071 0.446 0.439 0.027 0.074 0.0027 0.0011 
Brain 0.006 0.020 0.788 0.770 0.039 0.051 0.0533 0.0565 
Gut 0.027 0.017 0.749 0.718 0.029 0.049 0.0138 0.0163 
Heart 0.0033 0.0047 0.779 0.758 0.014 0.012 0.0118 0.0166 
Kidney 0.0073 0.0044 0.771 0.783 0.012 0.021 0.0284 0.0162 
Liver 0.037 0.026 0.705 0.751 0.014 0.035 0.0303 0.0252 
Lung 0.005 0.008 0.790 0.811 0.022 0.003 0.0140 0.0090 
Muscle 0.404 0.400 0.756 0.760 0.010 0.024 0.0090 0.0072 
Skin 0.200 0.037 0.651 0.718 0.024 0.028 0.0180 0.0111 
Spleen 0.0020 0.0026 0.771 0.788 0.008 0.020 0.0136 0.0198 
Blood 0.082 0.077 0.812 0.820 0.0013 0.0033 0.0022 0.0024 
Plasma 0.045 0.042 0.960 0.945 0.0015 0.0035 0.0008 0.0023 
Erythrocytes 0.037 0.035 0.630 0.640 0.0012   0.0039   
Rapidly perfused tissues:            
Brain+heart+kidney+lung+spleen 0.780 0.779 0.021 0.032 0.028 0.036 
Slowly perfused tissues:            
Bone+muscle    0.722 0.712 0.012 0.031 0.008 0.006 
 
 
The bone partition coefficient for human in Table 3.5 is, surprisingly, equally large as the different 
tissue partition coefficients, which is odd. Pesticides like tebuconazole and prochloraz are not 
considered to distribute much in bone tissue. As the equation used for estimating the partition 
coefficients only considers lipid and water content in tissues, only half of the bone material is taken 
into account when calculating Pbone (see Table 3.4).  This might introduce inaccuracies, resulting in 
the relatively high value obtained for bone. We decided to use the partition coefficient for muscles 
for both for muscle and bone tissue instead.  
 
The calculated partition coefficient for lung is strangely low compared to those of other tissue for 
human. Lung is less that 1% of human BW, but is ca. one fifth of the rapidly perfused compartment. 
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As lung is not a target organ for neither tebuconazole nor prochloraz, the accuracy of this partition 
coefficient is of less importance than for example the corresponding coefficient for the liver. We 
might, however use the rat value for human in this case, because we find the calculated value 
unlikely to provide realistic partitioning between lung and blood in human. 
 
TABLE 3.5.  
THE ESTIMATED TISSUE:BLOOD AND TISSUE:PLASMA PARTITION COEFFICIENT FOR TEBUCONAZOLE AND 
PROCHLORAZ. FOR ADIPOSE TISSUE, PARTITION COEFFICIENTS HAVE BOTH BEEN CALCULATED BASED ON BOTH 
PWOW AND POW, WITH THE TISSUE COMPOSITION GIVEN IN TABLE 3.4. 
 
                 Tebuconazole                  Prochloraz   
  Partition coefficients Partition coefficients 
  Pt:b Pt:p Pt:b Pt:p 
  Rat Human Rat Human Rat Human Rat Human 
Adipose 
(Pwow) 
45 22 51 21 52 24 60 23 
Adipose (Pow) 394 189 447 181 413 194 480 186 
Bone 13.0 17.8 14.8 17.1 13.6 18.2 15.8 17.5 
Brain 25.6 16.3 29.0 15.6 26.7 16.7 31.0 16.0 
Gut 15.5 12.8 17.5 12.3 16.2 13.1 18.8 12.6 
Heart 8.2 4.0 9.3 3.8 8.5 4.1 9.9 3.9 
Kidney 9.7 6.1 11.0 5.9 10.1 6.3 11.7 6.0 
Liver 10.6 10.2 12.1 9.7 11.1 10.4 12.9 10.0 
Lung 12.1 1.4 13.7 1.3 12.7 1.4 14.7 1.4 
Muscle 5.9 6.2 6.7 6.0 6.2 6.4 7.2 6.1 
Skin 13.6 7.6 15.4 7.3 14.2 7.8 16.5 7.5 
Spleen 5.5 6.3 6.2 6.0 5.7 6.4 6.6 6.1 
Blood 1.0 1.0   1.0 1.0   
Plasma   1.0 1.0   1.0 1.0 
Erythrocytes   1.3    1.3  
Rapidly 
perfused 
13.5 10.1 15.3 9.7 14.1 10.4 16.3 10.0 
Slowly perf.  6.7 8.0 7.6 7.7 7.0 8.2 8.1 7.8 
Pskin:surface 0.0294 0.0319   0.0294 0.0318   
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3.3.2.2 Parameters for Metabolism 
 
Tebuconazole: 
 
Metabolic constants for tebuconazole depletion measured in male rat microzomes are available in 
the literature (Shen et al., 2012). This study assessed the metabolic constants for the S- and the R- 
enantiomer separately, without and with the presence of the other enantiomer as an inhibitor 
(Table 3.6). Competitive inhibition was revealed between the two enantiomers in interaction 
studies, with the R-form being five times more potent inhibitor than the S-form (IC50R/S/IC50S/R = 
4.98).  Rac-tebuconazole was found to degrade by first-order kinetics, with the S-form degrading 
faster than the R-form (t1/2 = 22.31 min vs. t1/2 = 48.76 min). 
  
TABLE 3.6. 
VMAX AND KM PARAMETERS OF TEBUCONAZOLE (TEB) DEPLETION, ESTIMATED BY KINETIC CURVE-FIT EQUATION 
TO MALE RAT LIVER MICROSOME IN VITRO DATA. THE VMAX VALUE HAS BEEN CONVERTED TO ACCOUNT FOR THE 
METABOLIC CAPACITY OF ALL LIVER PROTEINS (SHEN ET AL., 2012). 
  
Sample Vmax KM R2 Vmax VmaxC 
  [µM min-1 mg-1 
protein] 
[µM]   [µmol hr-1] [µmol hr-1 
kg-0.75] 
R-TEB  1.27 ± 0.06  14.83 ±  2.19 0.992 67.8 192 
R-TEB with S-TEB (inhibitor) 1.27 ±  0.19  55.76 ±  15.18 0.985 67.8 192 
S-TEB 0.83 ±  0.07  12.23 ±  2.72 0.984 44.3 125 
S-TEB with R-TEB (inhibitor) 0.88 ±  0.11  31.70 ±  8.97  0.974 47.0 133 
Racemic R-TEB and R-TEB 1.05 13.53   56.1 159 
 
The experimentally in vitro determined Vmax needs to be converted to the corresponding value for 
the whole liver. The authors have reported Vmax in the unit [µM min-1 mg-1 protein] instead of [µmol 
min-1 mg-1 protein], they also report that 1 ml of solution contains 0.5 mg protein, e.g. 1 mg of 
protein is contained in 2 ml of solution. Thus we have to calculate how much tebuconazole there is 
in 2 ml of solution, because that is the amount that corresponds to 1 mg of protein. 
 1.0 𝜇𝑀min  ∙  𝑚𝑔 𝑝𝑟𝑜𝑡𝑒𝑖𝑛  ≡  1 𝜇𝑚𝑜𝑙1000𝑚𝑙 ∗ 1𝑚𝑖𝑛 ∗ 2 𝑚𝑙 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛𝑚𝑔 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 = 0.002 𝜇𝑚𝑜𝑙min  ∙  𝑚𝑔 𝑝𝑟𝑜𝑡𝑒𝑖𝑛    
 
𝑤𝑒𝑡 𝑤ℎ𝑜𝑙𝑒 𝑙𝑖𝑣𝑒𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 = 𝑙𝑖𝑣𝑒𝑟, 𝑝𝑒𝑟𝑐𝑒𝑛𝑡 𝑜𝑓 𝐵𝑊100 ∗ 𝐵𝑊 = 3.66100 ∗ 250 𝑔 = 9.15 𝑔  
 
 
𝑓 =  𝑚𝑔 𝑚𝑖𝑐𝑟𝑜𝑠𝑜𝑚𝑎𝑙 𝑝𝑟𝑜𝑡𝑒𝑖𝑛0.695 𝑛𝑚𝑜𝑙 𝑃450 ∗  33.8 𝑛𝑚𝑜𝑙 𝑃450𝑔 𝑤𝑒𝑡 𝑙𝑖𝑣𝑒𝑟 ∗ 9.15 𝑔 𝑤𝑒𝑡 𝑙𝑖𝑣𝑒𝑟 = 445 𝑚𝑔 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 
 
Thus, as an example, Vmax of a racemic mixture of R- and S- tebuconazole is: 
 
𝑉max = 1.05 𝜇𝑀min  ∙ 𝑚𝑔 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 ∗ 0.002 𝜇𝑚𝑜𝑙 𝜇𝑀 ∗ 445 𝑚𝑔 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 ∗ 60𝑚𝑖𝑛ℎ𝑟 = 56.1𝜇𝑚𝑜𝑙ℎ𝑟   
 
VmaxC is then calculated as follows: 
𝑉𝑚𝑎𝑥𝐶 = 𝑉𝑚𝑎𝑥𝐵𝑊0.75 =  56.1 𝜇𝑚𝑜𝑙ℎ𝑟0.250 𝑘𝑔0.75 = 159 𝜇𝑚𝑜𝑙ℎ𝑟 ∙ 𝑘𝑔0.75 
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As a racemic mixture of tebuconazole is used as a fungicide, it was decided to use the mean of the 
Vmax and KM  values for the R- and S-forms in their pure form for the PBTK modeling in this project. 
Also simulations for each of the enantiomers will be carried out. The corresponding values for the 
R- and S-forms in the presence of the other form as an inhibitor, reflects the metabolism of one of 
the enantiomer as affected by the inhibition caused by the other enantiomer. 
 
No information on the corresponding metabolic constants in human cells was found. By examining 
metabolic constants for similar compounds available in the literature (see Appendix 6), it is seen 
that there are significant species, gender and individual differences that need to be considered when 
deciding parameters for use in the PBTK simulations. In such cases, the traditional method is to use 
to use the same KM value and to use allometric scaling for Vmax (Campbell, Jr. et al., 2012).  
 
𝑉max(ℎ𝑢𝑚𝑎𝑛) = 𝑉𝑚𝑎𝑥𝐶(𝑟𝑎𝑡) 𝐵𝑊ℎ𝑢𝑚𝑎𝑛0.75  
 
In addition, we will use information for other similar compounds and the data for male rat above to 
define plausible intervals for the metabolic constants for humans, and thus we will base our 
evaluation on simulations for upper and lower levels defined by these intervals, rather than only 
using one defined set of values for Vmax or KM. For example, as described in the section on review of 
metabolic constants for related compounds (Appendix 6), the KM value for triadimefon is larger in 
human than in rat, and this we will take into consideration.  
 
Prochloraz: 
 
Data on metabolic stability (intrinsic clearance) of prochloraz has been published in Supplementary 
Table 8 in Wetmore et al. (Wetmore et al., 2012), but no information on metabolic constants (Vmax 
and KM) for prochloraz depletion was found.  Amble literature on prochloraz metabolic pathways, 
inhibition, induction, as well as on various toxic effects is available, see the section 2.1.2 .1 on 
prochloraz above. 
 
As discussed previously, prochloraz is known to be a potent CYP 1A inducer, and possible also a CYP 
2E1 inducer. In the QSAR modeling section below, we have predicted prochloraz to be a CYP 2C9 
substrate, but the prediction on whether it is an inhibitor to CYP 2C9 or not, was inconclusive. 
Prochloraz can therefore according to our QSAR predictions potentially interact with tebuconazole 
through CYP 2C9, as tebuconazole was predicted to be CYP 2C9 inhibitor, but not substrate (see 
section 4.1.1 for details). 
 
Prochloraz undergoes ring opening of the imidazole ring, which is likely to be either CYP 1A or CYP 
2E1 mediated. After the ring opening, metabolite 1 undergoes hydroxylation to form an alcohol and 
oxidation to form a carboxyl acid. These are common metabolic reactions among azole type 
compounds. 
 
At low prochloraz concentrations we used a first order implementation for the depletion rate and 
the measured intrinsic clearance from Wetmore et al.  (Wetmore et al., 2012), see Table 3.7.  These 
data were measured using an ensemple of different in vitro assays for metabolic stability at two 
different conscntrations of prochloraz (1 and 10 µM).  
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TABLE 3.7.  
CLIN FOR PROCHLORAZ DEPLETION MEASURED IN HUMAN IN VITRO HEPATOCYTES, USING 1 AND 10 µM 
PROCHLORAZ SOLUTION (WETMORE ET AL., 2012). 
 
Sample Cprocloraz CLint(human),exp r2 CLint(human) CLint(rat) 
  [µM] [µl min-1 10-6 cells]  [l hr-1] [l hr-1] 
Ensemple of in vitro 
assays 
1 16.3995 0.88 242.51 3.543 
Ensemple of in vitro 
assays 
10 3.9782 0.37 58.83 0.859 
 
𝐶𝐿int(human) � 𝑙ℎ𝑟� =  𝐶𝐿int(human) � µ𝑙𝑚𝑖𝑛 106𝑐𝑒𝑙𝑙𝑠� ∗ 137 106 ℎ𝑒𝑝𝑎𝑡𝑜𝑐𝑖𝑡𝑒𝑠𝑔 𝑤𝑒𝑡 𝑙𝑖𝑣𝑒𝑟 ∗ 1799 𝑔 𝑤𝑒𝑡 𝑙𝑖𝑣𝑒𝑟106 𝜇𝑙𝑙 ∗ 60𝑚𝑖𝑛ℎ𝑟  
 
𝑤𝑒𝑡 𝑤ℎ𝑜𝑙𝑒 𝑙𝑖𝑣𝑒𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 (ℎ𝑢𝑚𝑎𝑛) = 𝑙𝑖𝑣𝑒𝑟, 𝑝𝑒𝑟𝑐𝑒𝑛𝑡 𝑜𝑓 𝐵𝑊100 ∗ 𝐵𝑊 = 2.57100 ∗ 70000 𝑔 = 1799 𝑔 
 
𝐶𝐿int(𝑟𝑎𝑡), = 𝐶𝐿𝑖𝑛𝑡(ℎ𝑢𝑚𝑎𝑛) � 𝐵𝑊𝑟𝑎𝑡𝐵𝑊ℎ𝑢𝑚𝑎𝑛�0.75 
 
At higher prochloraz concentrations, we tried to adapt metabolic constants values for similar 
reactions to the PBTK model for prochloraz as the first option in the absence of experimental Vmax 
and KM data. To approximate the first part of the reaction (metabolic pathway), the ring opening for 
form metabolite 1 (see Figure 2.2), our working theory was to use the metabolic constants of furan, 
which undergoes CYP 2E1 mediated ring opening (Kedderis et al., 1993; Kedderis and Held, 1996). 
See the values for furan (human and rat data) in Table 3.8  The best option among the available 
metabolic constants could be to use the CYP 2C19 mediated hydroxylation of omeprazole, human 
data (Yamazaki et al., 1997), for the depletion of metabolite 1. See Table 3.9 and Appendix 6 for 
details on the metabolic constants for omeprazole.  
 
TABLE 3.8.  
VMAX AND KM PARAMETERS FOR RING OPENING OF FURAN, FROM HUMAN AND RAT IN VITRO HEPATOCYTE DATA 
(KEDDERIS ET AL., 1993; KEDDERIS AND HELD, 1996). THE VMAX VALUE HAS BEEN CONVERTED TO ACCOUNT FOR 
THE METABOLIC CAPACITY OF ALL LIVER PROTEINS. 
  
Sample Vmax KM Vmax VmaxC 
  [nmol hr-1 10-6 cells] [µM] [µmol hr-1] [µmol hr-1 kg-0.75] 
Human 1, male, 53 years 19.0 2.1 4683 193 
Human 3, male, 34 years 43.9 3.3 10820 447 
Mean (human 1 and 3) 31.4 2.7 7751 320 
F-344 rat 18.0 0.4 21.1 59.6 
 
Vmax for whole human and rat livers were calculated with the following scaling factors for 
hepatocites and VmaxC was then calculated as described above.  
 
𝑉max(human) �𝜇𝑚𝑜𝑙ℎ𝑟 � =  𝑉max (human) � 𝑛𝑚𝑜𝑙ℎ𝑟 106𝑐𝑒𝑙𝑙𝑠� ∗ 137 106 ℎ𝑒𝑝𝑎𝑡𝑜𝑐𝑖𝑡𝑒𝑠𝑔 𝑤𝑒𝑡 𝑙𝑖𝑣𝑒𝑟 ∗ 1799 𝑔 𝑤𝑒𝑡 𝑙𝑖𝑣𝑒𝑟1000 𝑛𝑚𝑜𝑙/𝜇𝑚𝑜𝑙 
 
𝑤𝑒𝑡 𝑤ℎ𝑜𝑙𝑒 𝑙𝑖𝑣𝑒𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 (ℎ𝑢𝑚𝑎𝑛) = 𝑙𝑖𝑣𝑒𝑟, 𝑝𝑒𝑟𝑐𝑒𝑛𝑡 𝑜𝑓 𝐵𝑊100 ∗ 𝐵𝑊 = 2.57100 ∗ 70000 𝑔 = 1799 𝑔  
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𝑉max(rat) �𝜇𝑚𝑜𝑙ℎ𝑟 � =  𝑉max (rat) � 𝑛𝑚𝑜𝑙ℎ𝑟 106𝑐𝑒𝑙𝑙𝑠� ∗ 128 106 ℎ𝑒𝑝𝑎𝑡𝑜𝑐𝑖𝑡𝑒𝑠𝑔 𝑤𝑒𝑡 𝑙𝑖𝑣𝑒𝑟 ∗ 9.15 𝑔 𝑤𝑒𝑡 𝑙𝑖𝑣𝑒𝑟1000 𝑛𝑚𝑜𝑙/𝜇𝑚𝑜𝑙 
 
𝑤𝑒𝑡 𝑤ℎ𝑜𝑙𝑒 𝑙𝑖𝑣𝑒𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑟𝑎𝑡) = 𝑙𝑖𝑣𝑒𝑟, 𝑝𝑒𝑟𝑐𝑒𝑛𝑡 𝑜𝑓 𝐵𝑊100 ∗ 𝐵𝑊 = 3.66100 ∗ 250 𝑔 = 9.15 𝑔  
 
 
 
TABLE 3.9.  
VMAX AND KM PARAMETERS FOR 5-HYDROLIZATION OF OMEPREZOLE IN CYP 2C19 FROM HUMAN  IN VITRO 
RECOMBINANT ASSAY DATA (YAMAZAKI ET AL., 1997). THE VMAX VALUE HAS BEEN CONVERTED TO ACCOUNT FOR 
THE METABOLIC CAPACITY OF ALL LIVER PROTEINS.  
  
Sample Vmax KM Vmax VmaxC 
  [nmol min-1 
nmol-1 P450] 
[µM] [µmol hr-1] [µmol hr-1 
kg-0.75] 
Human CYP 2C19 in insect 
liver microsomes 
8.3 
 
6.6 
 
134 
 
5.53 
 
Rat by inter-species scaling  6.6 1.95  
 
Vmax for human was then calculated with the following scaling factor for recombinant assay, where 
ISEF=0.4 was taken form  (Proctor et al., 2004). CYP 2C19 abundance was calculated as a mean of 
experimental values for three individuals taken from (Table 1 in (Yamazaki et al., 1997)). 
 
𝑉max(human) �𝜇𝑚𝑜𝑙ℎ𝑟 � =  𝑉max(human) � 𝑛𝑚𝑜𝑙min  𝑛𝑚𝑜𝑙 𝑃450� ∗ 0.4 ∗  9.33 10−3 𝑛𝑚𝑜𝑙 2𝐶19 𝑃450𝑚𝑔 𝑝𝑟𝑜𝑡𝑒𝑖𝑛  
∗
40 𝑚𝑔 𝑝𝑟𝑜𝑡𝑒𝑖𝑛
𝑔 𝑤𝑒𝑡 𝑙𝑖𝑣𝑒𝑟 ∗ 1799 𝑔 𝑤𝑒𝑡 𝑙𝑖𝑣𝑒𝑟1000𝑛𝑚𝑜𝑙𝜇𝑚𝑜𝑙 ∗  60 𝑚𝑖𝑛ℎ𝑟  
 
The corresponding rat value was then calculated by inter-species scaling.   
 
𝑉max(𝑟𝑎𝑡) = 𝑉𝑚𝑎𝑥𝐶(ℎ𝑢𝑚𝑎𝑛) 𝐵𝑊𝑟𝑎𝑡0.75 
 
3.3.2.3 Parameters for elimination 
 
Tebuconazole: 
 
Volumes of distribution were determined based on a QSAR model developed based on similar 
compounds with available data. See section 3.1.2.1 on predictions of volume of distribution at steady 
state for details. 
 
First order elimination rate constants for excretion through the urine and faeces were determined 
based on available data on excretion of tebuconazole in the rat. Data on cumulative excretion of 
radioactivity in urine and faeces in rat collected up to 72 hours after oral administration of [phenyl-
UL-14C]tebuconazole as cited by Joint FAO/WHO Meeting on Pesticide Residues (JMPR, 2010) 
was used to estimate the 1. order elimination constant for urine and faeces, respectively. The two 
elimination constants were determined in two ways: 1) by curve fit to data on male rats given a dose 
of 2 mg/kg BW and 2) given a dose of 20 mg/kg BW. The values determined by curve fit to 2 mg/kg 
BW were then used to simulate the elimination at 20 mg/kg BW and the values determined by 
curve fit to 20 mg/kg were used to simulate the elimination at 2 mg/kg BW. By visual inspection of 
the plots it was determined that the values for the two elimination constants established by curve fit 
to the dataset at 20 mg/kg BW gave better simulation of the dataset for 2 mg/kg  BW than the 
opposite way.  
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Further, it seems as the curve fit at 2 mg/kg BW overestimates the excreted amount when 
simulating at a dose of 20 mg/kg BW. This tendency means that the model with the two elimination 
constants determined at 2 mg/kg BW will underestimate the risk due to a too fast elimination and 
this is very undesirable. Therefore it was decided to use the elimination constants determined by 
curve fit to the 20 mg/kg BW dataset in the present model. 
 
The final parameter values for the elimination rate constants were obtained by a curve fit to the 
final model for tebuconazole, where all other parameters for the model had been selected. The fit 
was based on the data obtained for a given dose of 20 mg/kg BW. Thus the obtained rate constants 
for urinary (keu) and faecal (kef) excretion were as follow. 
 
𝑘𝑒𝑢(𝑟𝑎𝑡) = 0.0078 ℎ𝑟−1 
 
𝑘𝑒𝑓(𝑟𝑎𝑡) = 0.039 ℎ𝑟−1 
 
𝑘𝑒(𝑟𝑎𝑡) = 𝑘𝑒𝑢(𝑟𝑎𝑡) + 𝑘𝑒𝑓(𝑟𝑎𝑡) = 0.0468 ℎ𝑟−1 
 
Figure 3.6, shows a plot showing the fitted curve at 20 mg/kg BW oral dose and a predicted curve at 
2 mg/kg BW oral dose (ka set t0 1 hr-1). 
 
 
 
 
FIGURE 3.6.  CURVE FIT TO DATA ON MALE RATS GIVEN A DOSE OF TEBUCONAZOLE OF 20 MG/KG BW 
AND SIMULATION AT 2 MG/KG BW. THE CYAN AND VIOLET CURVES ARE THE FAECAL AND URINARY 
EXCRETION FOR THE 20 MG/KG BW DOSE, RESPECTIVELY AND THE CORRESPONDING CURVES FOR 2 
MG/KG BW DOSE ARE YELLOW AND BLUE.  THE DATA LABELLED WITH A # ARE THE EXPERIMENTAL 
DATA FROM JMPR (ALSO AVAILABLE IN DAR) AND ARE SHOWN WITH CIRCLES AND THE SIMULATED 
CURVES ARE SHOWN WITH LINES.  THE Y-AXIS IS THE AMOUNT EXCRETED IN µMOL AND X-AXIS IS 
THE TIME AFTER ORAL ADMINISTRATION OF DOSE IN HR. 
 
For human values, we use interspecies extrapolation as described by Campbell et al. (Campbell, Jr. 
et al., 2012), with the difference that the elimination rate constant was scaled proportionally to the 
body weight ratio in the power of 0.25, and not invers proportionally in the power of 0.25 as 
proposed in the paper. This change was made based on the empirical observations for rats, rhesus 
monkeys and humans shown below.   
 
As discussed before, compounds need to have significantly larger molecular weight for biliary 
excretion to occur in humans that rats. Therefore, we calculated the combined elimination rate 
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constant for humans (ke(C1M1) = keu(C1M1) + kef(C1M1)) based on the corresponding rat data. We thus 
assumed that the total excretion rate can estimated by interspecies scaling, but not the rate by 
specific route of excretion.   
 
𝑘𝑒(ℎ𝑢𝑚𝑎𝑛) = 𝑘𝑒(𝑟𝑎𝑡) �𝐵𝑊ℎ𝑢𝑚𝑎𝑛𝐵𝑊𝑟𝑎𝑡 �0.25 = 0.0468 ℎ𝑟−1 � 70 𝑘𝑔0.25 𝑘𝑔�0.25 =  0.19 ℎ𝑟−1 
 
 
The ratio between amount of metabolites excreted in the urine and faeces are not necessarily the 
same in humans and rats. As discussed above, rats excrete lower molecular weight in faeces via the 
bile, than humans. The above elimination rate constants for human should thus be seen as 
parameters for the total excretion in urine and faeces, and not as exact measures of the excretion for 
each of these routes separately.   
 
The corresponding value for rabbit and monkey is 
 
𝑘𝑒(𝑟𝑎𝑏𝑏𝑖𝑡) = 𝑘𝑒(𝑟𝑎𝑡) �𝐵𝑊𝑟𝑎𝑏𝑏𝑖𝑡𝐵𝑊𝑟𝑎𝑡 �0.25 = 0.0468 ℎ𝑟−1 �2.12 𝑘𝑔0.25 𝑘𝑔�0.25 =  0.080 ℎ𝑟−1 = 0.0013 𝑚𝑖𝑛−1  
 
𝑘𝑒(𝑚𝑜𝑛𝑘𝑒𝑦) = 𝑘𝑒(𝑟𝑎𝑡) �𝐵𝑊𝑚𝑜𝑛𝑘𝑒𝑦𝐵𝑊𝑟𝑎𝑡 �0.25 = 0.0468 ℎ𝑟−1 �6.19 𝑘𝑔0.25 𝑘𝑔�0.25 = 0.10 ℎ𝑟−1 
 
Three data sets for excretion in rhesus monkeys were available from DAR were used for validating 
the adjusted elimination rate constants for rat and the accuracy of the interspecies interpolation 
from rat to monkey.  Two of these data sets used dermal exposure (one and five animals, 
respectively) and in the third experiment iv exposure was used (one animal) (European 
Commission, 2007b). In the dermal experiment using one animal, all the administrated compound 
was collected again, either from urine and faeces or by rinsing the unabsorbed compounds from the 
skin. The same method was applied to five animals in the other dermal experiment, but 12% of the 
administered compound was not recovered. (We assumed that the uncovered compound was not 
absorbed.) 
 
In order to do calculations for rhesus monkey, we adapted the human PBTK model for tebuconazole 
(the version with human parameters) to implement a model for male rhesus monkey.  BW of 6.2 kg 
was taken from Brown (Brown et al., 1997) and the cardiac output (QC) was calculated by 
interspecies interpolation based on rat data (QCmonkey = 73 l/hr). The mean of experimental values 
for control rhesus monkey listed by Forsyth (Forsyth, 1970) is 77 l/hr and corresponds well with the 
interpolated value. For percent tissue volumes and organ blood flows, the human values were used 
and the same is the case for partition coefficients, fraction unbound in plasma. Like in all other 
cases the metabolic constants where based on the corresponding experimental constants for male 
rat, where the maximum velocity is scaled by interspecies interpolation and the KM value was used 
unchanged. It was assumed that the whole dermal dose was absorbed within an hour, with the 
absorbed dose equally distributed over this hour. 
 
The simulated curves are shown on Figure 3.7. The excretion curve for the iv dose is predicted were 
well with the model and good predictions are also obtained for the dermal curves. This validation 
result indeed shows that interspecies interpolation is a valuable option for estimating elimination 
rate constants in other species. 
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FIGURE 3.7.  
SIMULATED (VALIDATED) EXCRETION FOR MALE RHESUS MONKEY GIVEN 240 MG OF TEBUCONAZOLE BY IV 
BOLUS DOSE (RED LINE AND RED DOTS), EXPOSED TO 0.261 MG BY DERMAL ADMINISTRATION (0.0175 MG 
ABSORBED AND EXCRETED) (BLUE LINE AND GREEN DOTS) AND TO 0.132 MG DERMAL DOSE (0.0152 MG 
ABSORBED) (VIOLET CURVE AND BLACK DOTS). THE DATA LABELLED WITH A # ARE THE EXPERIMENTAL DATA 
FROM DAR AND ARE SHOWN WITH CIRCLES AND THE SIMULATED CURVES ARE SHOWN WITH LINES.   
 
In fact if we would have adjusted to ke(monkey) to the iv curve above, it would practically render the 
same value as the one calculated by interspecies scaling. In addition we tried to fit the elimination 
rate constant to the dermal data set for one animal, and obtained ke(monkey),adj = 0.0774 hr-1, and by 
carrying out interspecies interpolation from monkey to human, we obtained a slightly lower value 
than above.  
 
𝑘𝑒(ℎ𝑢𝑚𝑎𝑛),;𝑥𝑚𝑜𝑛𝑘𝑒𝑦 = 𝑘𝑒(𝑚𝑜𝑛𝑘𝑒𝑦),𝑎𝑑𝑗 � 𝐵𝑊ℎ𝑢𝑚𝑎𝑛𝐵𝑊𝑚𝑜𝑛𝑘𝑒𝑦�0.25 = 0.0774 ℎ𝑟−1 � 70 𝑘𝑔6.19 𝑘𝑔�0.25 =  0.14 ℎ𝑟−1 
 
If we extrapolate this value from monkey to rat in the same way, ke(rat),xmonkey = 0.035 hr-1, which is 
slightly lowe than the corresponding value (sum of the two values) adjusted to rat data. As seen on 
Figure 3.8, the accuracy of both the simulated dermal curves is improved, and poorer agreement is 
seen between the simulated iv curve and the corresponding data points. We thus use the values 
adjusted to rat data for simulations in all the species with ke(human) = 0.19 hr-1.  
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FIGURE 3.8.   
CURVE FIT TO EXCRETION DATA MEASURED FOR MALE RHESUS MONKEY GIVEN A DOSE OF 0.261 MG 
TEBUCONAZOLE BY DERMAL ADMINISTRATION (0.0175 MG ABSORBED AND EXCRETED), THE BLUE LINE IS THE 
ADJUSTED CURVE AND THE GREEN DOTS ARE THE EXPERIMENTAL DATA POINTS. SIMULATIONS (VALIDATIONS) 
FOR A DATA OBTAINED FROM DERMAL ADMINISTRATION OF 0.132 MG (0.0152 MG ABSORBED) (VIOLET CURVE AND 
BLACK DOTS) AND DATA FROM AND AN IV EXPERIMENT (240 MG DOSE) (RED LINE AND RED CIRCLES).  THE DATA 
LABELLED WITH A # ARE THE EXPERIMENTAL DATA FROM DAR AND ARE SHOWN WITH CIRCLES AND THE 
SIMULATED CURVES ARE SHOWN WITH LINES.   
 
Prochloraz: 
 
The parameters for prochloraz will be accessed in a similar way, using radio labelled data. Data sets 
were 100 mg/kg BW of 14C-BAS 590 F (Prochloraz) was administered as a oral bolus dose to 4 male 
and 4 female Wistar rats on day 15, after 14 days repeated oral dosing of 100 mg/kg BW/day  of 
unlabeled 12C-BAS 590 F (Prochloraz) are available in DAR ( European Commission, 2010e).  The 
total recovery for the male group was 97.2% 
 
Excretion data collected from five groups of Sprague-Dawley rats that received a single oral gavage 
doses as also available in DAR ( European Commission, 2010e): 1) One dose of 2 male rats, one 
dose with 10 mg/kg BW and another with 100 mg/kg BW and excretion measured 48 hr post dose. 
2) One dose group of 5 males and 5 females that received 10 mg/kg BW and excretion measure 24 
hrs post dose. 3) Three groups of 5 males and 5 females that dose with 10 mg/kg BW (1 single dose 
group and 1 repeated dose group) and 100 mg/kg BW (1 group) and excretion measured 168 hr post 
dose. The male groups measured after a single dose of 10 mg/kg BW provided excretion data at 
three time points, which we fused together into one data set for validation purpose. The total 
recovery was 90-94% for lower dose male groups, and 84% and 100% for the higher dose male 
groups. 
 
As the first attempt, we did choose to use the data set from the multiple dose experiment at 100 
mg/kg BW for adjusting the elimination rate constant. It was the most complete set at hand and the 
two data points measured for the single 100 mg/kg BW dose groups were in same range.  57.6 µmol 
were excreted at 48 hrs according to the multiple dose set, and for the one animal in the 
corresponding single dose set, 53 µmol were excreted at 48 hrs post administration (84% total 
recovery). If we scale the experiment to total of 98% recovery (excretion + tissue content) the 
number would change to 62 µmol. Especially the data point at 24 hrs post administration might 
however be slightly underestimated, as it is likely that the rat is also excreting remains from 
previous doses.  
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The elimination rate constant was obtained by a curve fit to the final model for prochloraz, where all 
other parameters for the model had been selected. The following rate constants (ke) for excretion 
(urine and faecal) was obtained, ke(rat) = 0.35 hr-1. It was seen that the prochloraz was excreted with 
168 hrs post administration, and not 72 hrs as stated in JMPR.  
 
Data for the total amount of prochloraz in all tissues is available for a few time points as a part of 
excretion data set in DAR, and those data have been used to analyse the tissue levels simulated by 
the PBTK model. The amount of prochloraz in blood and all tissue compartments of the model was 
summed together, i.e. liver, fat, rapidly and slowly perfused tissue. This analysis showed that the 
elimination rate constant fitted to excretion data from a multiple dose experiment did 
underestimate the elimination rate constant, and this parameter was therefore adjusted to match 
the experimental data points more accurately (Figure 3.9).  
 
𝑘𝑒(𝑟𝑎𝑡) = 0.070 ℎ𝑟−1 
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(a) 
 
(b) 
 
FIGURE 3.9.  
TOTAL MASS OF PROCHLORAZ AND METABOLITES IN BODY (BLOOD, LIVER, FAT, RAPIDLY AND SLOWLY PERFUSED 
TISSUE) FOR (A) 10 MG/KG BW AND (B) 100 MG/KG BW DOSE GROUPS. THE CYAN CURVE IS MASS OF PROCHLORAZ, 
GREEN CURVE IS THE MASS OF METABOLITES USING THE ADJUSTED ELIMINATION CONSTANT 0.035 HR-1 AND THE 
BLACK CURVE SHOWS WHEN THIS PARAMETER IS ADJUSTED TO 0.070 HR-1. EXPERIMENTAL DATA ARE SHOWN AS 
DOTS ARE FROM DAR. 
 
The excretion curves were then simulated both with elimination rate constant obtained by curve 
fitting to data multiple dose data, as well as the total mass data (Figure 3.10). Three data points 
from three different experiments at 10 mg/kg BW from DAR are shown. The 24 hrs data point in 
Figure 3.10(a) was obtained based on test on five animals, where the 48 hrs data point is only based 
on one rat. These data and the data point for total mass, indicate that the elimination rate constant 
of 0.070 hr-a is the optimal value. 
 
The total excretion curve contains contributions from absorbed portion of the dose excreted as 
metabolites and unabsorbed portion excreted in faeces as prochloraz. The different contributions to 
the total excretion are shown for the 10 mg/kg BW dose groups on Figure 3.11.  
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(a) 
 
(b) 
 
FIGURE 3.10.    
EXCRETION OF PROCHLORAZ AND METABOLITES USING ELIMINATION RATE CONSTANT OBTAINED BY CURVE FIT 
TO DATA FOR MALE RATS GIVEN A DOSE OF 100 MG/KG BW OF PROCHLORAZ  IN AN MULTIPLE DOSE EXPERIMENT 
(DOTTED LINE) OR ADJUSTMENT TO TOTAL MASS DATA (SOLID LINE).  SIMULATIONS FOR THE DATA FROM THE 10 
MG/KG BW DOSE GROUP (A) AND 100 MG/KG BW MULTIPLE DOSE GROUP (B) ARE SHOWN, WHERE THE CURVE FIT 
IS SHOWN AS THE DOTTED LINE IN (B). THE Y-AXIS IS THE AMOUNT EXCRETED IN µMOL AND X-AXIS IS THE TIME 
AFTER ORAL ADMINISTRATION OF DOSE IN HR. THE DATA LABELLED WITH A # ARE THE EXPERIMENTAL DATA 
FROM DAR AND ARE SHOWN WITH CIRCLES. 
 
Optimization of the cumulative risk assessment of pesticides and biocides using computational techniques: Pilot project 51 
 
 
 
FIGURE 3.11.    
DIFFERENT CONTRIBUTIONS TO THE EXCRETION TERM FOR MALE RATS GIVEN A DOSE OF 10 MG/KG BW, THE 
TOTAL EXCRETION IS THE SOLID LINE. THE EXCRETION OF THE NON-METABOLIZED PROCHLORAZ (26% OF THE 
DOSE NOT ABSORBED) IS ASSUMED AS LINEAR EXCRETION OVER 24 HRS (LONG DASHED CURVE). THE ABSORBED 
AND COMPLETELY METABOLISED PORTION OF PROCHLORAZ IS SHOWN AS DASHED LINE. THE DATA LABELLED 
WITH A # ARE THE EXPERIMENTAL DATA FROM DAR AND ARE SHOWN WITH CIRCLES.  
 
The corresponding value for prochloraz in human was calculated in the same way as before. 
 
𝑘𝑒(ℎ𝑢𝑚𝑎𝑛) = 𝑘𝑒(𝑟𝑎𝑡) �𝐵𝑊ℎ𝑢𝑚𝑎𝑛𝐵𝑊𝑟𝑎𝑡 �0.25 = 0.070 ℎ𝑟−1 � 70 𝑘𝑔0.25 𝑘𝑔�0.25 =  0.29 ℎ𝑟−1 
 
 
3.3.2.4 Fraction unbound and volume of distribution predicted by QSAR 
 
As discussed in 4.1.2.1, the volume of distribution at steady state (VdSS) was predicted by QSAR the 
the most important metabolite of each compound, and used for evaluating the body concentration 
of the metabolites.   
 
Vd(human)SS = 0.77 l/kg and Vd(rat)SS = 1.2 l/kg for tebuconazole metabolites.   
 
Vd(human)SS = 0.58 l/kg and Vd(rat)SS = 0.85 l/kg for prochloraz metabolites.   
 
Likewise, the fraction unbound was calculated from QSAR predictions for the plasma protein 
bidning given in section 4.1.2.2 (fu = (100-%PPB)/100). 
 
fu(human) = 0.34 and fu(rat) = 0.53 for tebuconazole. 
 
fu(human) = 0.07 and fu(rat) = 0.13 for prochloraz. 
 
Recently, we found an experimental value for prochloraz in Supplementary Table 8 to Wetmore et 
al. (Wetmore et al., 2012). The data were measured in vitro in human cells, and the rat value is 
calculated using interspecies extrapolation, as described in section 4.1.2.2. 
 
fu,exp(human) = 0.0224 and fu,extrapolated(rat) = 0.041 for prochloraz. 
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Taken the uncentainity of the developed QSAR model into account, the prediction is quite close to 
the experimental data. This illustrates the value of user QSAR methods to predict this propertiy in 
the absence of experimental data. 
 
We used the QSAR predicted values for tebuconazole and the experimental ones for prochloraz in 
the simulations. 
 
 
3.3.3 Parameters for the dermal model for tebuconazole 
 
Additional parameters are needed to describe the dermal part of the model. These parameters 
describe the absorption of a fluid on the skin surface into the skin.  
 
3.3.3.1 Physiological parameters and estimates of penetration through clothing 
and gloves 
 
In addition to the volume and blood flow rate of the skin, presented in section 3.3.1, one additional 
physiological parameter is needed in case of dermal exposure, namely area of the exposed skin (SA). 
This parameter is needed when the Ficks law based equation for dermal exposure, which is the 
traditional method used in the literature. Daniell et al. (Daniell et al., 2012) reviewed several 
methods proposed for determining the total surface area of  a human (SAhuman), among those the 
following equation by Reading and Freeman (Reading and Freeman, 2005), which we have chosen 
to use  
 
𝑆𝐴ℎ𝑢𝑚𝑎𝑛(𝑚2) = 𝐵𝑊(𝑘𝑔)0.5 ∗ ℎ𝑒𝑖𝑔ℎ𝑡 (𝑐𝑚) 0.5/ 60 
 
Poet et al. (Poet et al., 2000) have published a comprehensive overview on weight and height of 
various human subjects with SA in the range 1.57-2.24 m2.. For a 70 kg and 168 cm human: SAhuman 
= 1.81 m2  = 181 dm2. 
 
A simple equation for calculating the total body surface area for rats was used with a new value of 
Meeh’s constant (KMeeh) recently determined for 30 Wistar rats, weighing 195-240 g. 
 
𝑆𝐴𝑟𝑎𝑡(𝑑𝑚2) =  𝑘𝑀𝑒𝑒ℎ ∗ 𝐵𝑊(𝑔)23 ∗ 100 = 9.83 ∗ 25023 ∗ 100 = 3.9 
 
In cases where only part of the skin surface is exposed, the surface area of the exposed skin should 
be used. 
 
The Fick’s law based equation is well suited for experiments where a defined portion of the surface 
area is exposed to a solution applied directly on the skin surface. In this report, we attempt to 
evaluate exposure due to material spilled on clothing and skin/gloves during work situations, which 
substantially different from a situation where the whole body of a human or an animal would be 
intentionally exposed the active compound solution by applying it directly on the body surface.   
 
When considering whole body exposure of human, one has to account for reduced exposure due to 
clothing and gloves. Thus estimates for penetration through clothing and gloves were built in the 
exposure assessments were used in our simulation, and the alternative dermal implementation in 
section 3.1.2.2 was applied.  
 
The Danish EPA recommended to use 10% clothing penetration for coated overalls used for 
industrial pre-treatment of wood (reduction in exposure by 90%) and 50% clothing penetration for 
light clothing used for professional brush application. In both cases migration by gloves was 
assumed to be 100%, i.e. no protection is applied. 
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For the pesticide product, the assessment was calculated with a more complicated model that 
account for hand exposure during mixing and filling the concentrated product on the spraying 
equipment, and face, hand and body dermal exposure while spraying. The penetration through 
protective gloves is estimated to be 90% during mixing and filling, and 60% while spraying. 
Exposure estimates for specific products is presented together with the underlying assumptions in 
Appendix 9. 
 
 
3.3.3.2 Compound Specific Parameters for Tebuconazole 
 
The skin:surface  partition coefficient (Pskin:surface) has been calculated for exposure to a solution of 
polar organic compounds by the following equation. 
 
𝑃𝑠𝑘𝑖𝑛:𝑠𝑢𝑟𝑓𝑎𝑐𝑒  = �𝑃𝑜𝑤�𝐹𝑛𝑙,𝑠𝑘𝑖𝑛 + 0.3 𝐹𝑝ℎ,𝑠𝑘𝑖𝑛� + �𝐹𝑤.𝑠𝑘𝑖𝑛 + 0.7 𝐹𝑝ℎ,𝑠𝑘𝑖𝑛��𝑃𝑜𝑤   
 
Our calculated values are Pskin:surface (human) = 0.0319, Pskin:surface (rat) = 0.0294 
 
The skin permeability coefficient rate constant for tebuconazole was taken from Buist et al.(Buist et 
al., 2005), and is used for both species. Kp = 0.017 dm/hr 
 
Concentration of the liquid one is exposed to, which is used to calculate the concentration gradient 
across the skin (µmol/l). 
 
According to the Danish EPA, the typical concentration of tebuconazole in wood preserving paints 
around 0.5 % w/w, with density set to 1.0 kg/l.  
 
𝐶𝑠𝑢𝑟𝑓𝑎𝑐𝑒 = 0.5 % 𝑤𝑤 =  0.5 𝑔 𝑡𝑒𝑏𝑢𝑐𝑜𝑛𝑧𝑜𝑙𝑒100 𝑔 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 ∗ 1000𝑔𝑙307.8 𝑔𝑚𝑜𝑙 ∗ 106𝜇𝑚𝑜𝑙𝑚𝑜𝑙 = 1.6 ∙ 104 𝜇𝑚𝑜𝑙𝑙  
 
The dermal absorption is highly dependent on the type of formulation and the concentration of the 
product.  According to DAR the absorption percentage of tebuconazole was observed to be 
approximately 55 % in rats and 13 % in rhesus monkeys in specific experiments (European 
Commission, 2007a). As discussed in section 5.1.2.1, DAR reports an older study for rats that 
Danish EPA has evaluated to be erroneous.  
 
According to information provided by the Danish EPA, the dermal absorption in human is 
estimated to be 15.7 % for solvent based solution and 4.1 % for water based solution for a product 
with concentration of 0.6 % w/w. These numbers can be extrapolated to 0.5 % w/w. In the absence 
of corresponding information for rat, the dermal absorption in rat was assumed to be the same as in 
humans. 
 
For the pesticide formulation, the dermal absorption of a specific formulation was used. The dermal 
absorption of the specific formulation used as model product in this study, is 20 % for the 
concentrate and 12 % for the diluted solution (Table A9.4 Appendix 9). For another product, the 
corresponding numbers were 0.5 % and 13.5 % respectively. These two concentrates have the same 
active compound concentration of 1.0 g/l (3.2 mol/l), and thus the difference has to be due to 
different properties of the two oil-water emulsion formulations. 
 
In cases where no information on the dermal absorption is provided, dermal absorption of 25%  is 
assumed for concentrated pesticide formulation and 75 % for the diluted solution, as the worst case 
scenario.  
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3.4 Binary PBTK model for prohloraz and tebuconazole 
 
3.4.1 Model architecture and combination of the two individual models 
 
The two PBTK models for prochloraz and tebuconazole as individual compounds were combined 
into a binary model. The rat versions of the prochloraz and the tebuconazole model were used, and 
the following procedure was followed.  
 
1) A new version of the tebuconazole model was saved into a separate file, and the compound 
identifiers in the tebuconazole model were renamed from C1M0 to C2M0 (parent 
compound), and from C1M1 to C2M1 (metabolites). In this way it was ensured each 
variable had a unique name and associated with each compound. 
2) One set of physiological parameters were used.  
3) Then the compound specific parameters for each of the compounds were combined into 
one file.  
4) The set of equations used in each of the models were then combined in one file, i.e. all 
equations for both compounds. 
5) The Michaelis-Menten equation for each compound was modified to the form for 
reversible inhibition, and inhibition constants were added to the list of parameters. 
 
When the implementation was completed, it was checked and then the model was validated for each 
of the individual compound. This was done by setting all administration routes to zero for the other 
compound and then run simulations and compared with previous simulations and experimental 
data. Selection of the simulations for different exposure criteria were also repeated, such that both 
the oral bolus dose, dietary and dermal implementations were checked. A simple conceptual binary 
model is shown in Figure 3.12. 
 
When it had been made sure that the code was operational for each of the individual compounds, 
giving the same results as before, simulations for a binary mixture could be made. 
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FIGURE 3.12. THE BINARY MODEL FOR TEBUCONAZOLE (ABOVE) AND PROCHLORAZ (BELOW).  
 
3.4.2 Parameters needed for the binary model 
 
As no inhibition constants were available for tebuconzole inhibiting prochloraz and vice versa, we 
need to use information for similar cases. 
 
We thus calculated inhibition constants for an experiment with R and S tebuconazole, which was 
the most comprehensive information available for a similar case. Moreover, we looked through the 
literature to investigate in which range the inhibition constants used are.  
 
We used the parameters obtained for the kinetic curve fit from the manuscript (Table 3.6) and 
calculated the metabolic rate at concentrations in the concentration range of the measurement for 
four scenarios: R-tebuconazole in its pure form, and with S-tebuconazole as inhibitor (Table 3.10) 
and R-tebuconazole in its pure form, and with S-tebuconazole as inhibitor (Table 3.11). Then the 
reverse of the concentrations and the rates were calculated and plotted, showing typical reversible 
inhibition (Figures 3.13 and 3.14).  
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TABLE 3.10.  
METABOLIC RATES FOR PURE R-TEBUCONAZOLE (R-TEB) AND FOR AND R-TEBUCONAZOLE WITH S-
TEBUCONAZOLE (S-TEB) AS INHIBITOR CALCULATED FROM THE VMAX AND KM VALUES OBTAINED FROM THE 
CURVE FIT TO THE EXPERIMENTAL DATA. 
 
  R-TEB R-TEB / Inh. S-TEB   R-TEB R-TEB / Inh. S-TEB 
CV,liver dAML(R-
TEB)/dt 
dAML(R-TEB,inh)/dt 1/CV,liver (dAML(R-TEB)/dt)-
1 
(dAML(R-TEB,inh)/dt)-1 
[µM] [µM/min/ [µM/min/  [µM] -1 [µM/min/ [µM/min/ 
  mg protein] mg protein]   mg protein] -1 mg protein] -1 
5 0,32 0,10 0,20 3,12 9,57 
10 0,51 0,19 0,10 1,96 5,18 
20 0,73 0,34 0,05 1,37 2,98 
40 0,93 0,53 0,03 1,08 1,89 
80 1,07 0,75 0,01 0,93 1,34 
1000 1,27 1,27 0,00 0,79 0,79 
 
 
 
FIGURE 3.13 
REVERSE METABOLIC RATES (Y-AXIS) FOR PURE R-TEBUCONAZOLE (R-TEB) AND FOR AND R-TEBUCONAZOLE 
WITH S-TEBUCONAZOLE (S-TEB) AS INHIBITOR PLOTTED AGAINST THE REVERSE CONCENTRATION IN THE 
VENOUS BLOOD LEAVING THE LIVER (X-AXIS), SEE TABLE 3.10 FOR DETAILS. 
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TABLE 3.11.  
METABOLIC RATES FOR PURE R-TEBUCONAZOLE (R-TEB) AND FOR AND R-TEBUCONAZOLE WITH S-
TEBUCONAZOLE (S-TEB) AS INHIBITOR CALCULATED FROM THE VMAX AND KM VALUES OBTAINED FROM THE 
CURVE FIT TO THE EXPERIMENTAL DATA. 
 
  S-TEB S-TEB / Inh. R-TEB   S-TEB S-TEB / Inh. R-TEB 
CV,liver dAML(R-TEB)/dt dAML(R-TEB,inh)/dt 1/CV,liver (dAML(R-TEB)/dt)-
1 
(dAML(R-TEB,inh)/dt)-1 
[µM] [µM/min/ [µM/min/ [µM] -1 [µM/min/ [µM/min/ 
  mg protein] mg protein]   mg protein] -1 mg protein] -1 
5 0,24 0,12 0,20 4,15 8,34 
10 0,37 0,21 0,10 2,68 4,74 
20 0,52 0,34 0,05 1,94 2,94 
40 0,64 0,49 0,03 1,57 2,04 
80 0,72 0,63 0,01 1,39 1,59 
10000 0,83 0,88 0,00 1,21 1,14 
 
 
 
FIGURE 3.14 
REVERSE METABOLIC RATES (Y-AXIS) FOR PURE S-TEBUCONAZOLE (S-TEB) AND FOR AND S-TEBUCONAZOLE 
WITH R-TEBUCONAZOLE (R-TEB) AS INHIBITOR PLOTTED AGAINST THE REVERSE CONCENTRATION IN THE 
VENOUS BLOOD LEAVING THE LIVER (X-AXIS), SEE TABLE 3.11 FOR DETAILS. 
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Then the inhibition constants (KI(Y-TEB,X-TEB)) were calculated with the following equation, with X 
being the substrate (either the S or the R form), and Y being the inhibitor (the other enantiomer). CI 
= 10 µM (µmol/l) is the concentration of the inhibitor in the experiment. 
 
𝐾𝑀(𝑋−𝑇𝐸𝐵,𝑤𝑖𝑡ℎ 𝑖𝑛ℎ𝑏𝑖𝑡𝑜𝑟 𝑌−𝑇𝐸𝐵) =  𝐾𝑀(𝑋−𝑇𝐸𝐵,𝑝𝑢𝑟𝑒 𝑒𝑛𝑎𝑛𝑡𝑖𝑜𝑚𝑒𝑟)  �1 + 𝐶𝐼𝐾𝐼(𝑌−𝑇𝐸𝐵,𝑋−𝑇𝐸𝐵) � 
 
The resulting values are: KI(S-TEB,R-TEB) = 3.6 µmol/l for S-tebuconzole as an inhibitor to R-
tebuconazole and KI(R-TEB,S-TEB) = 6.3 µmol/l for R-tebuconzole as an inhibitor to S-tebuconzole. 
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4. Predictions of parameters 
for PBTK models by QSAR 
4.1  QSAR Modeling 
 
4.1.1  Prediction of CYP activity by QSAR 
 
We have used our battery of QSAR models for predicting CYP substrate recognition and inhibitor 
identification to tebuconazole and prochloraz, and their most important metabolites (Tables 4.1-
4.3). These models were developed prior to the project presented here, and can provide important 
information with regards to PBTK modelling by identifying which CYPs tebuconazole and 
prochloraz interact with.  
 
The CYP 2C9 and CYP 2D6 substrate and inhibitor models are described in detail in a recent 
publication (Jonsdottir et al., 2012), including model performances. A manuscript over the CYP 3A4 
substrate and inhibitor models is in preparation.  The data sets used to train these models, contain 
many drug compounds. Among those are several triazoles and imidazoles used as drugs. Thus we 
use information for drugs to make predictions for related pesticides and biocides. 
 
Tebuconazole is predicted as a CYP 3A4 substrate and inhibitor, and as a CYP 2C9 inhibitor, but not 
as a substrate. Prochloraz is predicted as CYP 2C9 substrate. Most of the other predictions for 
prochloraz are inconclusive. CYP 3A4 and CYP 2C9 are common metabolic enzymes for this type of 
compounds. 
 
Both compounds are predicted not to be CYP 2D6 substrates, tebuconazole is predicted as non-
inhibitor to CYP 2D6, and the corresponding prediction for prochloraz is inconclusive. This is not 
surprising, as the 2D6 isoform is not a common metabolizing enzyme for triazole and imidazole 
compounds. 
 
The metabolites of tebuconazole (2 3, 4 and 6), which are structurally similar to the parent 
compound, are generally predicted to interact with the same CYPs as tebuconazole. The same is the 
case for metabolite 1 of prochloraz, but not for metabolites 2 and 3, which are structurally quite 
distinct form prochloraz. For prochloraz we did the prediction for the glucoronide (metabolite 7) as 
well, a conjugated product not supposed to be metabolized by CYP enzymes, and it is predicted 
negative in all models.   
 
We have used this analysis to provide possible CYP interactions, in addition to those known before 
for these compounds. We have also provided a hypothesis on how tebuconazole and prochloraz 
might interact, namely through substrate activity and inhibition of CYP 2C9.  
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TABLE 4.1. PREDICTED CYP 2C9 ACTIVITY OF TEBUCONAZOLE, PROCHLORAZ AND THEIR METABOLITES. 
 
Compound    CYP 2C9 substrate    CYP 2C9 inhibitor 
  Probability Prediction Probability Prediction 
Tebuconazole 0.12 Negative 0.75 Positive 
Tebuconazole: Metabolite 
3 
0.09 Negative 0.75 Positive 
Tebuconazole: Metabolite 
6 
0.23 Negative 0.97 Positive 
Tebuconazole: Metabolite 
4 
0.03 Negative 0.82 Positive 
Tebuconazole: Metabolite 
2 
0.10 Negative 0.75 Positive 
Prochloraz 0.74 Positive 0.46 Inconclusive 
Prochloraz: Metabolite 1 
Prochloraz: Metabolite 2 
0.72 
0.20 
Positive 
Negative 
0.36 
0.09 
Inconclusive 
Negative 
Prochloraz: Metabolite 3 0.62 Inconclusive 0.53 Inconclusive 
Prochloraz: Metabolite 7 0.04 Negative 0.12 Negative 
 
 
TABLE 4.2. PREDICTED CYP 3A4 ACTIVITY OF TEBUCONAZOLE, PROCHLORAZ AND THEIR METABOLITES. 
 
Compound    CYP 3A4 substrate    CYP 3A4 inhibitor 
  Probability Prediction Probability Prediction 
Tebuconazole 0.79 Positive 0.82 Positive 
Tebuconazole: Metabolite 
3 
0.74 Positive 0.85 Positive 
Tebuconazole: Metabolite 
6 
0.58 Inconclusive 0.80 Positive 
Tebuconazole: Metabolite 
4 
0.64 Inconclusive 0.92 Positive 
Tebuconazole: Metabolite 
2 
0.82 Positive 0.84 Positive 
Prochloraz 0.35 Inconclusive 0.63 Inconclusive 
Prochloraz: Metabolite 1 
Prochloraz: Metabolite 2 
0.33 
0.22 
Inconclusive 
Negative 
0.55 
0.08 
Inconclusive 
Negative 
Prochloraz: Metabolite 3 0.21 Negative 0.05 Negative 
Prochloraz: Metabolite 7 0.21 Negative 0.21 Negative 
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TABLE 4.3. PREDICTED CYP 2D6 ACTIVITY OF TEBUCONAZOLE, PROCHLORAZ AND THEIR METABOLITES. 
 
Compound    CYP 2D6 substrate    CYP 2D6 inhibitor 
  Probability Prediction Probability Prediction 
Tebuconazole 0.14 Negative 0.34 Negative 
Tebuconazole: Metabolite 
3 
0.10 Negative 0.31 Inconclusive 
Tebuconazole: Metabolite 
6 
0.03 Negative 0.38 Inconclusive 
Tebuconazole: Metabolite 
4 
0.08 Negative 0.55 Inconclusive 
Tebuconazole: Metabolite 
2 
0.13 Negative 0.33 Inconclusive 
Prochloraz 0.15 Negative 0.64 Inconclusive 
Prochloraz: Metabolite 1 
Prochloraz: Metabolite 2 
0.21 
0.48 
Negative 
Inconclusive 
0.63 
0.49 
Inconclusive 
Inconclusive 
Prochloraz: Metabolite 3 0.02 Negative 0.13 Negative 
Prochloraz: Metabolite 7 0.01 Negative 0.05 Negative 
 
 
 
4.1.2  New QSAR Models for Predicting Parameters for PBTK Models 
 
New Quantitative Structure-Activity Relationship (QSAR) models were developed for three 
properties, volume of distribution at steady state (VdSS), plasma protein binding (%PPB) and %renal 
clearance. In all cases the models were based on human data for triazole and imidazole compounds 
with available experimental data.  2D drawings of all the compounds in the training sets for these 
properties are found in Appendix 7 and corresponding 2D drawings of tebuconazole and prochloraz 
are shown in Table 4.4. 
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TABLE 4.4. 
2D STRUCTURES OF TEBUCONAZOLE AND PROCHLORAZ, SHOWING IONIZABLE ATOMS AND PREDICTED LOGD 
VALUES AT PH=7.0 AND PH=7.4 (BLOOD PH). 
 
Name 2D-structure with ionizable atoms logD 
pH=7.0 
logD 
pH=7.4 
Comment 
Tebuconazole 
 
3.58 3.58  
Prochloraz 
 
3.98 3.98 N in the 
imidazole 
ring partly 
ionized to  
NH+ (1-0%) 
 
4.1.2.1 Prediction of volume of distribution at steady state (VdSS) 
 
A QSAR model was developed based on available human data for compounds that are similar to 
tebuconazole and prochloraz (namely triazoles and imidazoles). A data set of 20 compounds was 
retrieved from the PK/DB database, and data were gathered from several review articles as well (see 
Table 4.5 for references).  Generally, there was good agreement between data from different 
sources, and many of the data are also from the same original source. For three compounds, large 
differences were seen between data points listed in the different references, and these three 
compounds were only used for model validation and not for model training. We used the dataset 
from the PK/DB databases, as our training set, see values highlighted in bold in Table 4.5.  
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TABLE 4.5.  
TRAINING SET FOR DEVELOPING A QSAR MODEL FOR HUMAN VDSS. DATA SET RETRIEVED FROM THE PK/DB 
DATABASE WAS USED AS TRAINING SET (NUMBERS IN BOLD), AND DATA COLLECTIONS FROM OTHER SOURCES 
ARE SHOWN FOR COMPARISON. THREE COMPOUNDS WITH LARGE DIFFERENCES IN AVAILABLE DATA WERE ONLY 
USED FOR MODEL VALIDATION. COMPOUNDS USED FOR EXTERNAL VALIDATION OF THE SECOND MODEL ARE 
MARKED WITH *. 
 
Compound                Volume of Distribution (VdSS [l/kg]) 
  PK/DB Gleeson Obach Lombardo Lombardo 
  Database 
(Moda et 
al., 
2008) 
2006 
(Gleeson 
et al., 
2006) 
2008 
(Obach 
et al., 
2008) 
2004 
(Lombardo 
et al., 
2004) 
2002 
(Lombardo 
et al., 2002) 
Training set           
 Aripiprazole 4.9   4.9     
 Cefmetazole 0.13   0.13     
 Clomethiazole 6.6   6.6     
 Fluconazole 0.6 0.6 0.75 0.6 0.6. 
 Fosfluconazole* 0.15   0.15     
 Genaconazole 0.62   0.62     
 Lansoprazole 0.425   0.28     
 Letrozole 1.87   1.9     
 Mebendazole 1.23   1.2     
 Methimazole 0.86   0.86     
 Metronidazole 0.74 0.74 0.40 0.74 0.74 
 Omeprazole 0.34 0.34 0.24 0.34 0.34 
 Rabeprazole 0.22   0.22     
 Sulfisoxazole 0.15 0.15 0.17     
 Sulfamethoxazole 0.26 0.29 0.30     
 Tinidazole* 0.59   0.59     
 Voriconazole* 2.2   2.2 4.6   
Validation set           
 Itraconazole 14. 14. 7.4 3.9 3.9 
 Ketoconazole 2.4 0.15       
 Pantoprazole 23.6   0.17     
 
The following model was developed on all 17 training set data points (model 1), see Figure 4.1. 
 
VdSS [l/kg]  = 2.76658 * SaaS + 304.336 * xch10 - 10.2636 * MaxHp + 2.92685 
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• No. PLS-factors=3, no. descriptors=3 (see equation) 
• Training performances: r2=0.94, q2=0.94, rmsd=0.43 l/kg 
• Cross validated performances by LOO: r2CV=0.93, q2CV=0.93, rmsdCV=0.45 l/kg 
 
 
 
FIGURE 4.1.  
OBSERVED (X-AXIS) VERSUS PREDICTED (Y-AXIS) VDSS VALUES [L/KG] FROM THE CROSS-VALIDATED VERSION OF 
THE MODEL USING THE LEAVE ONE OUT (LOO) METHOD. THE FULL TRAINING SET OF 17 COMPOUNDS WAS USED 
IN MODEL 1. 
 
An additional model was developed on 14 data points from the training set, leaving the three data 
points corresponding with three compounds marked with * out, giving the following model (model 
2), see Figure 4.2. 
 
VdSS [l/kg]   = 2.83666 * SaaS + 313.478 * xch10 - 10.3384 * MaxHp + 2.8163 
 
• No. PLS-factors=3, no. descriptors=3 
• Training performances: r2=0.98, q2=0.98, rmsd=0.24 l/kg 
• Cross validated performances by LOO: r2CV=0.98, q2CV=0.98, rmsdCV=0.29 l/kg 
• External validation of model 2 for the three compounds marked with *, see Table 4.6, showed 
that voriconazole was not described as well by the regression equation for the full data set, as 
the other compounds (Figure 4.1). Similarly the predicted value is significantly 
underestimated, when used for external validation. 
 
TABLE 4.6.  
EXTERNAL VALIDATION OF MODEL 2, USING THE THREE COMPOUND MARKED WITH * IN TABLE 4.5. THE 
COMPOUNDS WERE LEFT OUT FROM MODEL 2, BUT USED FOR TRAINING MODEL 1.  
 
Compound       VdSS [l/kg] 
  Exp. Pred. 
Fosfluconzole 0.15 0.20 
Trinidazole 0.59 0.20 
Voriconazole 2.2 0.63 
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FIGURE 4.2.  
OBSERVED (X-AXIS) VERSUS PREDICTED (Y-AXIS) VDSS VALUES FROM THE CROSS-VALIDATED VERSION OF THE 
MODEL USING THE LEAVE ONE OUT (LOO) METHOD. A SUB-SET OF 14 COMPOUNDS FROM THE TRAINING SET 
(MODEL 2). 
 
Both models were then validated by using the validation set in Table 4.5, the three compounds that 
were not included in any of the of two models (Table 4.7). These are the compounds with different 
experimental data from different sources, and thus we can’t be certain what the correct 
experimental values are for these compounds. The predicted values for both ketoconazole and 
pantroprazole agree well with one of the listed experimental data points. For itraconazole, which is 
a considerably larger molecule than any of the compounds in the training set, the predicted value 
does not agree with any of the proposed experimental values. 
 
TABLE 4.7.  
EXTERNAL VALIDATION OF MODELS 1 AND 2, USING THE VALIDATION SET TABLE 4.5. SEE THE EXPERIMENTAL 
VALUES IN TABLE 4.5. 
  
Compound       VdSS ([l/kg] 
  model 1 model 2 
 Itraconazole 1.5 1.4 
 Ketoconazole 2.0 1.8 
 Pantoprazole 0.67 0.54 
 
The developed QSAR models are thus considered to be reliable for carrying out predictions for 
tebuconazole, prochloraz and their metabolites (Tabel 4.8).  
 
Whereas the metabolites formed for tebuconazole are similar to the parent compound, and have 
similar molecular structures to the training compounds, the metabolites of prochloraz are 
somewhat structurally different from the compounds in the data set. The predicted VdSS for 
tebuconazole and its metabolites are either identical, or very similar. It is a fair approximation to 
use the VdSS value of metabolite 3, which is one of the two most common metabolites, for the 
metabolites as a whole. The metabolites for prochloraz are somewhat more structurally distinct 
from the training set compounds, and thus the predictions for these metabolites might be less 
reliable, than those for the metabolites for tebuconazole. We have chosen the predicted value for 
metabolite 3 of prochloraz, as it is the most common of the metabolites.  
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The predictions for use in the human PBTK models are thus as follows: For tebuconazole 
metabolites Vd(human)SS = 0.77 l/kg and for prochloraz metabolites Vd(human)SS = 0.58 l/kg. 
 
TABLE 4.8.  
HUMAN VDSS VALUES OF TEBUCONAZOLE, PROCHLORAZ AND THEIR MOST IMPORTANT METABOLITES, PREDICTED 
USING MODEL 1, DEVELOPED ON THE FULL TRAINING SET. THE VALUE FOR THE METABOLITE OF EACH 
COMPOUND WHICH HAS THE LARGEST RELATIVE CONCENTRATION WAS USED (MARKED IN BOLD).  
 
Compound VdSS [l/kg] 
  model 1 
Tebuconazole 0.77 
Tebuconazole-met2 0.77 
Tebuconazole-met3 0.77 
Tebuconazole-met4 0.77 
Tebuconazole-met6 0.58 
Prochloraz 2.0 
Prochloraz-met2 0.78 
Prochloraz-met3 0.58 
 
We also tried to develop a QSAR model for the volume of distribution, based on a more structurally 
diverse data set. We retrieved all compounds that contained either an imidazole or a triazole ring 
from the PK/DB database, 55 compounds in total. The resulting model showed to be significantly 
less accurate, than the QSAR models developed for a smaller group of more similar compounds, see 
the models presented above. The same trend is seen for models published in the literature for this 
property.    
 
As volume of distribution data for triazoles and imidazoles in rats were scarce, we used a correlation 
between human and rat data from the literature to estimate rat VdSS from the predicted human VdSS 
values. We used the following relationship Caldwell et al. (Caldwell et al., 2004; Fagerholm, 2007)   
for a data set of 144 compounds. 
 log�𝑉𝑑(𝑟𝑎𝑡)𝑆𝑆 � = (log �𝑉𝑑(ℎ𝑢𝑚𝑎𝑛)𝑆𝑆 + 0.18 𝑙𝑘𝑔� 0.83�  
 
The predicted values in rat are therefore according to this correlation, Vd(rat)SS = 1.2 l/kg for 
tebuconzole metabolites and Vd(rat)SS = 0.85 l/kg for prochloraz metabolites. 
 
4.1.2.2 Prediction of Plasma Protein Binding (%PPB) 
 
A QSAR model was developed based on available human data for similar compounds (trizoles and 
imidazoles). A data set of 19 compounds was retrieved from the PK/DB database, and data were 
gathered from several review articles as well.  Generally, there was good agreement between data 
from different sources, and many of the data are also from the same original source. For one 
compound, large difference was seen between data points listed in the different references, and this 
compound, sulfamethoxazole, was only used for model validation and not for model training. We 
used the data set from the PK/DB databases, as our training set, see values highlighted in bold in 
Tabel 4.9.  
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TABLE 4.9.  
TRAINING SET FOR DEVELOPING QSAR MODEL FOR HUMAN PPB.  DATA SET RETRIEVED FROM THE PK/DB 
DATABASE WAS USED AS A TRAINING SET (NUMBERS IN BOLD), WITH THE VALUE FOR SULFISOXAZOLE TAKEN 
FROM OBACH ET AL. DATA COLLECTIONS FROM OTHER SOURCES ARE SHOWN FOR COMPARISON. THREE 
COMPOUNDS FROM OTHER PAPERS, AND ONE COMPOUND WITH LARGE DIFFERENCES IN AVAILABLE DATA, WERE 
ONLY USED FOR MODEL VALIDATION. COMPOUNDS USED FOR EXTERNAL VALIDATION OF MODEL 3 AND 4 ARE 
MARKED WITH *. 
 
Compound                               Plasma Protein Binding (PPB [%])1)     
  PK/DB Goodmann Obach Lombardo Lombardo Wan Kochansky 
  Database 
(Moda et 
al., 
2008) 
1985  
 
2008 
(Obach 
et al., 
2008) 
2004 
(Lombardo 
et al., 
2004) 
2002 
(Lombardo 
et al., 
2002) 
2006 
(Wan and 
Rehngren, 
2006) 
2008 
(Kochansky 
et al., 
2008) 
Training set              
 Albendazole* 70            
 Anastrozole* 40            
 Aripiprazole* 99   99        
 Cefmetazole 85   85        
 Clomethiazole 64   64        
 Fluconazole 11.5   11 11 11  11 
 Fosfluconazole 95.8   95.8        
 Itraconazole 99.8   99.8 87.2 87.2    
 Lansoprazole 97   97.9        
 Letrozole 60   59        
 Mebendazole 91.4   91.4     92.5   
 Metronidazole 11 10 4 11 11    
 Omeprazole 95   95 95 95     
 Pantoprazole 98   98        
 Rabeprazole 96.15   96.3        
 Sulfisoxazole 88.2 91.4 92.1        
 Tinidazole 12   20        
 Voriconazole 58   58 58      
Validation set               
 
Sulfamethoxazole 
53 62 77         
 Astemizole           98.5   
 Clotrimizole            99.65 
 Ketoconzole           98.9 98.2 
1) In many of the cited papers, the unbound (free) fraction in plasma (fu) was given. These 
values were converted to PPB (%PPB =(1-fu)*100). 
68 Optimization of the cumulative risk assessment of pesticides and biocides using computational techniques: Pilot project 
 
The SVM model described below was developed using all 18 training set data points (model 3) 
• SVM model type: epsilon-SVR, with radial distribution function kernel 
• SVM parameters: Cost=2, γ=0.5, termination criterion tolerance=0.1, epsilon=0.1 
• Model: No. Support vectors=10, no. descriptors=7  
• Descriptors selected: SsssCH, SsNH2, SssO, SdssS, SHBint3_Acnt, ABSQ, SpcPolarizability 
• Training performances: r2=0.99, q2=0.98, rmsd=3.9% 
• Cross validated performances by LOO: r2CV=0.93, q2CV=0.90, rmsdCV=10% 
 
(a) 
 
(b) 
 
FIGURE 4.3.  
OBSERVED (X-AXIS) VERSUS PREDICTED (Y-AXIS) %PPB VALUES FROM MODEL TRAINING (A) AND THE CROSS-
VALIDATED VERSION OF THE MODEL USING THE LEAVE ONE OUT (LOO) METHOD (B). THE FULL TRAINING SET OF 
18 COMPOUNDS (MODEL 3). 
 
An additional SVM model was developed on 15 data points from the training set, leaving the three 
data points marked with * out, giving the following model (model 4). 
• SVM model type: epsilon-SVR, with radial distribution function kernel 
• SVM parameters: Cost=2, γ=0.5, termination criterion tolerance=0.1, epsilon=0.1 
• Model: No. Support vectors=8, no. descriptors=5  
• Descriptors selected: SssO, SdsssP, SaasC_acnt, numHBd, SpcPolarizability 
• Training performances: r2=0.98, q2=0.98, rmsd=5.0% 
• Cross validated performances by LOO: r2CV=0.96, q2CV=0.94, rmsdCV=8.1% 
• External validation for the three compounds marked with *, see Table 4.10. Very good 
agreement is seen between experimental and predicted values. 
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TABLE 4.10.  
EXTERNAL VALIDATION OF MODEL 4, USING THE THREE COMPOUND MARKED WITH * IN TABLE 4.9. THE 
COMPOUNDS WERE LEFT OUT FROM MODEL 4, BUT USED FOR TRAINING MODEL 3. 
 
Compound         %PPB 
  Exp. Pred. 
Albendazole 70 76 
Anastrozole 40 39 
Aripiprazole 99 91 
 
 
(a) 
 
(b) 
 
FIGURE 4.4.  
OBSERVED (X-AXIS) VERSUS PREDICTED (Y-AXIS) %PPB VALUES FROM MODEL TRAINING (A)  AND THE CROSS-
VALIDATED VERSION OF THE MODEL USING THE LEAVE ONE OUT (LOO) METHOD (B). A SUB-SET OF 15 
COMPOUNDS FROM THE TRAINING SET (MODEL 4). 
 
Both models were then validated on an external data set, consisting of three compounds from 
different sources, as well as sulfamethoxazole, which had different experimental data in different 
papers. The results are listed Table 4.11. Good agreement between the predicted and the 
experimental values are seen for astemizole and ketoconazole, and for the highest of the three 
literature values for sulfametoxazole. For clotrimazole, the predicted values are only half of the 
experimental value. The differences in the predicted values from the two models, illustrate up to 10-
20% uncertainty in the predictions with QSAR the models developed for this data set, also 
illustrated by the variation in the cross-validated predictions, shown in Figures 4.3-4.4. 
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TABLE 4.11. EXTERNAL VALIDATION OF MODELS 3 AND 6, USING THE VALIDATION SET TABLE 4.9.  
 
Compound   %PPB 
  exp. model 3 model 4 
 Astemizole 98 96 76 
 Clotrimazole 99.7 50 55 
Ketoconazole 
Sulfamethoxazole 
98-99 
53-77 
99 
90 
96 
82 
 
The developed QSAR models are thus considered to be reliable for carrying out predictions for 
tebuconazole and prochloraz, predictions for their metabolites are not needed for this properties. 
The predicted human values are shown in Table 4.12. The human values predicted with model 3 
(the model developed on the largest number of data points) were used for the PBTK modelling. 
 
Table 4.12. Human PPB values of tebuconazole, prochloraz, predicted using model 3, developed on the full 
training set, and model 4. Predictions by model 3, are used in the PBTK model, as this model was developed 
using more data points and harbours thus the most information (values marked in bold).  
 
Compound          %PPBhuman 
  model 3 model 4 
 Tebuconazole 66 63 
 Prochloraz 93 83 
 
Available PPB values for triazoles and imidazoles in rats, were scarce, and therefore we used a 
correlation between human and rat data from the literature to estimate rat PPB based on the 
predicted human PPB values. Gleeson and coworkers (Gleeson et al., 2006) developed the following 
relationship from rat and human data for 548 in house compounds at Astra Zeneca. The rat and the 
human data were seen to be highly correlated (r2=0.78), where the protein binding was generally 
higher in humans than in rats. log𝐾𝑃𝑃𝐵(𝑟𝑎𝑡) = (log𝐾𝑃𝑃𝐵(ℎ𝑢𝑚𝑎𝑛) − 0.34 ) / 0.95 
 log𝐾𝑃𝑃𝐵 = 𝑙𝑜𝑔 �1 − 𝑓𝑢𝑓𝑢 � = log � %𝑃𝑃𝐵100 − %𝑃𝑃𝐵� 
 
The predicted values in rat are therefore according to this correlation and the human values 
predicted with model 3, PPBrat=47% for tebuconzole and PPBrat=87% for prochloraz. 
 
4.1.3 Prediction of Renal Clearance 
 
We have a small data set with information on the percentage of parent compound that is excreted 
with renal clearance, human data, from the PK/DB database (Moda et al., 2008). Including the 
compounds with high clearance in the model, made the model less accurate at lower clearance, and 
thus we only used the data points for %Cl between 0 and 14, ten compounds in total (Table 4.12). 
 
The following PLS model was developed on all 10 training set data points (model 5), see Figure 4.5. 
 
%Cl = 1.37741 * StsC + 2.37578 * SsNH2 - 17.4202 * SddsN + 0.972942 
 
• No. PLS-factors=3, no. descriptors=3 
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• Training performances: r2=0.93, q2=0.93, rmsd=1.2 % 
• Cross validated performances by LOO: r2CV=0.81, q2CV=0.81, rmsdCV=2.1% 
 
The predicted human values are 1% for both tebuconazole and prochloraz, which is similar to the 
corresponding experimental values for rat. 
 
TABLE 4.13. 
 THE TRAINING SET FOR PERCENT RENAL CLEARANCE FROM THE PK/DB DATABASE. ONLY THE COMPOUNDS WITH 
SMALL AMOUNT OF PARENT COMPOUND EXCRETED IN THE URINE ARE USED, AS THIS IS THE RANGE RELEVANT 
FOR TEBUCONAZOLE AND PROCHLORAZ. 
Compound Renal Clearance (%Cl) 
Training set   
 Anastrozole 
Flumazenil 
10 
1 
 Itraconazole 1 
 Ketoconazole 1 
 Lansoprazole 
Letrozole 
1 
3.9 
 Mebendazole 1.1 
 Metronidazole 10 
 Omeprazole 1 
 Sulfamethoxazole 14 
Not used in model   
 Fluconazole 75 
 Pantoprazole 71 
 Rabeprazole 90 
 Sulfisoxazole 49 
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(a) 
 
(b) 
 
 
Figure 4.5. Observed (x-axis) versus predicted (y-axis) %Cl values from model training (a) and the cross-
validated version of the model using the leave one out (LOO) method (b). The full training set of 10 compounds 
(model 5). 
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5. Results from PBTK 
modelling 
This section presents results for PBTK simulations carried out with the models developed in this 
project and described above. Simulations have been carried out in rat, rabbit and rhesus monkey for 
validating the models, and simulations on specific exposure criteria were then made using the 
human models. 
 
Validation of the elimination part of the models is discussed in section 3.3.2.3. 
 
 
5.1 Validation and analysis of PBTK model for tebuconazole 
 
The availability of good validation data in rat was rather limited. Plasma concentration data for the 
total radioactivity (tebuconazole and metabolites) measured in rats at different time points after 
administration as oral bolus dose have been published (JMPR, 2010; European Commission,  
2007b). These data are for two dose groups (2 and 20 mg/kg BW) in male and female rats, 
respectively. Concentrations in tissues were only measured 72 hrs after administration. These data 
confirm that almost the entire dose has been excreted at this time points. We have information on 
tebuconazole levels in rat, as tebuconazole and not as the sum of tebuconazole and metabolites, 
from a report by Hass and co-workers  (Hass and et al., 2012).  
 
Data were available on both concentrations in plasma and in several tissues at various time points 
after intra-venous (iv) administration to male rabbit (Zhu et al., 2007), which was the most 
complete validation data set available to us.  
 
5.1.1 Validation of model by using rabbit data 
 
A good data set with plasma and tissue concentrations at various time points in rabbits, after 
administration of tebuconazole by intra venous (iv) dose (30 mg/kg BW) was available (Zhu et al., 
2007). This data set was used for validating the model, and the rat model was extended and 
modified for the purpose of modelling rabbits, see section 5.1.1.2. Thus a special version of the 
model was made for simulation in rabbit, as described below. 
 
5.1.1.1 Adaptation of the rat model to a rabbit model 
 
Several changes and modifications of the model equations and parameters had to be made.  
• First, the model was extended to cover brain, heart, kidney, liver, lung, muscle and fat as 
separate compartments. The remaining tissue (skin and bone) were put to a separate 
compartment, called “rest of body”. The additional compartments were implemented in the 
same way as the compartments discussed in Appendix 2. 
• Second, we had to calculate tissue volumes and blood flows separately for all these 
compartments as described in section 3.3.1, using the values given in Table 3.3. We used tissue 
volume of liver (Vp,liver) given for rabbit, and for the other organs it was assumed that tissue 
volumes and blood flows were the same percentage of the body weight and cardiac output, 
74 Optimization of the cumulative risk assessment of pesticides and biocides using computational techniques: Pilot project 
 
respectively, as in rat.  Thus Vp,t and Qp,t  values as for rat, were multiplied by BW and QC for 
rabbit, respectively. QC for rabbit was estimated by interspecies scaling based on the 
corresponding value for rat, and BW was set to the mean body weight of the test animals used. 
We used the same tissue:blood partition coefficients and fraction unbound in plasma (fu) as 
used for rat. Vmax and elimination constants for rat were converted by interspecies scaling to be 
used for rabbit, as described by Campbell et al. (Campbell, Jr. et al., 2012). 
• Third, the equations were changed such that the time was calculated in minutes and not hours. 
This was done because an iv dose is administered and distributed within minutes. Thus, 
appropriate parameters and rates of administration of tebuconazole via the different routes 
had to be modified accordingly.     
• Fourth, the iv dose implementation was adjusted by modifying the following equation in the 
blood compartments.  As discussed in Appendix 2, the iv dose is added to the venous blood. 
The equation has also been modified to cover all the compartment used in the rabbit model. 
 
𝐶𝑉(𝐶1𝑀0) = �𝑄𝑏𝑟𝑎𝑖𝑛 𝐶𝑉,𝑏𝑟𝑎𝑖𝑛(𝐶1𝑀0) + 𝑄ℎ𝑒𝑎𝑟𝑡 𝐶𝑉,ℎ𝑒𝑎𝑟𝑡(𝐶1𝑀0) + 𝑄𝑘𝑖𝑑𝑛𝑒𝑦 𝐶𝑉,𝑘𝑖𝑑𝑛𝑒𝑦(𝐶1𝑀0)+ 𝑄𝑙𝑖𝑣𝑒𝑟  𝐶𝑉,𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0) +  𝑄𝑙𝑢𝑛𝑔 𝐶𝑉,𝑙𝑢𝑛𝑔(𝐶1𝑀0) + 𝑄𝑚𝑢𝑠𝑐𝑙𝑒 𝐶𝑉,𝑚𝑢𝑐𝑙𝑒(𝐶1𝑀0) + 𝑄𝑓𝑎𝑡 𝐶𝑉,𝑓𝑎𝑡(𝐶1𝑀0) +  𝐴𝐼𝑉𝑒𝑥𝑝(𝐶1𝑀0)′ �  / (𝑄𝑏𝑟𝑎𝑖𝑛 + 𝑄ℎ𝑒𝑎𝑟𝑡 + 𝑄𝑘𝑖𝑑𝑛𝑒𝑦 + 𝑄𝑙𝑖𝑣𝑒𝑟 + 𝑄𝑙𝑢𝑛𝑔+ 𝑄𝑚𝑢𝑠𝑐𝑙𝑒 + 𝑄𝑓𝑎𝑡) 
   
Where A´IVexp was calculated with the following equation, where AIVdose is the iv dose in 
[mg/kg BW] and A´IVexp and A´kiv have the unit [µmol/min]. It is assumed that the iv dose 
is administered and distributed in the blood in two minutes. (We could have used one 
minute as well, both values secure fast distribution of the compound in the body). 
 
𝐴𝐼𝑉𝑒𝑥𝑝(𝐶1𝑀0)′ = 𝐼𝐹 𝑇𝐼𝑀𝐸 ≤  2 𝑇𝐻𝐸𝑁 𝐴𝑘𝑖𝑣(𝐶1𝑀0)′  𝐸𝐿𝑆𝐸 0 
 
𝐴′𝑘𝑖𝑣(𝐶1𝑀0) = 𝐴𝐼𝑉𝑑𝑜𝑠𝑒(𝐶1𝑀0)  𝐵𝑊𝑟𝑎𝑏𝑏𝑖𝑡𝑀𝑊𝐶1𝑀0  12 𝑚𝑖𝑛  
 
 
5.1.1.2 Validation results 
 
Half of the administered tebuconazole in the model was metabolized after 94 min, which is the 
predicted half-life. Zhu et al. (Zhu et al., 2007) estimated the half-life of the R(-) and the S(+) 
enantiomers to 123 min and 88 min, respectively, from in vivo data measured in rabbits. The mean 
of these values is 104 min, and thus the predicted value is in good agreement with this value. This 
indicates that the rate of metabolism is correctly simulated with the model. 
 
The calculated blood concentrations and the measured plasma concentrations are shown in Figure 
5.1, showing good agreement between the simulated curve and the experimental data.  The 
simulated curve underestimates the blood concentration levels slightly at 15, 30 and 60 min after iv 
administration, the simulated values are around 60% of the experimental ones at 15 and 30 min 
post administration. The results are thus within the accuracy one can expect for such a fully 
predictive model. It is seen for this data that the elimination time in rabbit is about eight hours, and 
this is simulated excellently by the model. 
 
As the predicted partition coefficient between plasma and erythrocytes is estimated to be close to 
one, it is assumed that the plasma and blood concentration are similar, and thus plasma level data 
were used for validating blood concentrations simulated by the model.  
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FIGURE 5.1.  
PREDICTED BLOOD CONCENTRATIONS (LINE) AND EXPERIMENTAL PLASMA CONCENTRATIONS (CIRCLES) OF 
TEBUCONAZOLE IN RABBITS AS A FUNCTION OF TIME FROM ADMINISTRATION OF 30 MG/KG BW IV DOSE.  
 
(a) 
(b) 
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(c) 
 
(d) 
 
FIGURE 5.2.  
PREDICTED AND EXPERIMENTAL LIVER (A),  HEART (B), KIDNEY (C) AND BRAIN (D) CONCENTRATIONS OF 
TEBUCONAZOLE IN RABBITS AS A FUNCTION OF TIME FROM ADMINISTRATION OF 30 MG/KG BW IV DOSE. THE 
LINE IS THE CURVE SIMULATED BY PBTK AND THE CIRCLES ARE THE EXPERIMENTAL DATA.  
 
As seen on Figures 5.2 and 5.3, fairly good agreement is seen between predicted and experimental 
tissue concentrations for heart, kidney, brain and muscle, and within the levels on can expect from a 
simulation entirely based on other types of experimental data. The simulation curves for the heart 
and the kidney underestimate some of the experimental data points by a factor of two and the 
simulated curve for the brain overestimates the concentration by one third.  
 
The first data point at 15 min post administration is significantly lower than the subsequent data 
points in all these data sets, indicating a long lag time for the tebuconazole to distribute to the 
different tissues. A flow regulated PBTK model would not capture such lag time, as it assumes 
instantaneous distribution within the body, where thermodynamic equilibrium is simulated by the 
tissue:blood partition coefficients implemented in the model. It is possible that it takes some time to 
establish equilibrium in a living system, although the data show surprisingly long lag time. The flow 
regulated well stirred model approach can be considered appropriate on slightly longer time-scale, 
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and thereby at time scale relevant for this project. It should be mentioned that each data point is 
based on one animal only.     
The liver concentrations are significantly underestimated by the model. In the simulation it is 
assumed that all the tebuconazole is metabolised in the liver, but in the absence of the first pass 
effect of oral administration, metabolism in other organs like lung might be of importance too. It 
can be seen that the experimental levels in liver and kidney are similar, as the partition to these 
organs is similar in the model, but it seems that the metabolism simulation in the liver lowers the 
liver levels significantly. As the liver is the main target organ, the model has to be improved with 
respect to partition to the liver. 
 
It is seen in Figure 5.3, that the concentrations in the lung are largely underestimated by the model. 
The experimental manuscript discusses that the tebuconazole was stockpiled in the lung due to lung 
first-pass effect (Zhu et al., 2007). It is assumed that tebuconazole does not bind to tissue proteins, 
with the fraction unbound in the tissue term in the partition coefficient equation set to one. In fact, 
this assumption might not be correct for all the tissues, and thus the high experimental 
concentration in lung might be due to binding.   
 
The biological evidence is not sufficient to implement this in the model in this work, and thus we 
have to conclude that the present model does not capture the specific behaviour of the lung 
compartment. The lung compartment is considered of low importance with respect to the overall 
aims of the particular project, as it is normally lumped into the rapid tissues compartment, and thus 
we will not seek to improve the present model for this compartment.  
 
The simulated curve for fat matches three data points fairly well. It is often necessary to implement 
somewhat more complicated model  to simulate adipose tissue adequately, where the fat 
compartment is modified by adding a deep compartment (reservoir) to account for accumulation of 
the compound in fat tissue. Although the data indicate slight accumulation in fat over a short period 
of time, this would require fitting of two additional rate constants between the two fat 
compartments. As fat is not a target tissue and tebuconazole is not a persistent chemical, it was not 
considered necessary to implement such extension in this model. The simulation for the fat 
compartment might, however, be less accurate because of the simple implementation used in this 
model. 
 
The overall conclusion is that the model predicts the concentration in plasma and in most of the 
tissues within acceptable accuracy. An exception to this, are the predictions for the liver and lung 
compartments. We need to use a larger partition coefficient Pliver:b value in the simulations, in order 
to simulate better partitioning to the liver, because it is a target organ.  
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(a) 
(b) 
(c) 
 
FIGURE 5.3.  
PREDICTED AND EXPERIMENTAL LUNG (A), MUSCLE (B) AND FAT (C) CONCENTRATIONS OF TEBUCONZOLE IN 
RABBITS AS A FUNCTION OF TIME FROM ADMINISTRATION OF 30 MG/KG BW IV DOSE. THE LINE IS THE CURVE 
SIMULATED BY PBTK AND THE CIRCLES ARE THE EXPERIMENTAL DATA.  
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5.1.1.3 Optimization of partition coefficients for obtaining better tissue 
concentrations 
 
Only as few parameters as possible were adjusted and thereby it was possible to investigate the 
predictive power of the parameters selected for the model. Further it was investigated how much 
the parameters should be change to better match the experimental concentration curves. 
 
The partition coefficients for each tissue were thus adjusted to obtain better correlation between the 
experimental data and simulated curves. The following values were seen to give the best fit to the 
experimental data points. The results are presented in Figure 5.4, and the adjusted parameters are 
as follows:  Pliver:b,adj=80 (=7.5 Pliver:b), Pkidney:b,adj=20 (=2 Pkidney:b), Pheart:b,adjt=17 (=2 Pheart:b), 
Pbrain:b,adj=17 (=0.7 Pbrain:b) and Plung:b,adj=50 (= 4 Plung:b).  
 
The adjusted parameters gave better match with experimental data. The original partition 
coefficients for kidney, heart and brain needed to be multiplied by a factor in the range 0.5 and 2 to 
match the adjusted values, and the coefficient for muscle did not need to be adjusted. The adjusted 
partition coefficient for liver and the lung were, however, 7.5 and 4 times the original values. The 
adjusted Plungs:b,adj gave a good fit at higher time points, but significantly underestimated the lung 
levels at the lowest time points.      
 
One can expect that some uncertainty might be due to the relatively simple method used to predict 
the partition coefficients. The adjusted coefficients for liver and lungs is considered too large to be 
within reasonable uncertainty due the partition coefficient estimates, whereas for the other tissue 
we would consider the uncertainly to be within such levels.  
 
(a) 
(b) 
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(c) 
(d) 
 
FIGURE 5.4.  
SIMULATED AND EXPERIMENTAL LIVER (A), HEART (B), KIDNEY (C), BRAIN (D) AND LUNG (E) CONCENTRATIONS 
OF TEBUCONAZOLE IN RABBITS AFTER ADMINISTRATION BY AN ORAL DOSE OF 30 MG/KG BW. THE LINE IS THE 
CURVE SIMULATED BY PBTK AND THE CIRCLES ARE THE EXPERIMENTAL DATA. IN EACH CASE THE PARTITION 
COEFFICIENT FOR THE GIVEN TISSUE WAS ADJUSTED TO OBTAIN BETTER MATCH BETWEEN THE EXPERIMENTAL 
DATA AND THE SIMULATED CURVE, PLIVER:B,ADJ=80. PKIDNEY:B,ADJ=20, PHEART:B,ADJ=17, PBRAIM:B,ADJ=17 AND PLUNG:B,ADJ=50. 
 
 
5.1.1.4 Sensitivity key parameters on blood concentration 
 
It is important to have an idea about how sensitive the predictions are with respect to key 
parameters in the model. Above the influence of partition coefficients on tissue concentration was 
investigated. We also explored the effect of variation in fraction unbound in plasma and the 
metabolic constants (KM and Vmax) on plasma/blood concentration as well. The fraction unbound 
was predicted based on a QSAR model and in fact the value predicted for rat in the rabbit 
simulation. The metabolic constants were experimentally determined in rat liver microsomes and 
the corresponding parameters have been predicted for rabbit using interspecies extrapolation.   
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FIGURE 5.5. 
 THE INFLUENCE OF VARIATION IN THE FRACTION UNBOUND IN PLASMA ON THE SIMULATED BLOOD 
CONCENTRATION OF  TEBUCONAZOLE IN RABBITS, AFTER ADMINISTRATION OF A 30 MG/KG BW IV DOSE. 
EXPERIMENTAL DATA ARE SHOWN AS CIRCLES AND SIMULATED CURVES: FU=0.25 YELLOW, FU=0.40 RED, FU=0.53 
BLUE (VALUE FROM QSAR PREDICTION), FU=0.70 CYAN, FU=1.0 GREEN.  THE SCALE OF THE Y-AXIS HAS BEEN 
CHANGED AND HALF OF THE IV PEAK CUT OFF.  
 
The fraction unbound in plasma has significant influence on the blood concentration curve as 
expected, and it is seen that a value of 0.40 gives a perfect match to the experimental data (Figure 
5.5).  The value used in the PBTK model for rabbit has been calculated for rat by interspecies 
extrapolation based on a prediction made by a human QSAR model. Significant uncertainties are 
introduced by the interspecies extrapolation, as well as in the original QSAR prediction. Thus a fu 
value of 0.40 is within the uncertainty that might have been introduced by these operations. (We 
used the original predicted rat value in our analysis, but one can choose an adjusted value for rabbit 
instead.)  
 
The variation in the simulated tebuconazole levels introduced by multiplying or dividing the 
experimentally determined metabolic constants by a factor of two, is around 7 µmol/l for the 
maximum velocity and 4 µmol/l  for KM (Figure 5.6). The simulation is very sensitive to two-fold 
variation in these parameters. Multiplying and dividing by factor of 10 does introduces much more 
significant variation with respect to the experimental concentration, prolonging the time period 
until all the tebuconazole has been metabolised.  
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FIGURE 5.6.  
THE INFLUENCE OF VARIATION IN VMAX  (A) AND KM (B) ON THE SIMULATED BLOOD CONCENTRATION OF  
TEBUCONAZOLE IN RABBITS, AFTER ADMINISTRATION OF A 30 MG/KG BW IV DOSE. EXPERIMENTAL DATA ARE 
SHOWN AS CIRCLES AND SIMULATED CURVES USING METABOLIC CONSTANTS OBTAINED BY INTER-SPECIES 
EXTRAPOLATION BASED ON EXPERIMENTAL DATA FROM RAT ARE BLUE. SIMULATIONS WITH 10 X SMALLER VMAX  
AND KM  (YELLOW CURVES), 2 X SMALLER (RED), 2 X LARGER (CYAN), 10 X LARGER (GREEN).    
 
5.1.2 Validation and analysis based available data in rats 
 
A data set of plasma concentrations up to 72 hours after oral administration of  tebuconazole to rats 
[phenyl-UL-14C]tebuconazole cited by Joint FAO/WHO Meeting on Pesticide Residues has been 
published  (JMPR, 2010). The plasma concentration of the whole radioactivity (tebuconzole + 
metabolites) was measured after giving an oral dose of tebuconazole, 2 mg/kg BW and 20 mg/kg 
BW, respectively. Both data from male and female rats were collected at each dose, and five test 
animals were used for each data point.  
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As these data measured the whole radioactivity and not the part which is unmetabolized 
tebuconazole, these data are only of limited value for validation purposes. What is worse is that the 
levels of total radioactivity were a very low fraction of the administered dose, indicating that most of 
the metabolites were eliminated instantaneously. According to the available excretion data, this is 
not likely to be the case, and thus it seems that something is wrong with these data (The same data 
set was given in Draft Assessment Report for tebuconazole as well (European Commission, 2007b)). 
 
The input of the administered dose from the GIT tract to the liver is simulated by a pulse function, 
using an absorption rate constant (ka) which controls how fast the tebuconazole is delivered to the 
liver. As discussed before, practically all the tebuconazole is absorbed in rat, and thus the fractional 
absorption was set to 1.0. Detailed information on the absorption rate was not available. The Joint 
FAO/WHO Meeting on Pesticide Residues (JMPR, 2010) estimated that all the tebuconazole was 
absorbed within an hour in rat. However, no detailed observations were provided to support this 
information. Setting a realistic value for the absorption rate constant is therefore a challenge. 
 
As discussed in section 3.3.2.2, half-lives of the two enanti0mers were measured to be 22 min. and 
49 min in male rat microsomes, respectively. An average for a racemic mixture is thus 36 min., 
according to these measurements. These experiments are, however, made in a well stirred in vitro 
system, where the whole applied dose of tebuconazole was available to the metabolic enzymes from 
the beginning. In an in vivo experiment using oral administration, the dose is administrated 
reaches the liver over a period of time, and it would be oversimplification to assume that the 
metabolism can occur as fast in a rat liver, as in a well stirred cell model for a rat liver.  
 
The simulated amount of tebuconazole absorbed from the GIT to the liver and the total amount 
metabolites formed is shown on Figure 5.7.  As we do not know the exact value of the absorption 
rate, we have carried out simulations at different ka values.  According to a simulation where ka is 
set to 0.5 hr-1, half of the tebuconazole has been metabolized approximately. 1 hr and 40 min. after 
administration, which corresponds to the half-life obtained from these simulations. Changing the 
absorption constant, ka, to 1 and 2 hr-1 gives half lives of 50 min and 30 min, respectively, which is 
close to the half live measured in vitro in rat liver microsomes. Based on the analysis of half-lives 
and the JMPR estimate of one hour absorption time, the absorption rate constant, ka = 1 hr-1, was 
used for simulating absorption of an oral bolus dose.  
 
It is worth noticing that the experimental metabolic constants for tebuconazole do model the fast 
conversion of tebuconazole, which is experimentally observed. Thus according to this simple 
investigation of half-lives, the experimental metabolic constants seem to be reliable. 
 
Figure 5.8. shows the same data as Figure 5.7 (b) for the full simulation time, and the total masses 
of tebuconazole (AC1M0, total_massCiM0) and metabolites (AC1M1, total_massC1M1) in the rats body 
according to the simulation. These data illustrate the fast metabolism of tebuconazole, and that 
around 99% of the metabolites have been excreted from the rats body 72 hr after administration. 
The simulation at oral dose of 2 mg/kg BW is practically the same, but the amounts are lower by a 
factor of ten. 
 
By looking closer at Figure 5.8, it can be seen that according the simulation less than 1 µmol of 
tebuconazole is distributed in the different tissues and organs in the time period from one to seven 
hrs after administration of 20 mg/kg BW (16 µmol) tebuconazole (i.e. the difference between the 
total mass of C1M0 curve and the curve for the remaining tebuconazole in the GIT).  In the same 
time period there are 12-14 µmol of different tebuconazole metabolites in the rat body. If we make 
an experiment where all the tissue blood partition coefficients are changed to 1, which means that 
the compound is equally distributed between blood and tissue, less than one µmol of tebuconazole 
is distributed in the rat body in the first one and a half hour of the simulation, and after that 
practically no tebuconazole is found. According to this, only the partitioning to tissue and organs 
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causes the tebuconazole to be distributed in low concentrations in the rat body, hindering that all 
the tebuconazole would be metabolized as soon as it enters the body.  
 
(a) 
 
(b) 
FIGURE 5.7.  
SIMULATED AMOUNT OF TEBUCONAZOLE IN THE GIT (AOL) (THE DECREASE IN AOL IS THE INPUT TO THE LIVER) AS 
A RESULT OF AN ADMINISTERED ORAL BOLUS DOSE OF 2 MG/KG BW (A) AND 20 MG/KG BW (B), AND THE 
CORRESPONDING AMOUNT OF METABOLITES FORMED IN THE LIVER (AML). THE Y-AXIS IS THE AMOUNT OF 
TEBUCONAZOLE OR METABOLITES IN [µMOL] AND THE X-AXIS IS THE TIME FROM ADMINISTRATION IN [HR]. THE 
BLACK AOL CURVE AND THE CYAN AML CURVE RESULT FROM A SIMULATION WITH THE ABSORPTION RATE 
CONSTANT KA SET TO 2 HR-1, THE CORRESPONDING CURVES FOR KA SET TO 1 HR-1 ARE MAGENTA AND YELLOW, AND 
THE FOR KA SET TO 0.5 HR-1  BLUE AND GREEN. IT IS SEEN THAT ACCORDING TO THE SIMULATION, HALF OF THE 
ADMINISTERED DOSE HAS BEEN METABOLIZED AFTER CA. 30 MIN FOR KA=2 HR-1, CA. 50 MIN FOR KA=1 HR-1  AND 
CA. 1 HR AND 40 MIN FOR KA=0.5HR-1 . 
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FIGURE 5.8.  
SIMULATED AMOUNT OF TEBUCONAZOLE LEFT IN THE GIT (AOL) (CYAN LINE) AS A RESULT OF AN ORALLY 
ADMINISTERED BOLUS DOSE OF 20 MG/KG BW, THE CORRESPONDING AMOUNT OF COMPOUND METABOLIZED IN 
THE LIVER (AML) (VIOLET) AND THE RESPECTIVE TOTAL AMOUNTS OF TEBUCONAZOLE (TOTAL MASS OF C1M0, 
GREEN) AND METABOLITES (TOTAL MASS OF C1M1, BLUE) IN THE RATS BODY IN [µMOL] (Y-AXIS). THE X-AXIS 
SHOWS THE TIME FROM ADMINISTRATION IN [HR].  THE SIMULATION WAS MADE USING KA=1 HR-1.   
 
The elimination rate constants were optimized by a curve fit to the male high dose group, and the 
corresponding data for the low dose grouped served as a validation set, see section 3.3.2.3 for 
details.  
 
The excretion part was also validated on data for rhesus monkeys that had received an iv or a 
dermal dose of radio labelled tebuconazole (European Commission, 2007b) . The content of the 
radio labelled dose was measured in urine, faeces and by cage wash, and the data was used as 
validation sets. For this purpose, a rhesus monkey version of the PBTK was implemented, where the 
elimination rate constant and the metabolic constants were determined by interspecies 
interpolation based on the rat parameters.  
 
It was indeed seen that the simulated curves match the experimental data, showing that both the 
elimination rate constants adjusted to rat data, as well as the inter-species extrapolation procedure 
give accurate results. See Figure 3.9 and detailed description in section 3.3.2.3. The part of the dose 
not found in the excretion was recovered by washing the skin (100% total recovery in one 
experiment, and 88% recovery of material in the other experiment). Based on our validation results, 
we can conclude that the part of the tebuconazole absorbed through the skin eliminates at a 
corresponding rate to the orally administrated tebuconazole. 
 
In addition to the data from dermal exposure experiments on rhesus monkeys, data from rat studies 
are available in DAR as well (European Commission, 2007b) . The data for rhesus monkeys was 
only useful for validating the excretion part of the model, as the animals were not sacrificed and 
blood or tissue samples were not taken. In the rat experiment, concentrations in skin, blood, 
carcass, urine and faeces was measured at various time points after dermal dosing for four different 
dose groups. The non-absorbed material was washed of the skin.  
 
The overall total recovery in the rat study was almost complete, but the excretion rates were much 
slower according to these data than the corresponding data for the oral experiment. In the two 
lowest dose groups around 25% of the absorbed dose was excreted after 24 hr of exposure and in 
the oral experiments over 60% of the administered dose was excreted 24 hrs post dosing. Almost all 
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the tebuconazole was absorbed after 30 min of exposure (the first time point), indicating that the 
dermal absorption of tebuconazole dissolved in ethanol is rapid. This relatively slow elimination 
rate and high skin content of radio labelled material found in the rat study indicates two 
possibilities. One is that tebuconazole behaves differently in rat skin than rhesus monkey skin and 
another is that the washing procedure did not remove all the non-absorbed material,  and that some 
non-absorbed material were measured as part of the skin content. Danish EPA has referred to this 
study as an erroneous study that overestimated the dermal absorption in rat, and our results 
support this evaluation.  
 
5.1.3 Validation using rat data for female rats from the PestiMix project 
 
In a report be Hass and co-workers  (Hass and et al., 2012), blood samples were taken from two-
three female rats after treatment with tebuconazole in a mixture with other compounds. This was a 
repeated dose experiment where the animals were given a daily dose of 12.5 and 25 mg 
tebuconzole/ kg BW, and sacrificed on day 13 after birth. Blood sample was taken between 1-5 hrs. 
after the last oral dose was given. The two dams in the lower dose group had blood concentrations 
between 1.7 and 2.7 µmol/l and the three dams from the higher dose group had blood 
concentrations in the range 3.7-25 µmol/l, with a median of 6.6 µmol/l. These results illustrate 
relatively large variation between the three test animals.  
 
Our simulation (ka=1 hr-1) at the lower dose gave blood concentration of 1.6-0.25 µmol/l 1-5 hrs. 
after administration, and at the higher dose values 3.5-0.50 µmol/l in the same time range. (The 
results using oral absorption rate constants of ka=0.5 and ka=2 hr-1 were similar, illustrating that 
this result is not significantly influence by uncertainties in the absorption rate.)  The simulated and 
the experimental result can be considered to be of the same order of magnitude, especially for the 
low dose group. 
 
These are obviously not optimal data for validation of a PBTK model, as it is a repeated dose 
mixture experiment in female rats and the blood concentration is not measured at a well defined 
time point. As this is a mixture experiment, there might be issues with limited metabolic capacity of 
the liver enzymes, especially if the compounds in the mixture are using the same cytochrome P450 
(CYP) enzymes. To get an idea if the chemical mixture would reach the maximum metabolic 
capacity of the actual CYPs in the liver, we run a simulation with up to five-fold portion of the 
administered dose. We thus assume that all the pesticides are competing for the same CYP enzymes 
and that they have depletion rates corresponding to tebuconazole. This is not correct of course, but 
it gives us an indication on if the mixture could be affecting the results above. 
 
The rate of metabolism was not significantly reduced in the simulations carried out for the lower 
dose group up to a five-fold dose. For the high dose group the metabolic rate was significantly lower 
for three-fold portion of tebuconazole, and saturation was clearly reached. Saturation of the 
metabolic capacity leads to blood concentrations that are relatively higher fraction of the 
administered dose, compared to situations were the full metabolic capacity is available. As a result 
the measured blood concentrations would be higher than it would be the case if the compound was 
given in the dose as a single compound.  This is likely to be the case for the higher dose group, but 
not necessarily problem for the lower dose group. 
 
Thus one should use these validation results with caution, as they can of course not give accurate 
estimates of the model performance. They give us, however, a rough estimate that the blood 
concentrations simulated with our model, seem to be within appropriate range of the experiment. 
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5.1.4 Sensitivity of key parameters on blood concentration 
 
We also explored the sensitivity of variations in fraction unbound in plasma and the metabolic 
constants (KM and Vmax) on plasma/blood concentration for rat, like for the rabbit data. The 
simulations were made for the lower dose group (2 mg/kg BW) and the absorption rate constant 
(ka) was set to 1 hr-1 for this analysis, as discussed above.  
 
The fraction unbound in plasma was varied from 0.25 to 1.0 and like for rabbit data it showed 
significant influence on the blood concentration curve as expected (Figure 5.9). The two-fold 
variation the metabolic constants lead to a change of up to twice the peak concentration, while the 
form of the curves is similar (Figure 5.10), which is comparable to the corresponding change in the 
rabbit data.   
 
 
 
FIGURE 5.9.  
THE INFLUENCE OF VARIATION IN THE FRACTION UNBOUND IN PLASMA ON THE SIMULATED BLOOD 
CONCENTRATION OF  TEBUCONAZOLE IN RATS AFTER ORAL ADMINISTRATION, DOSE GROUP 2 MG/KG BW. 
SIMULATED CURVES: FU=0.25 (YELLOW), FU=0.40 (GREEN), FU=0.53 (RED) (VALUE FROM QSAR PREDICTION), 
FU=0.70 (BLUE), FU=1.0 (VIOLET).   
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(a) 
 
(b) 
 
FIGURE 5.10.  
THE INFLUENCE OF VARIATION IN VMAX (A) AND KM (B) ON THE SIMULATED BLOOD CONCENTRATION OF 
TEBUCONAZOLE IN RATS AFTER ORAL ADMINISTRATION, DOSE GROUP 2 MG/KG BW (RED). SIMULATED CURVES: 2 
X SMALLER (GREEN), EXPERIMENTAL VALUE FROM RAT (RED), 2 X LARGER (BLUE).    
 
 
5.2 Validation and analysis of PBTK model for prochloraz 
 
Like for tebuconazole, the data set published in DAR ( European Commission, 2010e), shows the 
blood concentration of the total radioactivity (prochloraz + metabolites) at different time points 
after administration by oral bolus dose.  Data from two dose groups, 10 and 100 mg/kg BW, each 
measured in male and female found in DAR. This data set is not particularly useful for use for 
model validation, as the fraction of prochloraz in the total radioactivity is not specified. We have not 
been able to find data on the concentration of prochloraz only in blood and tissues. Therefore we 
have very limited data for model validation. 
 
We calculated the amount of prochloraz left in the GIT, the amount metabolized and the total 
amount of prochloraz and metabolites in the rat body after administration of 20 mg/kg BW 
prochloraz by an oral bolus dose, Figure 5.11. Simulation was both carried out by calculating the 
depletion rate of prochloraz with the experimental intrinsic clearance value from Wetmore et al. 
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(Wetmore et al., 2012), as well as using the metabolic constants from similar reactions. The 
resulting curves are practically identical, indicating that the last mentioned implementation can be 
used to estimate the metabolic rate at doses where saturation of the metabolic enzymes has been 
reached. That the match is so exact is of course a mere coincidence. 
 
(a) 
 
(b) 
 
FIGURE 5.11.  
SIMULATED AMOUNT OF PROCHLORAZ LEFT IN THE GIT (AOL) (BLUE LINE) AND THE CORRESPONDING AMOUNT OF 
COMPOUND METABOLIZED IN THE LIVER (AML) (GREEN) IN RAT AS A RESULT OF ORALLY ADMINISTERED BOLUS 
DOSE OF 20 MG/KG BW USING EXPERIMENTAL CLINT  FOR PROCHLORAZ (A) OR VMAS OG KM FOR SIMILAR 
METABOLIC REACTIONS (B) (KA=1 HR-1).  THE GRAPH ALSO SHOWS THE RESPECTIVE TOTAL AMOUNTS OF 
PROCHLORAZ (TOTAL MASS OF C1M0, CYAN) AND METABOLITES (TOTAL MASS OF C1M1, BLACK) IN THE RATS BODY.  
IT IS SEEN THAT THE DIFFERENT PARAMETERS FOR DESCRIBING THE METABOLISM BASICALLY GIVE IDENTICAL 
RESULT, AND THAT PROCHLORAZ UNDERGOES FAST METABOLISM IN THE LIVER AFTER ADMINISTRATION 
(DIFFERENCE BETWEEN THE CYAN AND THE BLUE CURVES) ACCORDING TO THESE RESULTS. 
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The calculated half-life is around 50 min. in both cases, with the oral absorption rate constant (ka) 
set to 1 hr-1 (Figure 5.11). In another simulations using ka=0.3 hr-1, rendered half-life of two and a 
half hours (Figure 5.12).  We made simulations of the concentration of prochloraz in blood after 10 
and 100 mg/kg BW oral dose and compared with the experimental data for the total radioactivity 
(prochloraz + metabolites). We did the simulation using two different values for the fraction 
unbound for rat, obtained by inter-species extrapolation of the experimental human in vitro value 
and the value predicted by QSAR.  The absorption rate constant was set to 0.3 hr-1, such that the 
prochloraz did not have higher concentration alone than the combined concentration of prochloraz 
and metabolites. The accuracy of these predictions cannot be validated based on these data, but the 
curves are presented here for illustration (Figure 5.13). 
 
 
 
FIGURE 5.12  
SIMULATED AMOUNT OF PROCHLORAZ LEFT IN THE GIT (AOL) (BLUE LINE) AND THE CORRESPONDING AMOUNT OF 
COMPOUND METABOLIZED IN THE LIVER (AML) (GREEN) IN RAT AS A RESULT OF ORALLY ADMINISTERED BOLUS 
DOSE OF 20 MG/KG BW USING EXPERIMENTAL CLINT  FOR PROCHLORAZ  AND KA=0.3 HR-1 THE GRAPH ALSO SHOWS 
THE RESPECTIVE TOTAL AMOUNTS OF PROCHLORAZ (TOTAL MASS OF C1M0, CYAN) AND METABOLITES (TOTAL 
MASS OF C1M1, BLACK) IN THE RATS BODY. 
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(b) 
 
FIGURE 5.13.  
SIMULATED BLOOD CONCENTRATIONS OF PROCHLORAZ AND THE EXPERIMENTAL DATA (CIRCLES) FOR THE 
TOTAL RADIOACTIVITY (PROCHLORAZ + METABOLITES) IN RAT AFTER ADMINISTRATION BY ORAL BOLUS DOSE OF 
10 MG/KG BW (A) AND 100 MG/KG BW (B).  THE BLACK CURVE IS THE SIMULATION RESULT WITH FU=0.13 
(EXTRAPOLATED BASED ON THE QSAR PREDICTION FOR HUMAN) AND THE CYAN CURVE IS MADE WITH FU=0.041 
(EXTRAPOLATED BASED ON THE EXPERIMENTAL VALUE IN HUMAN. THE YELLOW AND RED CURVE IS THE MEAN 
BODY CONCENTRATION OF THE METABOLITES.  
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FIGURE 14. BLOOD CONCENTRATIONS OF PROCHLORAZ AFTER ORAL ADMINISTRATION I RAT, WHERE 
METABOLISM IS SIMULATED USING INTRINSIC CLEARANCE, THE BLUE CURVE FOR 100 MG/KG BW DOSE AND 
MAGENTA CURVE FOR 200 MG/KG BW DOSE, OR METABOLIC CONSTANTS FOR SIMILAR REACTIONS, THE GREEN 
CURVE FOR 100 MG/KG BW DOSE AND RED CURVE FOR 200 MG/KG BW DOSE. SATURATION OF THE METABOLIC 
PATHWAY IS SIMULATED AT THE HIGHER DOSE. THE SIMULATION WAS MADE WITH KA=0.3 HR-A AND FU=0.041. 
 
Figure 5.14 illustrates that the metabolic enzyme capacity is saturated at higher dose, and thus one 
cannot accurately simulate the metabolism at higher doses using the first order kinetics and 
intrinsic clearance. Such high exposures are not relevant considering realistic exposures to 
prochloraz in daily live, and thus for any practical purpose the first order kinetic implementation 
should be considered sufficient.   
 
The adjustment and validation of the elimination rates is shown in section 3.3.2.3.  
 
5.2.1 Validation using rat data for female rats from the PestiMix project 
 
The mixture study by Hass and co-workers  (Hass and et al., 2012) also contained prochloraz, the 
blood samples data taken from two-three female rats after treatment with a mixture were used for 
validating the prochloraz model as well. This was a repeated dose experiment where the animals 
were given a daily dose of 8.75 and 17.5 mg prochloraz/ kg BW, and sacrificed on day 13 after birth. 
Blood sample was taken between 1-5 hrs. after the last oral dose was given. The two dams in the 
lower dose group had blood concentrations between 0.08 and 0.16 µmol/l and the three dams from 
the higher dose group had blood concentrations in the range 0.14-0.74 µmol/l, with a median of 
0.20 µmol/l. These results illustrate relatively large variation between the three test animals.  
 
Our simulation (ka=0.3 hr-1 and fu=0.041) at the lower dose gave blood concentration of 5.9-2.4 
µmol/l 1-5 hrs. after administration, and at the higher dose groups values 12-4.8 µmol/l in the same 
time range.  We rerun the simulations using the fraction unbound based on a QSAR prediction 
(ka=0.3 hr-1 and fu=0.13). At the lower dose the resulting blood concentration was 1.9-0.7 µmol/l 1-5 
hrs. after administration, and at the higher dose 3.8-1.5 µmol/l in the same time range.  The 
simulated result was at least 10 times higher than the experimental result. (ka was set to 0.3 hr-1 in 
these simulation, and this parameters also influence the predicted values.)  
 
One should use these validation results with caution, and consider this as a rough estimate that the 
blood concentrations simulated with our model seem  to be somewhat overestimated compared to 
the experimental data. 
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5.2.1.1 Sensitivity of key parameters on simulated blood concentration 
 
We explored the sensitivity of variations in the absorption rate constant, the fraction unbound in 
plasma and the intrinsic clearance (CLint) on blood concentration for rat. The simulations were 
made for the lower dose group (10 mg/kg BW).  
 
The absorption rate constant controls the form of the pulse function by which the oral dose is 
administered to the liver, primarily influences the blood concentration curve in the first hours of the 
simulation, and has significant impact to the peek concentration (Figure 5.15). The higher the ka 
value, the faster the oral bolus dose is administered to the liver, the higher peak concentration and 
the faster the depletion of prochloraz is done. 
  
The fraction unbound in plasma was varied from 0.02 to 0.13 showing significant influence on the 
blood concentration curve as expected (Figure 5.16a). Two-fold decrease in the intrinsic clearance 
caused the peak blood concentration to become twice as large, and vice versa (Figure 5.16b).  
 
 
 
FIGURE 5.15.  
THE INFLUENCE OF VARIATION IN ABSORPTION RATE CONSTANT ON THE SIMULATED BLOOD CONCENTRATION 
OF PROCHLORAZ IN RAT, DOSE GROUP 10 MG/KG BW. SIMULATED CURVES: KA=0.30 HR-1 BLACK (VALUE USED IN 
SIMULATIONS), KA=0.5 HR-1 CYAN, KA=1.0 HR-1 VIOLET.  
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FIGURE 5.16.  
(A) THE INFLUENCE OF VARIATION IN THE FRACTION UNBOUND IN PLASMA ON THE SIMULATED BLOOD 
CONCENTRATION OF PROCHLORAZ IN RATS, DOSE GROUP 10 MG/KG BW. EXPERIMENTAL DATA AS CIRCLES AND 
SIMULATED CURVES: FU=0.02 CYAN, FU=0.042 (VALUE EXTRAPOLATED FROM THE HUMAN IN VITRO EXPERIMENT) 
BLACK AND FU=0.13 CYAN (VALUE BASED ON THE QSAR PREDICTION) VIOLET. (B) THE INFLUENCE OF VARIATION 
IN CLINT (A) ON THE SIMULATED BLOOD CONCENTRATION OF PROCHLORAZ IN RATS, DOSE GROUP 10 MG/KG BW. 
SIMULATED CURVES USING 2 X SMALLER THAN THE EXPERIMENTAL VALUE (CYAN), THE EXPERIMENTALLY 
DERIVED VALUE (BLACK), AND 2 X LARGER VALUE (VIOLET).    
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5.3 Binary models 
 
5.3.1 Simulations and validation for a binary mixture of R and S tebuconazole in 
rat 
 
Simulations were carried out with the binary model for the R- and S-tebuconazole treated as two 
different compounds. The main model for tebuconazole uses the mean metabolic constants 
measured for the R and the S form and treats tebuconazole as one compound, whereas the binary 
model uses the measured metabolic constants for each of the two forms (Table 3.6), and takes 
inhibition of the other enantiomer into account.  
 
It is seen in Figure 5.17 that the R form has the fastest metabolism (lowest blood concentration) and 
the S form the slowest. The intrinsic clearance of the R form was 1.26 times greater than the one of 
the S form according to the measurements by Shen et al. (Shen et al., 2012). Their interaction study 
shows that IC50 for R-tebuconazole inhibiting S-tebuconazole is five times larger than the 
corresponding value for S-tebuconazole inhibiting R-tebuconazole. Yet the inhibition constant (KI 
value) of the latter reaction is slightly lower than for the first one. 
 
 The blood concentration of the racemic mixture is in between the curves for R and S in the low dose 
simulations, but only slightly lower than the S form curve in the higher dose mixture. The effect of 
the inhibition is significant in the simulation for the 20 mg/kg dose group, and only slight effect is 
seen in the simulation for the 2 mg/kg BW dose group (the yellow and the cyan curves almost 
overlap one another).  Thus, it is seen that the capacity of the metabolic enzymes is reduced for the 
higher dose group, and thus competitive inhibition takes place, whereas for the low dose group 
inhibition has not started to show any effect.  
 
  
96 Optimization of the cumulative risk assessment of pesticides and biocides using computational techniques: Pilot project 
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(b) 
 
 
FIGURE 5.17.  
(A) SIMULATIONS OF THE TOTAL BLOOD CONCENTRATION OF TEBUCONAZOLE IN RAT RESULTING FROM AN ORAL 
DOSE OF 2 MG/KG BW PURE R- (BLUE CURVE) AND S- (RED CURVE) TEBUCONAZOLE, AND A RACEMIC MIXTURE OF 
R AND S, 1 MG/KG BW OF EACH ENANTIOMER (CYAN CURVE). (B) THE CORRESPONDING SIMULATION FOR A TOTAL 
DOSE OF 20 MG/KG BW. THE YELLOW CURVES ARE SIMULATIONS FOR THE RACEMIC MIXTURES IN EACH DOSE 
GROUP, WITH NO INHIBITION CONSIDERED, ILLUSTRATING THE IMPACT INHIBITION HAS ON THE BLOOD 
CONCENTRATION. 
 
Figure 5.18 illustrates the increased effect of the competitive inhibition at a dose of 100 mg/kg BW. 
The effect of the inhibition is very significant at this dose, and the peak blood concentration of the 
racemic mixture is now significantly larger than the level for the respective enantiomers, indicating 
that the racemic mixture metabolises slower than the pure enantiomers.  
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FIGURE 5.18.   
SIMULATIONS OF THE TOTAL BLOOD CONCENTRATION OF TEBUCONAZOLE IN RAT RESULTING FROM AN ORAL 
DOSE OF 100 MG/KG BW PURE R (BLUE CURVE) AND S (RED CURVE) TEBUCONAZOLE, AND A RACEMIC MIXTURE OF 
R AND S, 50 MG/KG BW OF EACH ENANTIOMER (CYAN CURVE). IT IS SEEN THAT EFFECT OF INHIBITION HAS 
BECOME SO LARGE THAT THE RACEMIC MIXTURE METABOLISES SLOWER THAN THE PURE ENANTIOMERS. THE 
YELLOW  CURVE SHOWS SIMULATION FOR THE RACEMIC MIXTURE WITH NO INHIBITION CONSIDERED. 
 
5.3.2 Simulations for a binary mixture prochloraz and tebuconazole in rat 
 
As we do not have experimental data for the inhibition constants between prochloraz and 
tebuconazole, we have used values for the R- and S- tebuconazole a worst case possibility, and then 
used inhibition constants found in the literature for a range of compounds as an inspiration too. 
 
The two tebuconazole enantiomers are metabolised by the same CYPs and thus one can expect 
those to inhibit one another rather strongly, which is also seen in the high dose simulations above. 
Prochoraz and tebuconazole only partly use the same CYPs according to available information from 
our QSAR predictions (section 4.1.1). Thus according to the QSAR models prochloraz was predicted 
to be a CYP2C9 substrate, and the prediction on whether it is also an inhibitor was inconclusive. 
Tebuconazole was predicted to be a CYP2C9 inhibitor, and not a CYP2C9 substrate. Tebuconazole is 
predicted to be both a substrate and an inhibitor to CYP3A4, whereas for prochloraz the 
corresponding predictions were inconclusive. 
 
In order to explore the potential effect of inhibition, we made a series of simulation where we set up 
theoretical criteria, and used the results to draw conclusion on effects that could be caused by 
inhibition. Simulations were made at relatively low doses, up to extremely high doses, in order to 
explore the effect of inhibition for broad range of exposures. 
 
We made a series of simulation were the inhibition constant (KI) was set to 1, 5, 50 and 500 µmol/l 
(µM) for both compounds, respectively. KI =5 µM is the mean of the values determined for R- and 
S-tebuconazole, KI =50 µM is in the range of values seen for many compounds in the literature 
(Timchalk and Poet, 2008; El-Masri et al., 2004),  1 µM to visualize the effect of very strong 
inhibition and 500 µM for low or no inhibition at the dose levels considered (Figure 5.19). 
 
It is seen that the blood levels are fairly different for pure prochloraz and tebuconazole, respectively, 
mostly because significantly larger portion of the prochloraz is bound the plasma proteins. The 
depletion rates for these compounds were seen to be rather similar, only giving a minor 
contribution to the different blood levels of these two compounds. For the 10 mg/kg BW dose group 
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(for the mixture 5 mg/kg BW were administered for each of the two compounds in the simulation), 
only significant inhibition was seen for KI =1 µM. This is not a likely scenario, as this would require 
stronger inhibition between the two compounds, than between R- and S-tebuconazole. For the 100 
mg/kg BW dose group inhibition is seen for KI =5 µM as well, and at KI =1 µM an overload of the 
metabolic pathways seems to occur, causing a different form of the curve. 
 
(a) 
 
(b) 
 
FIGURE 5.19.  
SIMULATIONS OF THE COMBINED BLOOD LEVELS (C1M0+C2M1) MADE FOR A BINARY MIXTURE OF PROCHLORAZ 
AND TEBUCONAZOLE IN RAT AT (A) 10 MG/KG BW OF PURE COMPOUNDS AND 5 MG/KG BW FOR EACH COMPOUND 
IN A MIXTURE AND (B) 100 MG/KG BW OF PURE COMPOUNDS AND 50 MG/KG BW FOR THE COMPOUNDS IN A 
MIXTURE. PURE TEBUCONAZOLE (VIOLET), PURE PROCHLORAZ (GREEN), MIXTURE OF PROCHLORAZ AND 
TEBUCONAZOLE KI = 1 µM (BLACK), KI = 5 µM (RED), KI = 50 µM (YELLOW), KI = 500 µM (BLUE). THE SAME KI VALUE 
WAS USED FOR BOTH COMPOUNDS IN THIS SIMULATION. 
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(a) 
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(c) 
FIGURE 5.20.  
THE BLOOD CONCENTRATIONS OF PROCHLORAZ (C1M0) AND TEBUCONAZOLE (C2M0) IN RAT, WITH EACH 
COMPOUND ADMINISTERED BYAN  ORAL BOLUS DOSE OF (A) 1, (B) 10 AND (C) 50 MG/KG BW.  SIMULATION 
WITHOUT INHIBITION (C1M0 CYAN CURVE, C2M0 RED CURVE), WITH TEBUCONAZOLE INHIBITING PROCHLORAZ 
KI(C2M0,C1M0) = 5 µM (C1MO BLUE, C2MO VIOLET), AND WITH BOTH COMPOUNDS INHIBITING ONE ANOTHER 
KI(C2M0,C1M0) = KI(C1M0,C2M0) = 5 µM (C1M0 BLACK, C2M0 GREEN). 
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In another series of simulation we calculated the blood concentration levels of prochloraz and 
tebuconazole, respectively, where no inhibition took place, where tebuconazole inhibited prochloraz 
with KI =5 µM, and where both compounds inhibited one another with KI =5 µM (Figure 5.20). At 
the lowest dose where the compounds were administered by 1 mg/kg BW each, no inhibition effect 
was seen. At the higher doses increased effects on the inhibition are seen as increased blood levels. 
At dose level of 50 mg/kg BW of each compound and higher, significant influence of inhibition is 
seen. 
 
We also explored the liver concentrations for the same series of simulations (Figure 5.21). Like for 
the blood concentration no inhibition effects were seen at the lowest dose, 1 mg/kg BW of each 
compound. At the higher doses increased effects on the inhibition are seen as increased blood 
levels. At dose level of 50 mg/kg BW of each compound and higher significant influence of 
inhibition is seen for both compounds. Due to the different concentration levels, the inhibition of 
prochloraz is not very clear on the figure, but it does happen. 
 
Prochloraz is only distributed to the liver in low concentrations, caused by the low fraction 
unbound. This is strange, as there are documented liver toxic effects associated with prochloraz. 
 
For one of these dose groups, namely 10 mg/kg BW of each compound, an additional simulation 
was made where the predicted Pliver:b (the liver:blood partition coefficient) was multiplied by two for 
each compound (Figure 5.22). This was done to illustrate the influence uncertainty in this 
parameter has on the resulting liver concentrations.   
 
It is seen that the liver levels are around twice as high as the liver levels simulated with the original 
prediction Pliver:b. The peak concentration in the liver is thus doubled when the liver: blood partition 
coefficient is multiplied by a factor of two. If this parameter is multiplied by four the peak 
concentration become four time as high.  We do not have sufficient data at present to adequately 
evaluate the uncertainty of this parameter.  
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(a) 
(b) 
(c) 
FIGURE 5.21.  
THE SIMULATED LIVER CONCENTRATIONS OF PROCHLORAZ (C1M0) AND TEBUCONAZOLE (C2M0) IN RAT, WHERE 
EACH COMPOUND WAS ADMINISTERED BY ORAL BOLUS DOSE OF (A) 1, (B) 10 AND (C) 50 MG/KG BW.  SIMULATION 
WITHOUT INHIBITION (C1M0 YELLOW CURVE, C2M0 GREEN CURVE), WITH TEBUCONAZOLE INHIBITING 
PROCHLORAZ KI(C2M0,C1M0) = 5 µM (C1MO RED, C2MO CYAN), AND WITH BOTH COMPOUNDS INHIBITING ONE 
ANOTHER KI(C2M0,C1M0) = KI(C1M0,C2M0) = 5 µM (C1M0 VIOLET, C1M0 BLUE). THE LIVER:BLOOD PARTITION COEFFICIENTS 
WERE USED. 
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(a) 
 
(b) 
 
FIGURE 5.22.  
(A) THE SIMULATED LIVER CONCENTRATIONS OF PROCHLORAZ (C1M0) AND TEBUCONAZOLE (C2M0) IN RAT, 
WHERE EACH COMPOUND WAS ADMINISTERED BY ORAL BOLUS DOSE OF 10 MG/KG BW. IN THIS SIMULATION, 
BOTH COMPOUNDS INHIBITED ONE ANOTHER KI(C2M0,C1M0) = KI(C1M0,C2M0) = 5 µM AND THE SIMULATION WAS CARRIED 
WITH THE PLIVER:B AS PREDICTED (TABLE 3.5) (C1M0 YELLOW, C2M0 GREEN), AND THE PREDICTED VALUE 
MULTIPLIED BY TWO (C1M0 RED, C2M0 CYAN). THIS WAS DONE TO ILLUSTRATE THE INFLUENCE OF EVENTUAL 
UNCERTAINTIES IT THIS PARAMETER ON THE SIMULATED LIVER LEVELS. (B) THE CURVES FOR PROCHLORAZ 
SHOWED ON A SMALLER SCALE. 
 
 
  
Optimization of the cumulative risk assessment of pesticides and biocides using computational techniques: Pilot project 103 
 
5.4 Predictions for specific exposure criteria in humans 
 
5.4.1 Exposure scenarios 
 
5.4.1.1 Dietary exposure 
 
The oral exposure criteria are based on detected pesticide residues in food for human nutrition, sold 
on the Danish market. It was decided in collaboration with the Danish EPA to use evaluations on 
oral consumption of tebuconazole and prochloraz from a recent report over pesticide residues found 
in samples from commodities of food (fruit, vegetables, cereals, etc.) on the Danish market from 
2004 and 2011 (Petersen et al., 2013). The samples were collected by the pesticide monitoring 
program under The Danish Veterinary and Food Administration, and the report was prepared by 
the National Food Institute at DTU. 
 
The mean daily consumption of a group a pesticides has been evaluated based on pesticide residues 
found in food in 2004-2011. According to the report, the mean consumption is 0.0064 µg/ kg 
BW/day for prochloraz and 0.013 µg/ kg BW/day for tebuconazole (Table 5.1) (Petersen et al., 
2013).  These values are used as the daily exposure of an average consumer, and are thereby the 
primary oral exposure criteria used in this work. 
 
A consumer that eats more than 550 g/day of fruit and vegetable is assumed to be exposed to twice 
the amount of an average consumer is exposed to, according to the report. This constitutes a second 
exposure criteria used in the report, were the mean exposures are multiplied by two.   
 
For making an estimate of the combined effect of the 13 different triazoles and two imidazoles, one 
pyrazole and two benzimidazoles detected in samples from fruit and vegetables sold in Denmark, 
the daily exposure to all the pesticides were added together.  Following, simulations were made 
where the combined exposure to these 18 compounds was treated as it all came from either 
tebuconazole or prochloraz. In such a way we made an estimate of a combined exposure by 
providing a third exposure criteria to illustrate an example with large exposure. 
 
When implemented in the model, the daily dose is divided equally over 12 hours (7-19 hrs), with the 
remaining 12 hrs as resting time with no exposure. It should be mentioned that according to the 
yearly reports on pesticides residues found in the monitoring program, residues of tebuconazole 
and prochloraz were only found in fruit and vegetables, and not in other products like cereals 
(Jensen et al., 2010; Jensen et al., 2011; Jensen et al., 2012). 
 
  
104 Optimization of the cumulative risk assessment of pesticides and biocides using computational techniques: Pilot project 
 
TABLE 5.1.  
THE ESTIMATED MEAN DAILY CONSUMPTION AND CALCULATED HAZARD QUOTIENTS (EXPOSURE/ADI) OF 
TRIAZOLE, IMIDAZOLE, PYRAZOLE AND BENZIMIDAZOL PESTICIDES FROM RESIDUES IN FRUIT AND VEGETABLES 
ON THE DANISH MARKED BETWEEN 2004 AND 2011 (PETERSEN ET AL., 2013). THESE ESTIMATES ARE BASED 
PESTICIDE RESIDUES FOUND IN FOOD SAMPLES, AND AN ESTIMATE OF THE VOLUME OF FRUIT AND VEGETABLES 
EATEN BY AN AVERAGE CONSUMER ACCORDING DIETARY SURVEYS. CORRECTIONS HAVE BEEN MADE FOR 
PEELING, AND TO ACCOUNT FOR SAMPLES WITH NON-DETECTED RESIDUES.    
 
Active compound Class Exposure Hazard 
Quotient 
  [µg/kg BW/day] [%] 
Bitertanol Triazole 0.009 0.3 
Difenoconazole Triazole 0.0066 0.066 
Diniconazole Triazole 0.0009 0.0045 
Epoxiconazole Triazole 0.000077 0.00097 
Fenbuconazole Triazole 0.00036 0.0059 
Flusilazole Triazole 0.00039 0.02 
Hexaconazole Triazole 0.00037 0.0075 
Imazalil 
(eniconazole) 
Imidazole 0.072 0.29 
Myclobutanil Triazole 0.006 0.024 
Penconazole Triazole 0.0019 0.0064 
Prochloraz Imidazole 0.0064 0.064 
Propiconazole Triazole 0.00035 0.00087 
Tebuconazole Triazole 0.013 0.042 
Tetraconazole Triazole 0.00037 0.0092 
Triadimefon (sum) Triazole 0.028 0.055 
Tebufenpyrad Pyrazole 0.0064 0.064 
Thiabendazole Benzimidazole 0.11 0.11 
Thiophanate-methyl Benzimidazole 0.031 0.039 
Sum / Hazard Index All compounds 0.293 1.11 
Sum / Hazard Index Triazoles/imidazoles 0.146 0.896 
 
 
5.4.1.2 Dermal exposure 
 
The Danish EPA has chosen that we primarily focus on dermal exposure criteria for tebuconazole 
used as pesticide and biocide for professional use.  This is partly due to that the professional 
exposure is the most relevant and partly because the results are needed providing additional 
information and insight for use in their risk assessment of products used on the Danish marked. 
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With regard to dermal exposures to pesticides, is it considered most relevant to consider 
downwards spraying of liquid mixtures on fields by a professional employee from a machine station 
(downwards spraying by a spraying device attached to a tractor). The exposure occurs partly while 
filling a concentrated solution on the spraying equipment and mixing with water, and partly while 
spraying the diluted solution on the field. Dermal absorption of the concentrated solution is lower 
than for the diluted solution, but on the other hand there is substantially larger exposure to the 
concentrated solution (see section 3.3.3.2 for details).  
 
The Danish EPA has provided information on the dermal absorption of two common products and 
the evaluated exposure to those products. See detailed description on exposure to and health 
evaluations of these products in Appendix 9.  The exposure is evaluated on the basis of a model for a 
professional spraying 20 ha field per day. Protection due to clothing and gloves is included in the 
exposure model, but data without use of gloves are provided as well (see section 3.3.3.1). 
 
Exposure of a profession spraying pesticide mixtures downwards by a tractor, is estimated to take 8 
hrs. a day (8-16 hrs), 5-7 days a week.  
 
The Danish EPA has provided data on dermal absorption of water and solvent based formulations 
of tebuconazole used as a biocide, and well as exposure models for these formulations used for 
brushing and for industrial treatment of wood. These data and the provided exposure models are 
presented in Appendix 9. In this report we have primarily focused on solvent based formulations, as 
those are absorbed in larger quantities and the PBTK model is better optimized for simulating 
exposure from solvent based formulations. A concentration of 0.5% w/w is assumed for these 
products, and protection due to clothing and gloves is incorporated in the exposure model. 
 
Biocide exposure due to brushing is estimated to take 3 hrs/day (13-16 hrs), as  the rest of the 
working day would be used for preparing the wood surface for brushing. Industrial wood treatment 
is evaluated to take 4 hrs/day (12-16 hrs) for each employee. Both brushing of wood surfaces and 
industrial wood treatment are considered to be 5 days a week, with a two day break in between.  
 
For all three applications, spraying, brushing and industrial wood treatment, the primary oral 
exposure criteria is assumed as well. Thereby the combined oral and dermal exposure is simulated. 
 
Finally a combined “worst case” scenario with 8 hour spraying, followed by two hour brushing, and 
consumption of >55o g fruit and vegetables per day (the second oral criteria) was constructed. This 
criteria thus combines professional and private usage, professional spraying combined with private 
brushing. 
 
 
5.4.2 Results 
 
5.4.2.1 Simulations for the proposed dietary exposure scenarios for tebuconazole 
 
We carried out simulations for the three dietary exposure criteria for tebuconazole proposed above. 
There are, exposure of an average consumer of fruit and vegetable in the Danish population 
(scenario 1), exposures of consumers that eat more than 55o g/day which is set to twice the mean 
exposure (scenario 2), and the combined exposure to triazoles and related compounds found in 
food samples on the Danish market (scenario 3), see Table 5.2. These estimates are for consumers 
eating only fruits and vegetables from conventional production. 
 
Figure 5.23 shows the simulated curves for amount of tebuconazole (labelled C1Mo) and 
metabolites (labelled C1M1) in the human body at each time point.  The three curves are identical, 
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with except for the numerical values of the amounts present, which scale with increased sizes of the 
dietary dose. 
 
 
TABLE 5.2. THE PROPOSED EXPOSURE SCENARIOS 
 
  Scenario 1 Scenario 2 Scenario 3 
  (µg/kg BW/day) (µg/kg 
BW/day) 
(µg/kg 
BW/day) 
Tebuconazole 0.13 0.026 0.29 
Prochloraz 0.0064 0.0128 0.29 
 
(a) 
(b) 
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(c) 
 
FIGURE 5.23.   
PREDICTED CURVES FOR THE TOTAL AMOUNT OF TEBUCONAZOLE (C1M0, GREEN CURVE) AND METABOLITES 
(C1M1,  BLUE CURVE) IN THE HUMAN BODY AFTER ORAL DIETARY ADMINISTRATION OF  0.013 µG/KG BW/DAY 
(SCENARIO 1) (A), 0.026 µG/KG BW/DAY (SCENARIO 2)(B) AND 0.29 µG/KG BW/DAY (SCENARIO 3) (C). THE GRAPHS 
FOR THE THREE DIFFERENT EXPOSURE CRITERIA FOR DIETARY EXPOSURE ARE VERY SIMILAR, WERE THE 
AMOUNT OF TEBUCONAZOLE AND METABOLITES IS INCREASED PROPORTIONAL TO THE INCREASED EXPOSURE. 
 
The exposure criteria with normal exposure (scenario 1) was analysed in greater detail. Figure 5.24 
shows the amount of tebuconazole and metabolites together with the total amount excreted and the 
total amount of metabolites formed for the first three days of exposure. The simulated 
concentration of tebuconazole in blood, liver and skin, as well as the mean concentration of 
metabolites in the body for the first three days of the simulation is shown in Figure 5.25(a) and the 
concentration of tebuconazole in all the compartments in the model in Figure 5.25(b). All the 
simulated concentrations are in the range of nmol/l and lower, with total amount of tebuconazole 
and metabolites in the body up to 0.15 nmol and 1 nmol, respectively.  
 
 
 
FIGURE 5.24.    
PREDICTED CURVES FOR THE TOTAL AMOUNT OF TEBUCONAZOLE (C1M0, GREEN CURVE), METABOLITES (C1M1, 
BLUE CURVE) IN THE HUMAN BODY AT EACH TIME AFTER ORAL DIETARY ADMINISTRATION OF 0.013 µG/KG 
BW/DAY (CRITERIA 3). THE TOTAL AMOUNT OF METABOLITES FORMED IN (BLACK CURVE) AND EXCRETED FROM 
(READ CURVE) THE BODY DURING THE SIMULATION, IS SHOWN AS WELL.   
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(a) 
 
(b) 
 
FIGURE 5.25.    
(A) PREDICTED CONCENTRATION OF TEBUCONAZOLE IN HUMAN BLOOD (BLACK), LIVER (RED) AND SKIN (GREEN), 
AND THE MEAN CONCENTRATION OF METABOLITES IN THE BODY (BLUE) AT EACH TIME AFTER ORAL DIETARY 
ADMINISTRATION OF 0.013 µG/KG BW/DAY. (B) THE CONCENTRATIONS OF TEBUCONAZOLE IN ALL THE 
COMPARTMENTS IS SHOWN AS WELL, WITH CURVES FOR FAT (CYAN), RAPIDLY (YELLOW) AND SLOWLY (VIOLET) 
PERFUSED TISSUE INCLUDED AS WELL.   
 
5.4.2.2 Simulations for the proposed dietary exposure scenarios for prochloraz 
 
Similarly, simulations were carried out for the three oral exposure scenarios for prochloraz. Figure 
5.26 shows the simulated curves for amount of prochloraz (labeled C1Mo) metabolites (labelled 
C1M1) in the human body at each time point.  The three curves are  identical, except for the 
numerical values of the amounts present, which scale with increased sizes of the dietary dose. The 
curves for prochloraz are similar to those for tebuconazole, as these compounds are metabolized at 
similar rate. 
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(a) 
(b) 
(c) 
 
FIGURE 5.26.    
PREDICTED CURVES FOR THE TOTAL AMOUNT OF PROCHLORAZ (C1M0, GREEN CURVE) AND METABOLITES (C1M1,  
BLUE CURVE) IN THE HUMAN BODY AFTER ORAL DIETARY ADMINISTRATION OF  0.0064 µG/KG BW/DAY 
(SCENARIO 1)  (A), 0.0128 µG/KG BW/DAY (SCENARIO 2) (B) AND 0.29 µG/KG BW/DAY (SCENARIO 3) (C). THE GRAPHS 
FOR THE THREE DIFFERENT EXPOSURE SCENARIOS FOR DIETARY EXPOSURE ARE VERY SIMILAR, THE AMOUNT OF 
PROCHLORAZ AND METABOLITES IS INCREASED PROPORTIONAL TO THE INCREASED EXPOSURE. 
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The exposure scenarios with normal exposure (scenario 1) was analysed in greater detail. Figure 
5.27 shows the amount of prochloraz and metabolites together with the total amount excreted and 
the total amount of metabolites formed for the first three days of the exposure. The simulated 
concentration of prochloraz in blood, liver, as well as the mean concentration of metabolites in the 
body for the first three days of the simulation is shown in Figure 5.28(a) and the concentration of 
tebuconazole in all the compartments in the model in Figure 5.28(b). All the simulated 
concentrations are in the range of nmol/l and lower, with total amount of prochloraz and 
metabolites in the body up to 0.072 nmol and 0.24 nmol, respectively. It is seen that the simulated 
blood concentration of prochloraz is relatively larger in blood compared to tebuconazole, due to the 
larger fraction bound to plasma proteins. It should be mentioned that the prochloraz model could 
not be validated properly. Thus these results are the prediction we could make based on the data we 
had, and or not necessary accurate. 
 
 
 
FIGURE 5.27.    
PREDICTED CURVES FOR THE TOTAL AMOUNT OF PROCHLORAZ (C1M0, GREEN CURVE), METABOLITES (C1M1, BLUE 
CURVE) IN THE HUMAN BODY AT EACH TIME AFTER ORAL DIETARY ADMINISTRATION OF 0.0064 µG/KG BW/DAY 
(SCENARIO 1) FOR 3 DAYS. THE TOTAL AMOUNT OF METABOLITES FORMED IN (BLACK CURVE) AND EXCRETED 
FROM (RED CURVE) THE BODY DURING THE SIMULATION, IS SHOWN AS WELL.   
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(b) 
 
FIGURE 5.28.    
(A) PREDICTED CONCENTRATION OF PROCHLORAZ IN BLOOD (BLACK), AND LIVER (RED), AND THE MEAN 
CONCENTRATION OF METABOLITES IN THE BODY (BLUE) AT EACH TIME AFTER ORAL DIETARY ADMINISTRATION 
OF 0.0063 µG/KG BW/DAY ) FOR 3 DAYS. (B) THE CONCENTRATION OF PROCHLORAZ IN ALL THE COMPARTMENTS 
BUT BLOOD IS SHOWN AS WELL, WHERE THE CURVES FOR FAT (CYAN), RAPIDLY (YELLOW) AND SLOWLY (VIOLET) 
PERFUSED TISSUE ARE INCLUDED.   
 
5.4.2.3 Simulations for the proposed dermal exposure scenarios for tebuconazole 
 
Likewise, the four specific dermal exposure criteria specified in section 5.3.1.2 were simulated. The 
dermal absorption has been evaluated for each product, as the extent of absorption can vary 
depending concentration and formulation of the product. The simulations have thus been carried 
out for examples of products that can be considered as typical representatives for each product 
category, and selected by the help of collaborators at the Danish EPA, see section 5.3.1.2 for details. 
 
The simulated amounts of tebuconazole and metabolites according to the two dermal exposure 
scenario for tebuconazole used as biocide for industrial wood treatment and for brushing are shown 
in Figure 5.29.  Dermal absorption of 15.7% was assumed for the biocide products. All the PBTK 
simulations are made for an average human of 70 kg, risk assessment of biocides normally done for 
a small human, 60%. 
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(b) 
 
FIGURE 5.29.    
PREDICTED CURVES FOR THE TOTAL AMOUNT OF TEBUCONAZOLE (C1M0, BLUE) AND METABOLITES (C1M1, 
GREEN) IN THE HUMAN BODY AFTER DERMAL EXPOSURE OF TEBUCONAZOLE AS BIOCIDE 0.292 MG/DAY BY FOUR 
HR INDUSTRIAL TREATMENT (A) AND 1.37 MG/DAY BY THREE HOUR BRUSHING (B). TWO DAY WEEKEND BREAK  IS 
INCLUDED IN THE SIMULATION, AND IT IS SEEN THAT THE SURPLUS OF CHEMICALS ARE EXCRETED FROM THE 
BODY DURING THESE DAYS ACCORDING TO THE SIMULATION. 
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FIGURE 5.30.    
PREDICTED CURVES FOR THE TOTAL AMOUNT OF TEBUCONAZOLE (C1M0, GREEN CURVE), METABOLITES (C1M1, 
BLUE CURVE) IN THE HUMAN BODY AT EACH TIME AFTER DERMAL EXPOSURE AFTER SPILLING 1.75 ML OF 
SOLUTION USED FOR BRUSHING ON HANDS IN GO. THE TOTAL AMOUNT OF METABOLITES FORMED IN (BLACK 
CURVE) AND EXCRETED FROM (RED CURVE) THE BODY DURING THE SIMULATION, IS SHOWN AS WELL. 
 
The daily systemic exposure as a result of three hour brushing was estimated to 1.37 mg active 
compound mg/day). According the estimates made by the Danish EPA (Appendix 9), this 
corresponds to that 1.75 g (or 1.75 ml assuming density of 1 g/ml) of the biocide product is spilled 
on unprotected human skin during this time period. If we assume that a professional spills 1.75 ml 
on his/her hands in one go, we can explore how the corresponding curves looks by using the Fick’s 
law implementation of the dermal absorption model. The surface area of the hands was assumed to 
be 2.6% of the total body surface area.  
 
The simulation results show that the whole dose of tebuconazole is absorbed within a short time 
period, and that the peak concentration of the metabolites corresponds to the one obtained in the 
previous simulation (Figure 5.30). It is absolutely a possible scenario that a person spills this 
amount of material on his/her hands, either in smaller portions over three hour period, or even in 
one go. The mitigation by gloves is set to 100% in the estimate by the Danish EPA, and there should 
be some protections due to gloves (if used).  
 
The corresponding results for tebuconazole product used as pesticide for spraying fields, with and 
without protection, are shown in Figure 5.31. Dermal absorption of 12% was assumed for the 
concentrated pesticide formulation and 20% for the diluted solution. 
  
It is seen that the tebuconazole and the sum of metabolites are present in similar quantity in these 
for simulation, and that a trace of the chemical is continuously present in the workers body while 
subject to repeated dermal dosing. During a two day break all this trace of chemical is excreted. The 
exposure using protection, results in similar levels as those resulting from the brushing scenario. 
When spraying fields without taking weekend break, this trace would remain in the body according 
to our simulation (Figure 5.32).  
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FIGURE 5.31.    
PREDICTED CURVES FOR THE TOTAL AMOUNT OF TEBUCONAZOLE (C1M0, BLUE) AND METABOLITES (C1M1, 
GREEN) IN THE HUMAN BODY AFTER DERMAL EXPOSURE OF TEBUCONAZOLE WHILE SPRAYING FIELDS WITH 
PRODUCT MYSTIC 250 EC FOR EIGHT HOURS A DAY: 1.96 MG/DAY EXPOSURE WITH PROTECTION (A) AND 3.48 
MG/DAY EXPOSURE WITHOUT (B).  
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FIGURE 5.32.    
PREDICTED CURVES FOR THE TOTAL AMOUNT OF TEBUCONAZOLE (C1M0, BLUE) AND METABOLITES (C1M1, 
GREEN) IN THE HUMAN BODY AFTER DERMAL EXPOSURE OF TEBUCONAZOLE WHILE SPRAYING FIELDS WITH 
PRODUCT MYSTIC 250 EC FOR EIGHT HOURS A DAY: 1.96 MG/DAY EXPOSURE WITH PROTECTION FOR 12 DAYS IN A 
ROW WITHOUT BREAK. ACCORDING TO THE SIMULATION TWO DAYS WITHOUT EXPOSURE ARE NEEDED TO 
EXCRETE THE TRACE OF THE MATERIAL (FIGURE 5.31).  
 
One exposure scenario was analysed in greater detail for the dermal route as well, and for that 
purpose we chose the scenario for spraying pesticide on field and using protection. Figure 5.33 
shows the amount of tebuconazole and metabolites together with the total amount excreted and the 
total amount of metabolites formed for the first three days of exposure. The simulated 
concentration of tebuconazole in blood, liver and skin, as well as the mean concentration of 
metabolites in the body for the first three days of the simulation is shown in Figure 5.34(a) and the 
concentration of tebuconazole in all the compartments in the model in Figure 5.34(b). All the 
simulated concentrations are in the range from o.o1-0.14 µmol/l (Fig 5.34), with total amount of 
both tebuconazole and metabolites in the body up to a level of 2.5 µmol (Fig 5.32).  
 
 
FIGURE 5.33.   PREDICTED CURVES FOR THE TOTAL AMOUNT OF TEBUCONAZOLE (C1M0, GREEN CURVE), 
METABOLITES (C1M1, BLUE CURVE) IN THE HUMAN BODY AT EACH TIME AFTER DERMAL EXPOSURE OF 1.96 
MG/DAY. THE TOTAL AMOUNT OF METABOLITES FORMED IN (BLACK CURVE) AND EXCRETED FROM (RED CURVE) 
THE BODY DURING THE SIMULATION, IS SHOWN AS WELL.   
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FIGURE 5.34.    
(A) PREDICTED CONCENTRATION OF TEBUCONAZOLE IN BLOOD (BLACK), LIVER (RED) AND SKIN (GREEN) AND THE 
MEAN CONCENTRATION OF METABOLITES IN THE BODY AT EACH TIME AFTER DERMAL EXPOSURE OF 1.96 
MG/DAY. (B) THE CONCENTRATION OF TEBUCONAZOLE IN ALL THE COMPARTMENTS IS SHOWN AS WELL, WHERE 
THE CURVES FOR FAT (CYAN), RAPIDLY (YELLOW) AND SLOWLY (VIOLET) PERFUSED TISSUE ARE INCLUDED AS 
WELL.   
 
Finally, Figure 5.35 illustrates which effect a relatively small variation in the elimination rate 
constants has on the simulated amount of metabolites. In addition to the elimination constants 
adjusted to the rat excretion data and extrapolated to the other species, we did adjust an elimination 
constant excretion data for a dermal experiment in a rhesus monkey. The excretion data for a 
rhesus monkey receiving an iv dose, were simulated better with the scaled rat values, than the value 
adjusted to the dermal data. However, this experiment provided an alternative elimination constant 
to explore the influence of this parameter on the simulation, which increases the amount of 
metabolites present in the workers body slightly, but has no influence on the overall conclusion 
from these simulations.   
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FIGURE 5.35.    
PREDICTED CURVES FOR THE TOTAL AMOUNT OF TEBUCONAZOLE (C1M0, BLACK) AND METABOLITES (C1M1) IN 
THE HUMAN BODY AFTER DERMAL EXPOSURE OF TEBUCONAZOLE WHILE SPRAYING FIELDS WITH MYSTIC 250 EC 
FOR EIGHT HOURS A DAY:  1.96  MG/DAY EXPOSURE WITH PROTECTION.  THE SIMULATION WAS CARRIED OUT 
WITH THE NORMAL ELIMINATION RATE CONSTANT EXTRAPOLATED FROM RAT, KE(HUMAN) =0.19 HR-1  (C1M1, GREEN) 
AND THE ELIMINATION RATE CONSTANT EXTRAPOLATED FROM RHESUS MONKEY, KE(HUANA),XMONKEY =0.10 HR-1 
(C1M1, RED), ILLUSTRATING THE INFLUENCE OF UNCERTAINTIES IN THIS PARAMETER ON THE SIMULATION 
RESULT.  
 
5.4.2.4 Simulations for the combined dietary and dermal exposure scenarios 
 
Simulations were then carried out assuming aggregate exposure (dietary and dermal), as the 
professionals working with applying biocides and pesticides, are also exposed to pesticides through 
their diet. We used the biocide industrial treatment cased to illustrate this aggregate exposure. This 
application results in the lowest dermal dose, and relatively smaller contribution from the dietary 
exposure have impact the simulation, than in the case for the other dermal scenarios.   
 
For dietary exposure scenario 1 and 2, no contribution from the dietary exposure, but for scenario 3 
where contribution from 18 related active compounds were combined, some contribution was seen 
in the simulation (Figure 5.36).  We thus tried two different constructed cases, with the dietary 
exposure in criteria 3 was multiplied by a factor of 10 (Figure 5.39). The contribution due to dietary 
exposure is increased with respect to the contribution from the dermal exposure, and is finally 
dominant exposure in the simulation. A small trace especially of the metabolites is not excreted 
from the body according to these simulations. The highest dose corresponds to exposure that has 
reached a hazard index of 110% from dietary exposure alone. 
 
Finally, we simulated at situation were a professional worker spraying fields between 8 and 16, 
works with brush application for two hours from 19 to 21, and is exposed to pesticide residues 
according to dietary exposure scenario 2 (Figure 5.37). The dietary exposure is so small that it has 
no impact on the overall simulation. The dermal exposure is significantly larger, but the body 
eliminates all the material during the two day weekend break. 
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(a) 
(b) 
(c) 
FIGURE 5.36.    
SIMULATED CURVES FOR THE TOTAL AMOUNT OF TEBUCONAZOLE (C1M0, BLUE) AND METABOLITES (C1M1, 
GREEN) IN THE HUMAN BODY AFTER DERMAL EXPOSURE OF TEBUCONAZOLE AS BIOCIDE, 0.292 MG/DAY BY FOUR 
HR INDUSTRIAL TREATMENT, AND DIETARY ORAL EXPOSURE OF 0.01 µG/KG BW/DAY (EXPOSURE SCENARIO 1) (A), 
0.29 µG/KG BW/DAY (EXPOSURE SCENARIO 3) (B) AND 2 µG/KG BW/DAY (THEORETICAL SCENARIO 10X EXPOSURE 
SCENARIO 3) (C).  SMALL CONTRIBUTION IS SEEN FROM THE DIETARY EXPOSURE IN CASE OF EXPOSURE 
SCENARIO THREE, BUT BY MULTIPLYING THE AMOUNT BY 10, THE CONTRIBUTION FROM THE DIETARY EXPOSURE 
BECOMES SIGNIFICANT, AND A TRACE OF THE CHEMICALS IS NOT EXCRETED.  
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FIGURE 5.37.    
SIMULATED CURVES FOR THE TOTAL AMOUNT OF TEBUCONAZOLE (C1M0, BLUE) AND METABOLITES (C1M1, 
GREEN) IN THE HUMAN BODY AFTER DERMAL EXPOSURE OF TEBUCONAZOLE AS PESTICIDE 1.96 MG/DAY BY 
EIGHT HOUR SPRAYING FIELDS, AND AS BIOCIDE 0.91 MG/DAY BY TWO HOUR BRUSH APPLICATION, AND DIETARY 
ORAL EXPOSURE OF 0.026 µG/KG BW/DAY (EXPOSURE SCENARIO TWO). 
 
5.4.2.5 How would corresponding dermal criteria look in the rat and the monkey 
models 
 
We selected one of the dermal exposure criteria above, and extrapolated to rat by scaling with 
respect to total body skin area of the two species. We chose the criteria for spraying a pesticide 
solution with protection: 1,96 mg/day*(3,9 cm2/181 cm2) = 0,042 mg/day exposed over eight hour 
time interval a day, like for the human case.  
 
The simulation shows that the rat excreted the metabolites more slowly than the human, leading to 
relatively larger trace of the metabolites present in the rat body, than in the human body (Figure 
5.38). 
 
Likewise, we made a simulation in rhesus monkey, with a dose of 0.4 mg/day exposed during 8 
hours each day (Figure 5.39). It is seen that the excretion is faster in monkey than rat, but slower 
than in human. Studies have shown that elimination constants scales by body weight lifted to the 
potency of 0.25 between species, whereas for the maximum velocities of the metabolic reaction and 
cardiac output the body weight is given the potency of 0.75 in interspecies interpolation. This makes 
the excretion in a larger animal like human more effective.  
 
120 Optimization of the cumulative risk assessment of pesticides and biocides using computational techniques: Pilot project 
 
(a) 
 
(b) 
 
FIGURE 5.38.    
PREDICTED CURVES FOR THE TOTAL AMOUNT OF TEBUCONAZOLE (C1M0, GREEN CURVE), METABOLITES (C1M1, 
BLUE CURVE) IN THE RAT BODY AT EACH TIME AFTER DERMAL EXPOSURE OF 0.042 MG/DAY IN A 12 DAY (A) AND A 
THREE DAY (B) SIMULATION. THE TOTAL AMOUNT OF METABOLITES FORMED IN (BLACK CURVE) AND EXCRETED 
FROM (RED CURVE) THE BODY DURING THE SIMULATION, IS SHOWN AS WELL IN (B).   
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FIGURE 5.39.    
PREDICTED CURVES FOR THE TOTAL AMOUNT OF TEBUCONAZOLE (C1M0, GREEN CURVE), METABOLITES (C1M1, 
BLUE CURVE) IN THE RHESUS MONKEY BODY AT EACH TIME AFTER DERMAL EXPOSURE OF 0.4 MG/DAY IN A 12 
DAY SIMULATION.  
 
  
122 Optimization of the cumulative risk assessment of pesticides and biocides using computational techniques: Pilot project 
 
 
Optimization of the cumulative risk assessment of pesticides and biocides using computational techniques: Pilot project 123 
 
6. Discussion 
6.1 Quality of the PBTK models, strengths and weaknesses 
 
We have developed a pilot version of a toolbox of relatively simple PBTK models for tebuconazole 
and prochloraz in rat and human, with additional models developed for tebuconazole in rabbit and 
rhesus monkey.   
 
In the development of the PBTK models, much work was devoted to creating as good and accurate 
PBTK models for the individual compounds as possible, based on the available data for the 
compounds studied. It is important that the blood and tissue concentration levels are simulated 
sufficiently accurately for the individual compounds.  
 
The strength of the models developed in this work is that almost all the parameters used are based 
on available experimental data, and no parameters were adjusted to experimental blood and tissue 
concentration data. The elimination rate constant was adjusted to experimental excretion data for 
rats for each compound (and for tebuconazole also for rhesus monkeys), and this is the only 
parameter in the respective models that was adjusted to in vivo data.  
 
The weakness of the models is that we could only properly validate the tebuconazole model with 
respect to blood and tissues levels, as good a data set was not available for prochloraz. Blood and 
tissue concentrations of tebuconazole were validated in another species, namely rabbit, which also 
introduces some uncertainties.  Another consideration is that the human versions of the PBTK 
models for tebuconazole and prochloraz could not be validated on in vivo data, as no such data exist 
in human for the compounds studied.  
 
To do the best evaluation of the models we possibly could, a variety of available data were used.  For 
example, data on the rough estimate of the blood levels in rat after oral administration of a mixture 
of pesticides could be used to evaluate the approximate levels of tebuconazole and prochloraz in 
blood, respectively. This was very useful, as these data could verify that the simulated blood levels 
were within reasonable order of magnitude with respect to the experimental data. Also these data 
verify the fast metabolism tebuconazole and prochloraz measured in vitro.  
 
The extrapolations of parameters between species seem to work well. Obviously some uncertainties 
are introduced by applying such techniques. Also some uncertainties are introduced by using QSAR 
predicted parameters for the fraction unbound. This is discussed in greater detail in the following 
section.   
 
The models for the individual compounds are flow regulated PBTK models that assume 
instantaneous equilibrium between levels in blood and tissues.  Essentially, one assumes the 
organism to be a well stirred system, and that no significant accumulation of the active compound 
occurs in fat or other tissue. Although a small accumulation was seen in rabbit fat, the tebuconazole 
was excreted within a short period of time. As fat is not a target tissue it was not considered worth 
while to include a diffusion based deep compartment, with the need of including additional 
parameters in the model.  
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Such flow based models may have some limitations at very low tissue concentrations (Baelum et al., 
1993). The simulated concentration levels of tebuconazole in rabbit plasma and tissues match the 
experimental data points well at the highest time points, indicating that the model is suitable for 
simulating the low concentration levels of the experiments terminal phase for this particular 
compound.    
 
6.2 The sensitivity of the parameters on the simulation 
 
Species dependent physiological parameters like body weight, tissue volumes, cardiac output and 
blood flow rates are important in the sense that they define the species simulated. In the work 
presented here, simulations have been made for an average male rat and an average human male, 
the physiological parameters for those have been well defined in the literature (Brown et al., 1997).  
The influence of variability in body weight, etc. can be explored by PBTK (Clewell et al., 2004; Yoon 
et al., 2011), but it is not the scope of this work.  
 
The compound specific parameters are normally also specific for each species. Some of these 
parameters can be extrapolated from one species to another, and thus it can be sufficient to have 
experimental values in one of the species. We have investigated the accuracy of the parameters used 
in the developed PBTK models and the influence of variability in these parameters on the simulated 
blood and tissue concentrations. It was found that parameters like fraction unbound in plasma, the 
metabolic constants, the tissue:blood partition coefficients, and the elimination rate constant are 
particularly important.  
 
Available ADME data for tebuconazole and prochloraz were fed into the models. An experimental 
value for the fractional absorption in rat is available for each of the compounds, and the rat values 
were assumed for humans. The oral absorption rate constant was assumed, and it does influence 
the absorption rate of an oral bolus dose in the model, but is not used in dietary administration part 
of the model. 
 
Experimental in vitro data on the depletion rate are available in the literature, metabolic constants 
measured in rat microsomes for tebuconazole and intrinsic clearance measured in human 
hepatocytes for prochloraz. The experimental maximum velocity for tebuconazole was extrapolated 
from rat to human, and the intrinsic clearance of prochloraz was extrapolated from human to rat. 
The first order elimination rate constants for the urinary and faecal excretion of both compounds 
were adjusted to experimental excretion data in rat (accumulated excretion), in the case of 
tebuconazole and to rhesus monkeys as well for validation purposes.  
 
We do not have sufficient data to evaluate the uncertainty introduced in the depletion rate due to 
such extrapolations. On the other hand, we show some analysis of the sensitivity of these 
parameters on the simulated blood concentration levels in rat to illustrate the influence of intra-
species variability. The simulation showed that two-fold change in the maximum velocity and 
intrinsic clearance lead to two-fold change in the peak concentration level in blood.  
 
Also the use of parameters predicted by QSAR models developed based on structurally similar 
compounds introduce uncertainties as well. One of the two parameters predicted by QSAR has 
substantial influence on the simulated blood and tissues concentrations of the mother compound, 
namely the fraction unbound in plasma. The predicted QSAR models were validated before they 
were applied for predicting parameters for tebuconazole and prochloraz (section 4.1.2.2). The QSAR 
predictions for the fraction unbound and the volume of distribution were obtained from models 
trained on human data, and extrapolated to rat. We have evaluated the uncertainty of the predicted 
fraction unbound in human to be ± 0.1, and ± 0.2 for rat. An experimental value for the fraction 
unbound of prochloraz measured in human cells found after the QSAR models had been developed, 
is well within the prediction uncertainty of the QSAR model.   
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The distribution to the different tissues are modelled by tissue:blood partition coefficients, that are 
calculated on the basis of the octanol:water partition coefficient, fraction of water, neutral lipid and 
phospholipids in the tissue and fraction unbound in plasma. These values are predicted, and not 
adjusted to experimental blood and tissue concentrations.  
 
The validation and analysis of tebuconazole in rabbit indicated that for most tissue, the predictions  
deviated from the experiment data within factor of two, which is our preliminary rule of thumb for 
evaluating ranges for possible tissue levels. In cases of iv and dermal administration, we would 
estimate the liver concentration to be at the same level as the other rapidly perfused tissues, instead 
of using the predicted liver level, which is significantly underestimated. This needs to be 
investigated further for other compounds, before we can make any more general conclusions, as our 
experience is based on small number of data.  
 
See detailed discussion on the accuracy of the different parameters in the following sections. 
 
6.2.1 The oral absorption rate constant and fractional absorption 
 
Data on the extent of oral absorption (fractional absorption) were available for both tebuconazole 
and prochloraz (JMPR, 2010; JMPR, 2001) On the other hand, no precise data on the absorption 
rate of these compounds were found, but it was stated that tebuconazole absorbs within an hour 
(JMPR, 2010).  Thus it was necessary to assume the absorption rate constants governing the pulse 
function that simulates the oral absorption rate of an oral bolus dose from the GIT to the liver, via 
the portal vein. This can affect the simulated blood and tissue concentrations at low time points 
upon oral bolus dose administration, but does not influence on the dietary exposure simulation. In 
the case of dietary exposure it is assumed that we are evenly exposed to the chemical from the food 
12 hrs a day, with 12 hr rest. This is of course an estimate as well.  
 
6.2.2 Fraction unbound in plasma 
 
The fraction unbound in plasma has significant influence on the blood concentration levels, as only 
the fraction of the active compound that is not bound to plasma proteins can be distributed to the 
tissues at each time point. 
 
This parameter was not available for tebuconazole in the literature. We thus developed a QSAR 
model on corresponding human data for triazoles and imidazole that are used as drugs and 
predicted the fraction unbound for tebuconazole and prochloraz in human with the resulting QSAR 
model. Then we extrapolated the human values to rat values using correlative equation between 
human and rat from the literature. There is of course some error introduced by using predicted 
values, rather than experimental ones. Our results indicate that these predicted values gave realistic 
levels of the free fraction of the compounds in plasma, to the extent we can evaluate it by comparing 
simulated blood concentration levels with experiments.  
 
After the QSAR model had been developed experimental value for prochloraz measured in vitro was 
found in the literature (Wetmore et al., 2012). The QSAR prediction (fu,human(QSAR) = 0.07) can be 
considered in acceptable agreement with the experimental value (fu,human(exp) = 0.0224) for 
prochloraz. If these values are calculated as percentages and not fractions, this amounts to a 5% 
difference.  
 
Uncertainty of 20% can easily be expected for the predicted rat values, as an interspecies 
extrapolation has been done based on the QSAR prediction from the human model. As seen by the 
validation results, the QSAR predictions were fairly accurate in most cases. For compounds that had 
less structural similarity with the training set compounds, larger uncertainties were seen. For 
example, when tebuconazole was predicted with two different QSAR models, one based on all 14 
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training set compounds and one based on a subset of 11 compounds, the predicted value differed by 
3% (Table 3.12). For prochloraz the difference was 10%, which we can use as an estimate for the 
uncertainty in the QSAR prediction with the human model. 
 
Thus one has to be aware that some uncertainties are associated with using a parameter predicted 
by QSAR, yet it is a greatly valuable help to be able to predict parameters that are within range of 
the actual value, and helps us to develop more realistic models than we would otherwise be able to 
do.  
 
6.2.3 The metabolic constants 
 
Accurate values for the Michaelis-Menten constant and the maximum velocity of the metabolic 
reaction are essential for any PBTK simulation. Experimental values measured in rat microsomes 
were available for tebuconazole (Shen et al., 2012). Corresponding parameters were not available 
for prochloraz, but instead experimental intrinsic clearance data in human hepatocytes have been 
published in Supplementary Table 8 in (Wetmore et al., 2012). 
 
We explored the influence caused by the two-fold variation in these constants by multiplying the 
experimental parameters with two or dividing them by two. For tebuconazole the simulated blood 
levels in rat scales essentially reversely with the altered Vmax and scales proportionally with the 
altered KM (Figure 5.10). Probably, in situations when a compound is essentially metabolised as 
soon as it enters the liver, changes in the blood levels scale so directly with changes in the metabolic 
constants. The blood levels are much less influenced by alterations in the metabolic constants in the 
rabbit simulation that used iv administration according to the model, where the first pass effect of 
liver metabolism is absent (Figure 5.6).  In reality there might be some first pass effect due to 
enterohepatic recirculation in rat, but this is not included in the model. Similarly, the simulated 
blood levels of prochloraz scales inversely with the altered CLint (Figure 5.17). 
 
The intrinsic clearance can be used to describe the linear part of the Michaelis-Menten curve, and it 
thus well suited for simulating the depletion rate at low exposure levels, but not at higher exposure 
levels where saturation of the metabolic enzymes is reached. 
 
We investigated if it was possible to use experimental metabolic constants from similar compounds, 
undergoing similar metabolic reactions in the same CYP, to simulate the metabolism of prochloraz 
at higher concentrations. Prochloraz follows a rather special metabolic pathway, where the 
imidazole ring opens and cleaves off, and the resulting metabolite follows similar metabolic 
reactions like many triazole and imidazole compounds. Unfortunately we did not have such 
constants for a structurally similar compound to prochloraz, undergoing a sufficiently similar 
metabolic pathway.  
 
The closest we could get was to use metabolic constants for furan measured in liver hepatocytes for 
the ring opening reaction, and metabolic constant determined for the 5-hydroxilation of omeprazole 
in human CYP2C19 in insect liver microsomes measured in a recombinant assay for the remaining 
reactions. These “transferred” constants did result in depletion rate similar to the one calculated 
with the experimental intrinsic clearance value at lower exposure levels. Although this can be 
considered a long shot, we evaluated that we could use these parameters for the high exposure level 
simulations of prochloraz for studying the influence of inhibition by tebuconazole. 
 
Our collection of experimental metabolic constants for azole type compounds can probably be 
useful in more generic modelling (Appendix 6), and will be further explored in that respect.         
 
 
6.2.4 Tissue:blood partition coefficients and fraction unbound in tissue 
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We have used a relatively simple approach for predicting tissue:blood partition coefficients based 
on the octanol:water partition coefficients for the two compounds, the tissue composition, and the 
fraction unbound in plasma and tissue (Poulin and Theil, 2002). The advantage of this approach is 
that it can be used to predict the partition coefficients from readily available data.  
 
Experimental values for the octanol:water partition coefficients, and data for the fractional content 
of water, neutral lipids and phospholipids for the different tissue were available in the literature.  
A value for the fraction unbound in plasma was predicted by QSAR, but no data for the fraction 
unbound in tissue was available for these compounds. It was assumed to be unlikely that substantial 
binding to tissue proteins occurs for compounds that are eliminated rather fast, within 72 hrs, and 
we set the fraction unbound in the tissues to one. The correctness of this assumption can be 
discussed, and some underestimation of the partition coefficient indicated in our simulation could 
be due to this parameter. 
 
We estimated the accuracy of these predicted partition coefficients for the PBTK model for 
tebuconazole in rabbit, where tissue level curves were available in a number of tissue (sections 
5.1.1.2 and 5.1.1.3). According to these results, the predicted partition coefficient in muscle can be 
considered to be accurately predicted by the method, and it seems that two-fold increase in the 
value for the rapidly perfused tissue types can capture the uncertainty in this parameter. The lungs 
behaved very differently from other tissue, possibly governed by some additional biological 
mechanism not included in the model. As the lungs are not a target organ, it is not a significant 
problem for the model.  
 
The experimentally measured tebuconazole concentrations in liver were comparable to the 
concentrations in other rapidly perfused tissue like kidney and heart. The model assumes that the 
entire metabolism takes place in the liver, and it looks like tebuconazole is drained from the liver by 
the fast metabolism in the simulation. Such trait is seen in all simulations that use either iv or 
dermal administration, instead of oral administration. Thus simulations where the tebuconazole is 
distributed in the body before it reaches the liver for metabolism render very low concentration 
levels in liver, compared to other rapidly perfused tissues.   
 
The measured liver levels could be matched by using approximately seven fold value of the 
predicted partition coefficient in the simulation. The experimental data show liver concentrations 
on comparable level to other tissue like kidney, and it is unlikely that the partition coefficient should 
be three times larger for liver than for kidney in this case.  This might be an artefact of the model, 
when simulations are carried out for compounds with very high depletion rate. We assume that all 
the metabolism occurs in the liver, which is an over-simplification, and for non-oral exposure routes 
the compound might be metabolised in other tissue as well, as it is distributed to the body, 
including the liver, and does not benefit from the first pass effect like oral exposure. Both the first 
pass effect in the liver and the distribution to the liver from the blood stream are included in the 
models.  
 
It should be mentioned, that a mathematical description of enterohepatic recirculation has not been 
included in the model. It is known to occur in rats, and does possibly also occur in other rodents like 
rabbits, and in such case enterohepatic recirculation might contribute to some first pass like effect 
in rabbits upon iv administration.   
 
These results indicate that specific consideration needs to be made for the present model, when 
liver levels are estimated for non oral administration routes, like when the iv and the dermal routes 
are applied. A simple solution would be to assume that the liver concentration level is similar to the 
corresponding concentration level for the other rapidly perfused tissue. This needs to be 
investigated further, especially in relation to the use of simulated liver levels in risk assessment.   
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Many other methods have been proposed for predicting the tissue:blood partition coefficients. 
Some of them incorporate the influence of ionization of the active compounds (Rodgers et al., 2005; 
Rodgers and Rowland, 2006; De Buck et al., 2007; Peyret et al., 2010; Poulin and Haddad, 2012), 
which is not relevant for the two compounds studied here as they are neutral at blood pH levels 
(Table 3.4). Another model has also included the fractional volume of the binding proteins in 
different tissue as well, and computed cell:water, interstitial fluid:water, plasma:water and 
erythrocyte:water partition coefficients in the process of determining the tissue:blood partition 
coefficient(Peyret et al., 2010). This algorithm seems highly biologically relevant, yet quite 
complicated and not straight forward to use. The authors compared predictions with their 
algorithm with predictions from several other algorithms, indicating that overall similar results are 
obtained with the different algorithms, including the relatively simple algorithm we have adapted in 
this work. 
 
6.2.5 Elimination rate constants  
 
The elimination rate constants govern the excretion rate the compounds, and in this work the rate 
whereby the metabolites are excreted from the body. In the models developed in this work, the 
absorbed fraction of the active compounds is fully metabolised. The body levels of metabolites are 
therefore strongly affected by this parameter, but not the blood and tissue levels of the active 
compounds.  
 
The elimination rate constants were determined by adjusting calculated excretion variable in the 
PBTK model to available excretion data (accumulated excretion) for the compounds studied. This 
approach was chosen due to lack sufficient data for predicting these parameters otherwise. We 
would have had to make a much more complicated model, including enterohepatic recirculation 
and to add one or more compartment for the stomach and the intestines. Without proper data for 
doing so, this would only have made the overall model less accurate, and thus we chose make a 
specific excretion compartment and adjust this parameter to available experimental data.  
 
This simple approach of making a specific excretion compartment is often used in PBTK models in 
the literature, and when good excretion data are available, it can be highly recommended. It makes 
it possible to simulate compounds that are partly excreted via the bile in a simple way. 
  
The human values were calculated based on the rat values using inter-species extrapolation. Where 
the literature proposes an allometric scaling equation inversely proportional to the body weights in 
the power of 0.25  (ke,human = ke,rat (BWrat/BWhuman)0.25) (Campbell, Jr. et al., 2012), excretion data of 
tebuconazole from rhesus monkeys could be accurately simulated using an elimination rate 
constant that was proportionally scaled to the body weights of rat and monkey in the power of 0.25 
(ke,monkey = ke,rat (BWmonkey/BWrat)0.25).  Moreover, when an elimination rate constant was adjusted 
to the rhesus monkey data, the monkey to human extrapolated ke value corresponded to the rat to 
human extrapolated value, when allometric scaling proportional to the respective body weights in 
the power 0.25 was used (section 3.3.2.3).  Our empirical data indicate that the altered allometric 
scaling equation can be used to for extrapolating elimination rate constants between the different 
species.     
 
 
6.2.6 Inhibition constants and induction 
 
It was confirmed in our analysis with the binary model for prochloraz and tebuconazole that 
inhibition does not have to be considered at exposure levels in the range of the human relevant 
exposure scenarios, constructed in this work. In the absence of experimental data on inhibition 
constants between the two compounds, inhibition was explored with a set of relevant inhibition 
constants taken from the literature. One was retrieved from an inhibition study between R- and S-
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tebuconazole representing relatively strong inhibition (Shen et al., 2012), and another was within a 
range of KI values determined between many organic compounds in the literature (El-Masri et al., 
2004; Timchalk and Poet, 2008), representing less strong inhibition.  
 
It was considered to include enzyme induction in the models, especially as prohcloraz is 
documented to induce CYP metabolism at higher dose levels. This would require an additional 
parameter added to the model. The simulated concentration levels at higher exposure levels were 
considered to be at an acceptable level for the purpose of the developed models, although induction 
is likely to occur for both compounds. As the developed tool is mainly aimed at low dose simulations 
for application in risk assessment, we did not include induction in this version of the models. The 
models can be refined if the need arises at a later point.  
 
6.3 Applicability of the developed PBTK model 
 
Optimally we would need both single dose and multiple dose data on concentration levels in blood 
and tissues for validating the models adequately for an all-purpose application. Data for compounds 
administrated via different routes, orally, dietary or dermally, are a plus for the validation.  
 
Even with so limited data for validation, we have learned much about the two compounds by 
pooling together all relevant and available data for these compounds in the developed PBTK 
models. The following considerations are based on the limited validation that could be performed 
and analysis of trends seen in the simulation. 
 
The concentration levels are affected by the route of exposure. The dermal routes lead naturally to 
relatively larger skin concentration, and slower metabolism than it is the case for compounds 
administrated by the oral and dietary routes that benefit from the first pass effect of the liver. These 
differences in blood and tissue concentration levels are described by the same set of parameters 
describing the compounds ADME. In accordance to the available data, it seems that it is generally 
not of importance which exposure route is applied with respect to the accuracy of blood and tissue 
levels simulated by the models. There is an unfortunate exception to this, namely the liver 
concentration level, which seems to be significantly underestimated (more than a factor of two) for 
the dermal and iv exposure routes. 
 
We assume that the compounds have the same ADME at high and low doses. It is possible that the 
depletion rate is overestimated at very low liver concentration levels, in case the well stirred flow 
based model does describe the system adequately at very low concentrations. The experimental data 
for rabbit indicate that this is not a problem. Such issues we will seek to investigate in our future 
work. The important thing is to be able evaluate which are the uncertainties in the model, and to 
incorporate that in the risk assessment. 
 
This project provides valuable information for developing a more generic toolbox for cumulative 
risk assessment, where similar compounds are grouped together, and assuming similar ADME for 
the compounds. Another application area is aggregate exposure from different routes, as illustrated 
with combined dietary and dermal exposure of tebuconazole discussed in section 5.4.2.4. For such 
purpose we will have to do with validating well for some compounds and assume similar behaviour 
for others. That will be a useful approach for pesticides and biocides, and many other compounds 
where data are scarce. For this purpose it is important to group the compounds based on structural 
similarity and available data for ADME properties, such that we indeed group compounds that do 
behave similarly. 
 
Although the binary simulations are rather theoretical, they illustrate important principles with 
respect to inhibition, and verify that inhibition is not likely to be a problem at low exposure levels. 
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We need to investigate this for more chemicals, to explore if this as a general trend, or specific 
behaviour for the compounds studied here. 
 
6.3.1 Evaluation of the models with respect to WHO IPCS guidance on PBTK 
models to be used in risk assessment 
 
As discussed in background section 1.2, there is increased interest in using PBTK models for risk 
assessment purposes. A recent report proposes a checklist for selecting and evaluating the quality of 
PBTK models for use in risk assessment (WHO, 2010b) and we will discuss the models presented in 
this report with respect to this check list. 
 
Biological basis:  
• Relevant biological processes are included in the models, the equations for ADME are 
based on sound theoretical basis, and the parameters used in these equations are based on 
available experimental data for ADME properties of tebuconazole and prochloraz.  
• The species specific physiological parameters are taken from a review with a 
comprehensive collection of such parameters (Brown et al., 1997) , the volume of the 
compartments are within known physiologically limits and the total sum of the tissue 
blood flow rates was normalized to equal the cardiac output in each case.  
• An accepted method was used for calculating the tissue:blood partition coefficients, it is a 
generalised method that introduces some uncertainties.  
• Allometric scaling was done according to literature guidelines with the exception of the 
elimination rate constant, which was extrapolated according to empirical observations 
made in this work.  
• The computer model code was carefully checked for syntax errors and correctness of units, 
and a proven integration algorithm was used for solving the equations.  
• An adequate method was used to estimate elimination rate constants. The elimination rate 
constants for the metabolites formed, are the only parameters that were adjusted to in viv 
experimental data, namely accumulated excretion data in each case. 
 
Conclusion: The biological basis of the developed PBTK models is considered to be well described . 
 
Model simulation of data:  
• The models were explored for their ability to predicting kinetics under various conditions, 
both at low exposures levels, which is the intended application area of the models, and at 
higher exposure levels up to saturation of the metabolic enzymes.  
• The influence of inhibition of a binary mixture was explored based on theoretical 
considerations.  
• It was investigated if the models were able to reproduce general trends of the data, using 
the limited data available for validation. Where the simulations for tebuconazole in various 
tissues in rabbit showed trends corresponding to the experimental data at higher time 
points, discrepancies were seen at the lowest time point (15 min after iv injection). The 
corresponding simulated plasma concentration followed the trend in of the experimental 
data. The lag time observed for tissue concentrations in this experiment was considerably 
larger than for comparable experiments for other compounds using iv administration 
(Sweeney et al., 2010; Hamelin et al., 2010; Hamelin et al., 2009). An exception to this was 
the lung, where no lag time was observed. We do not have an explanation of this behavior, 
which cannot be capture by a simple flow-based model. It should be mentioned that each 
time point is measured on one animal only. As the model is overestimating rather than 
underestimating the experimental levels at this early time point, it is not considered a 
problem with respect to application of the model for risk assessment.   
• In most cases the simulated plasma and tissue concentrations of tebuconazole in rabbit 
were within factor of two with respect to the experimental data. An exception to this, were 
the liver and lung levels in the rabbit experiment.  
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Conclusion: Based on the limited validation data available, the models seem generally to simulate 
blood and tissue concentration levels within a factor of two. Thus if the developed models were used 
for risk assessment, the best advice we can give is to multiply the simulated blood and tissue 
concentration levels by two. When dermal or iv administration is applied, it would be better to 
assume liver concentration at the same level as the other rapidly perfused tissue, than using the 
simulated concentration levels for liver, that seem to be significantly underestimated. 
 
Reliability (model testing, uncertainty and sensitivity):  
• The models seem to underestimate the concentration levels in blood and tissue somewhat, 
as discussed in the section above.  
• Simulations have been made for many relevant exposure conditions, but in the absence of 
data for validation, the uncertainty of the model cannot be fully assessed at these 
conditions.  
• We have to rely on the inter-species extrapolations and the high dose to low dose 
extrapolations made, if deemed feasible in the investigation of the biological basis of the 
models.  
• The experiments providing the data used for parameters describing the ADME of these 
compounds are to best of our knowledge reliable, and the reliability of the model is highly 
linked to the reliability of these parameters, as well as the reliability of the few available 
validation data.  
• The sensitivity of key parameters has been investigated with respect to the simulated blood 
concentration levels.  
Conclusion: Based on the evaluation of all the data fed into the models, we evaluate that it is 
acceptable to make predictions the developed models. Some uncertainty estimates for the rat model 
are discussed under the model simulation of data part, but corresponding estimates for the human 
models are difficult to make at present. Corresponding investigations for other compounds need to 
be made before assessing more accurate uncertainty estimates. Thus predictions with the present 
models, especially the human versions of the models, should be considered to give a more 
qualitative rather than quantitative estimate, and can be considered useful as such.   
 
Applicability of the developed  models:  
• The tebuconazole model was developed for rat, rabbit, rhesus monkey and human, and the 
prochloraz model for rat and human. The models were evaluated using available data for 
the different animal species, but we had no human data to evaluate the human model, 
although some human data were fed into the model. As these compounds follow the same 
metabolic pathways in a variety of species, it was assumed that these compounds would 
undergo similar metabolic reactions in humans.  
• The oral, dietary and dermal exposure routes were implemented, corresponding to the 
anticipated routes of human exposure. The inhalation route is not implemented in the 
present model, but can be added if the need arises.  
• Simulations were made for relevant exposure scenarios in human were, but it was not 
possible to validate the human models in similar situations. 
• The models were developed and parameters selected with respect to the purpose of 
application, namely cumulative and aggregate risk assessment at low exposure levels. Thus 
relatively simple models with focus on obtaining estimates of concentration levels in blood 
and selected tissues within factor of two were developed. 
Conclusion: The models developed in this pilot project can be considered as the first step in 
developing an applicable tool box to provide input to risk assessment of pesticides, biocides and 
other chemicals. Further development of this pilot project is needed before making sufficient 
conclusions of the applicability of the developed models. Some overall conclusion on the accuracy of 
the model predictions are given in the conclusions in the model simulation of data part, and these 
are the conclusions we can make based on the current pilot project. It is important to point out that 
all the relevant exposure levels of the individual compounds are much lower (>100) than the 
NOAEL measured in animal studies.   
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7. Conclusion 
In this report we present new PBTK models for two individual active compounds in pesticides and 
biocides, tebuconazole and prochloraz, and a binary mixture of these two compounds. The models 
were developed in both rats and humans. 
 
The model development was based on thorough investigation of the ADME, toxicology and a broad 
range of biological and physic0-chemical parameters available in the literature for the compounds 
studied, and related compounds. The PBTK models of the individual compounds were carefully 
developed, validated to the extent it was possible and analysed, before combining them into a 
binary model for both compounds.  
 
We considered  how uncertainties in the model parameters could affect the simulated blood and 
tissue levels, and it is of particular importance to have access to accurate parameters for the 
metabolism. Tebuconazole and prochloraz have available data for metabolic rates, measured  in in 
vitro experiments. It was seen from our simulation for a binary mixture that inhibition of metabolic 
enzymes did not have to be considered at lower exposure levels like the ones of the exposure 
scenarios used. Simply speaking, there is sufficient metabolic capacity to metabolise the compounds 
in the low exposure simulations, such that the two compounds do not inhibit the metabolism of 
each other. 
 
Despite the lack of experimental in vivo data for better validating the models, the biological basis of 
the models is considered adequate. The developed models showed to be very useful for exploring 
trends in ADME, interactions at higher concentration levels, influence of aggregate exposure. It was 
evaluated that such models can be useful for providing input to risk assessment at lower exposure 
levels, well below NOAEL, if potential uncertainties in the model due to parameters used and 
extrapolations are considered as well. 
 
The exposure scenarios constructed based on detected pesticide residues in fruit and vegetable gave 
low body levels for tebuconazole in our simulation, but somewhat higher body levels for prochloraz 
that had lower fraction unbound in plasma. The dermal exposure scenarios were based on exposure 
assessment made by the Danish EPA for specific applications of tebuconazole as biocide or pesticide 
by professional workers. Simulations with these scenarios gave not surprisingly internal body levels 
that were relatively larger than those resulting from dietary exposure. 
 
Another issue is that at repeated daily exposure, the metabolism of prochloraz and the excretion of 
tebuconazole did not have the capacity to remove the active compound and its metabolites before 
the organism was exposed again, according to our simulation. Thus it was important with exposure 
free days to clear the body.  Unfortunately, we do not have experimental data to verify this.  
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8. Perspectives 
The motivation behind this project was to develop a pilot version of a tool box, intended for use in 
risk assessment of mixtures of pesticides, biocides and hazardous organic chemicals in general. The 
present pilot project was aimed at developing PBTK models for two individual compounds, 
tebuconazole and prochloraz, and a binary mixture of those. It was focused on developing the 
models, validating them on available data and carrying out simulations for specific exposure 
scenarios. 
 
As discussed previously, several examples of PBTK based risk assessment of individual organic 
volatile and other organic compounds can be found in the literature (Gargas et al., 2009; Sweeney 
et al., 2012; Sweeney et al., 2009; Sweeney et al., 2001; Clewell and Clewell, III, 2008; Andersen et 
al., 1987; Clewell and Andersen, 2004a). Experiences from these works will provide input to 
performing PBTK based cumulative risk assessment for pesticides, were only limited work has been 
done up to now.  Presently it is debated which standards should apply to PBTK model development, 
and how the risk assessment should be carried out. 
 
It is generally agreed that there is increasing need for using such methods for higher tier cumulative 
risk assessment. Aggregate exposure by different exposure routes is another application area for 
PBTK based risk assessment, for example combined dietary and dermal exposure.  PBTK can 
potentially incorporate more detailed information on ADME in the risk assessment by assessing the 
internal doses (concentration levels) of chemicals within the body upon exposure. For doing so, 
appropriate data need to be available for the chemical studied and the developed PBTK  model 
should be considered adequate for the intended application. 
 
An important issue is that a PBTK model needs to be of appropriate quality to be used for risk 
assessment, as discussed above. The abovementioned IPCS report on application of PBTK in risk 
assessment has set up a checklist to evaluate the biological basis, reliability and applicability of the 
model, as well as the models capability to simulate different trends and conditions. These principles 
are important for ensuring that a PBTK model is properly developed, validated, tested and 
documented, before it is used for risk assessment and for providing framework for conducting 
PBTK based risk assessment (Meek et al., 2013). First and foremost it is important to document all 
the choses and assumptions made, both in the PBTK modelling work and in the risk assessment.  
 
The possibility of making inter-species extrapolations and high dose to low dose extrapolations 
makes PBTK highly applicable. It is not always possible to validate the model with respect to in vivo 
data for every species, nor at all relevant exposure conditions. Often a PBTK model can only be 
validated on in vivo data from animal studies performed at relatively high doses (compared to 
exposures to human).  
 
Therefore, it is important to establish a sound biological basis for each PBTK model based on 
available data, and to evaluate the feasibility of using extrapolations in each case. High dose to low 
dose and inter-species extrapolations seem to work adequately for the models developed in this 
work. In such cases, estimation of the internal concentration levels in humans at low exposure 
levels is a viable option, although the human version of the PBTK models have not been validated 
on human in vivo data.  
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It is important to consider that such predictions have significant uncertainties. A practical solution 
to that problem is to multiply the simulated levels with a predefined factor based on an uncertainty 
estimate for the given model, for example a factor between two and five. In such a way one can seek 
to avoid underestimation of blood and tissue levels, as some overestimation of these concentration 
levels is much less of a problem when the results are used for risk assessment purposes. We are thus 
proposing to introduce an alternative assessment type factor to account for uncertainties in the 
PBTK simulation. It is important to point out that such models would not be applicable for drugs, as 
drugs are administrated at relatively high doses, and may have narrow therapeutic window. 
 
An assessment factor (previously called safety factor) of 100 has been used as a default in risk 
assessment for more than 50 years, 10 to account for inter-species differences between laboratory 
animals and humans, and 1o to account for inter-individual differences in humans. It has been 
suggested that the inter-species difference should be further divided to two parts, accounting for 
uncertainties in toxicokinetics (100.6 = 4) and toxicodynamics  (100.4 = 2.5), respectively.  The inter-
individual assessment factor should likewise be subdivided by (100.5 = 3.2) for uncertainties in both 
toxicokinetics and toxicodynamics (Dourson et al., 2013). 
 
PBTK modelling has a large potential to refine the present risk assessment. One can do simulations 
in the individual species, and thereby study the actual concentration levels in human versus rat. 
One of the possibilities is to simulate simultaneous exposures from different routes, for example 
dermal, oral and inhalation, and thereby assess aggregate exposure for risk assessment. PBTK 
modelling is also considered for cumulative risk assessment by different bodies, like EFSA, as a 
higher tier approach.  
 
There are two very important directions one can chose for further work in this area.  
 
• One possibility is to make relatively simple PBTK models for many compounds with basis 
in the pilot version of the toolbox developed in this project, and to use such models in 
cumulative and aggregate risk assessment at relatively low exposure levels, well below 
NOAEL. In such case the focus will be on establishing as good and sound biological basis 
for the models, feed available data into the models as parameters, validate the models as 
well as possible, and accept that all models cannot be validated at all conditions due to lack 
of data. It is important to use knowledge about similarity between chemicals, especially 
with respect to molecular structure and ADME characteristics, to group chemicals that can 
be handled by similar PBTK model architecture, and that can interact with one another via 
similar metabolism.  
 
• The other main direction is to develop much more accurate PBTK models that are 
validated at relevant conditions. This can either be done by selecting chemicals that are 
rich on in vivo data both from animal studies and have some human data, or by acquiring 
the necessary data by collaboration with experimental groups. 
It is important to follow both these direction. In this way a practical tool box for providing input to 
cumulative and aggregate risk assessment in the pesticide and biocide area can be developed. Such 
tool box should be applied in situations where data is generally scarce and strong need exist for 
estimates of internal concentration levels in the low dose area. At the same time more detailed 
analysis can be done for other compounds, were strengths and limitations of the underlying 
methods used for inter-species extrapolations are explored for compounds where thorough 
validation can be performed.    
 
To develop a comprehensive tool box for use in cumulative risk assessment, the model for a binary 
mixture needs to be extended to models for multiple component mixture. Technically this can be 
done in the framework of the modular approach developed in this project. In such case one would 
have to make estimates of inhibition constants between the compounds in the mixture at higher 
exposure levels. In the low exposure level range, like the scenarios used in this work, a possibility 
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would be to use a simple procedure where the actual blood and tissue levels for the different 
compounds are added together at each time point in the simulation. In such case, the curve for each 
compound needs to be scaled by a reference value for the same compound. 
 
It is therefore important to adjust present risk assessment methods to accommodate the use of 
internal concentration levels in blood and tissues, and to develop reference values suitable for PBTK 
based risk assessment. Present reference values like ADI are made for traditionally risk assessment, 
which is carried out with respect to the exposed dose, are not considered appropriate for use in 
PBTK based risk assessment. The recent IPCS report on application of PBTK in risk assessment 
(WHO, 2010a) points out that the dose metric for the exposure scenario to be risk assessed should 
be calculated in the same way as the critical toxicological study. A simple solution would be to carry 
out simulations at the actual exposures and then simulations at an exposure equal to a specific 
reference value as well.  Thereby, internal concentration reference values would be created based on 
the present reference values. 
 
An important question is which reference value would be the most appropriate to use in PBTK 
based risk assessment of chemicals, and for pesticides and biocides in particular. As PBTK models 
can be extrapolated from one species to another by inserting the appropriate parameters, inter-
species differences are incorporated in the simulation. The ADI, which is derived from NOAEL 
obtained from animal studies, generally by division with an assessment factor of 100 to account for 
inter-species and inter-individual differences, is thus not necessarily the most appropriated 
reference values to use. A possibility would be to base the risk assessment on NOAEL. In such case 
it would be necessary to account for the inter-individual differences, for example by applying an 
assessment factor that only accounts for inter-individual and not inter-species variability. These 
questions need to be addressed. The bench mark dose (BMD) is also mentioned in relation to PBTK 
based risk assessment among other.  
 
Judson et al.  proposed a relatively simple and innovative approach where human in vitro data from 
the ToxCast program of U.S.EPA was combined with a simple human PBTK model ling to define so-
called Biological Pathway Altering Dose. This approach could be applied as a surrogate risk 
assessment in cases where no animal data in available.   
 
In some cases one might choose to use the external exposure as a reference value, basically 
assuming complete absorption and no degradation. In such case, this should be clear from 
documentation of the work. For compounds like tebuconazole and prochloraz, which are almost 
completely metabolised upon absorption, such approximation would underestimate the risk, 
because the internal levels are so small compared to the exposed doses.   
 
More sophisticated ideas can be realised with present methods in PBTK modelling, given that 
appropriate data for model parameter, as well as for model validation, are available. The pesticide 
and biocide area suffers from lack of toxicokinetic data in contrast to the rich toxicological 
information available. Thus it will take time to acquire the necessary data to develop advanced 
PBTK models in this area. Nevertheless, some key possibilities are mentioned below.  
 
One possibility is to include inter-individual variability into the model, for example by carrying out 
simulations for different age groups and to do probabilistic estimates of the influence of genetic 
variability. In such case appropriate experimental data on variability in metabolism between 
individuals is needed, among other, and new data has to be acquired for vast amount of chemicals. 
 
Another important extension of the present model would be to make a specific model for children. 
There are many physiological and toxicokinetic differences between children and adults which may 
result in different internal concentration levels . Children are the most sensitive group of individuals 
as their metabolic pathways are still developing. The exposure levels of pesticide residues from the 
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food are higher for children the adults, as children eat larger quantities of food in relation to their 
body weight. Simulating the distribution of compounds to the fetus by developing a model for at 
pregnant woman is also an important possibility to assess the internal dose during fetal life. 
 
Probabilistic methods are very useful to account for variability and uncertainty in data used for the 
risk assessment,  and can be used to evaluate the variability in key parameters and to incorporate 
variation due to inter-individual differences in the PBTK based risk assessment (Rietjens et al., 
2008; Bois et al., 2010; Nong et al., 2008). Such work could eventually be used to modify the 
assessment factors presently used to account for inter-species and inter-individual variability. 
Probabilistic methods are also powerful tools for estimating variation in exposure levels, and are 
also used as tools for estimating cumulative risk assessment (Bos et al., 2009; Muller et al., 2009; 
Petersen et al., 2013). 
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Appendix 1: Overview of studies used for toxicological evaluation in (JMPR, 
2010).  
Species / 
study type 
Dose 
[mg/kg 
BW/day] 
Findings NOAEL [mg/kg 
BW/day] 
Reference 
(all 
references 
as cited in 
(JMPR, 
2010)) 
Rat 
Gavage,  28 
days  
0, 30, 100 
and 300 
Decrease in red blood cell 
parameters. Increased activity 
of liver enzymes. Increased 
weight of liver, spleen – and 
kidney (only females) 
30 
Changes in 
haematological 
and clinical 
chemical 
parameters and 
organ weights 
Heimann & 
Kaliner, 
1984 
Rats 
Oral, 2 years 
M: 0, 5.3, 
15.9, 55.0 
F: 0, 7.4, 
22.8, 86.3 
Decreased triglyceride conc in 
females – and increased spleen 
weight. Increased incidence of 
pigmented Kupffer cells, 
increased haemosiderin 
accumulation in 
spleen.Increased incidence of 
C-cell adenomas and 
carcinomas of thyroid at all 
dose levels (5, 16, 55 mg/kg 
bw/day) – no clear dose-
response relationship – 
concluded: Not carcinogenic. 
Endometrical adenocarcinoma 
– small, not dose-related 
15.9 
Increased 
incidence of 
pigmented 
Kupffer cells 
 
Bomhard & 
Ramm, 
1988; Sander 
& Schilde, 
1993 
Rats 
Gavage, 
developmental 
tox study  
Pregnant 
rats from 
GD6 to 
GD15: 0, 
10, 30, and 
100 
Dose-related reduction in body 
weight gain. 
At 100 m/kg bw/day: Faecal 
alterations (eg loose stools) in 
11 dams. Increased number of 
losses and decrease in mean 
fetal weight. Increased number 
of runts and foetuses with 
malformations (mostly 
microphthalmia) 
30  
Maternal toxicity: 
decreased bw 
gains. 
30 
Developmental 
toxicity: 
decreased fetal 
weight, increased 
incidence of 
malformations, 
increased 
incidence of 
postimplantation 
losses and 
increased number 
of runts 
Renhof, 
1985a 
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Rats 
Dieary,  
two-
generation 
study of 
reproductive 
toxicity 
M: 0, 7.1, 
21.6 and 
72.3 
F: 0, 9.1, 
27.8 and 
94.8 
Reduced feed consumption, 
decreased body weights, 
decreased liver and kidney 
weights. 
Decreased pub body weights 
and decreased litter size. 
No reproductive toxicity seen. 
21.6 
Parental systemic 
toxicity and 
offspring toxicity 
Eiben, 1987 
Mice 
Oral, 21 
months 
M: 0, 5.9, 
18 and 53 
F: 0, 9.0 
26 and 81 
Increased liver weight at 
highest dose level 
Slight increase in prevalence of 
lipid-containing periportal 
vacuoles in liver. No evidence 
of carcinogenic potential. 
5.9 
Centrilobular fine 
vacuolization in 
the liver (lipids) 
Bomhard & 
Ramm, 
1988a 
Mice, 
developmental 
tox study 
0, 1,3, 10, 
30, 100 
Maternal toxicity: increased 
hepatic enzyme induction 
(increased cytochrome P450 
content and N-demethylase 
activity), severity of 
vacuolization in liver cells. 
Developmental toxicity: 
marginal increase in 
postimplantation loss and 
statistically significant increase 
of common malformations 
30 
Maternal toxicity 
10 embryo and 
fetal toxicity 
Becker and 
Biedermann, 
1995a 
Dogs 
Oral, 1 year 
M: 0, 2.96, 
4.39 
F: 0, 2.94, 
4.45 
Slight hypertrophy of adrenal 
zona fasciculate cells – 
accompanied by an increased 
incidence of large fatty 
vacuoles 
2.94 
Histopathological  
changes in the 
adrenals. 
4.39  
Cataract 
induction (no 
effects found in 
the study) 
Porter et al, 
1989, 1993 
Rabbit, 
gavage, 
developmental 
tox study 
0, 10, 30, 
100 
Maternal decreased body 
weight gain, decreased food 
consumption. 
Increased postimplantation 
loss and malformations, 
hydrocephalus and increased 
external and skeletal 
abnormalities at 100 mg/kg 
bw/day 
30  
Maternal, embryo 
and fetal toxicity 
 
According to  
DAR (2006): 
NOAEL for 
embryotoxic and 
teratogenic 
effects: 10 mg/kg 
bw/day and 30 
mg/kg bw/day 
for maternal 
toxicity in the 
Becker and 
Biedermann-
study 
Two studies: 
Becker, 
Vogel and 
Terrier, 
1988b; 
Becker and 
Biedermann, 
1995c) 
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Appendix 2: Detailed mathematical description of the tebuconazole model 
Equations for liver concentration, metabolism and oral exposure 
 
The concentration of the mother compound in the liver (Cliver) is calculated by the following 
differential equation for change in the concentration over time [µmol/l/hr].  
 
𝑑𝐶𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0)
𝑑𝑡
= 𝑄𝑙𝑖𝑣𝑒𝑟
𝑉𝑙𝑖𝑣𝑒𝑟
� 𝐶𝐴(𝐶1𝑀0) − 𝐶𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0)𝑃𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0)� + 1𝑉𝑙𝑖𝑣𝑒𝑟  �–𝑑𝐴𝑀𝐿(𝐶1𝑀0)𝑑𝑡  –𝑑𝐴𝑂𝐿(𝐶1𝑀0)𝑑𝑡 + 𝐴′𝐷𝑖𝑒𝑡𝑒𝑥𝑝(𝐶1𝑀0)�  
 
The concentration change is a function of the difference in the concentration of free (unbound) 
tebuconazole in arterial blood entering the liver (CA) and the concentration of free tebuconazole in 
the venous blood leaving the liver (CV,liver = Cliver/Pliver). Qliver is the blood flow through the liver in 
[l/hr], Vliver is the liver volume in [l] and Pliver is the liver:blood partition coefficient. All 
concentrations are calculated in [µmol/l] and the partition coefficient is unit less. The mother 
compound, tebuconazole in this case, is labelled C1M0. (The metabolites formed, are labelled 
C1M1.) 
 
CA is calculated by multiplying the total blood concentration with the fraction unbound (fu), which 
we have calculated from percent plasma binding (%PPB). 
𝐶𝐴(𝐶1𝑀0) = 𝐶𝑏𝑙𝑜𝑜𝑑(𝐶1𝑀0) 𝑓𝑢(𝐶1𝑀0) = 𝐶𝑏𝑙𝑜𝑜𝑑(𝐶1𝑀0)  (100 − %𝑃𝑃𝐵𝐶1𝑀0)100  
 
The concentration in the liver depends also on the rate of metabolism (dAML/dt) and the amount of 
orally administered compound entering the liver via the portal vein over time. The metabolism in 
the liver is described by Michaelis-Menten kinetics. As we use Vmax and KM values obtained by in 
vitro measurement in rat liver microsomes, we need to use concentration of free tebuconazole in 
the venous blood leaving the liver (Cliver/Pliver) rather than the concentration of tebuconazole in the 
liver (Cliver) (Campbell, Jr. et al., 2012).  In our model Vmax and KM have the units [µmol/hr] and 
[µmol/l], respectively. 
 
𝑑𝐴𝑀𝐿(𝐶1𝑀0)
𝑑𝑡
= 𝑉max(𝐶1𝑀0)  𝐶𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0) 𝑃𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0)⁄
𝐾𝑀(𝐶1𝑀0) + 𝐶𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0) 𝑃𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0)⁄   
 
Input to the liver from the gastro intestinal tract is either described by a bolus dose, when a dose is 
given at a specific time point or with a function describing dietary intake over period of time. In our 
model a bolus dose is sent directly to the liver by using a pulse function (AOL), where the absorption 
rate in modelled by a rate constant (ka) with the unit [hr-1]. AOL is the amount of compound left in 
the GIT. The following equation describes the decrease of AOL in GIT over time, after administration 
of oral dose. The corresponding rate of delivering tebuconazole to the liver is thus (- dAOL/dt). 
 
𝑑𝐴𝑂𝐿(𝐶1𝑀0)
𝑑𝑡
= − 𝑘𝑎 𝐴𝑂𝐿(𝐶1𝑀0) 
 
𝐴𝑂𝐿(𝐶1𝑀0) (𝑇𝐼𝑀𝐸 = 0) = 𝐴𝑂𝑟𝑎𝑙(𝐶1𝑀0) =  𝐹𝑎(𝐶1𝑀0) 𝐴𝑂𝑟𝑎𝑙𝑑𝑜𝑠𝑒(𝐶1𝑀0)  𝐵𝑊𝑀𝑊𝐶1𝑀0 
 
AOral  is the total amount of compound entering the liver in [µmol], Fa is the fractional absorption of 
the compound, AOraldose is the orally administered dose in [mg/kg BW], BW is the body weight in 
[kg] and MW is the molecular weight in [mg/µmol].  
 
The dietary exposure (A´Dietexp)  is calculated with the following equation, where it is assumed that 
the daily exposure from the diet (AOraladm) is distributed equally throughout 12 hours (the A´kzero 
function), with 12 hour rest. AOraladm has the unit [mg/kg BW] and A´Dietexp and A´kzero [µmol/hr]. 
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𝐴𝐷𝑖𝑒𝑡𝑒𝑥𝑝(𝐶1𝑀0)′ = 𝐼𝐹 𝑀𝑂𝐷(𝑇𝐼𝑀𝐸, 24) ≤  12 𝑇𝐻𝐸𝑁 𝐴𝑘𝑧𝑒𝑟𝑜(𝐶1𝑀0)′  𝐸𝐿𝑆𝐸 0 
 
𝐴′𝑘𝑧𝑒𝑟𝑜(𝐶1𝑀0) = 𝐹𝑎(𝐶1𝑀0) 𝐴𝑂𝑟𝑎𝑙𝑎𝑑𝑚(𝐶1𝑀0)  𝐵𝑊𝑀𝑊𝐶1𝑀0  112ℎ𝑟  
 
Normally the time the dietary intake is assumed between 7 and 19 hours and when simulating 
aggregate exposure it is important to add exact time points of the exposure via each route. Thus the 
equation takes the following form. 
 
𝐴𝐷𝑖𝑒𝑡𝑒𝑥𝑝(𝐶1𝑀0)′ = 𝐼𝐹 𝑀𝑂𝐷(𝑇𝐼𝑀𝐸, 24) ≥  7 𝐴𝑁𝐷 𝑀𝑂𝐷(𝑇𝐼𝑀𝐸, 24) ≤  19 𝑇𝐻𝐸𝑁 𝐴𝑘𝑧𝑒𝑟𝑜(𝐶1𝑀0)′  𝐸𝐿𝑆𝐸 0 
 
Equations for skin concentration and dermal exposure 
 
The concentration of the compound in the skin (Cskin) is calculated as a function of the 
concentration of free compound entering the skin by arterial blood (CA) and the concentration of 
free compound in the venous blood leaving the skin (Cv,skin = Cskin/Pskin), as well as the amount of 
compound penetrating the skin by dermal exposure when relevant.  
 
𝑑𝐶𝑠𝑘𝑖𝑛(𝐶1𝑀0)
𝑑𝑡
=  𝑄𝑠𝑘𝑖𝑛
𝑉𝑠𝑘𝑖𝑛
� 𝐶𝐴(𝐶1𝑀0) −  𝐶𝑠𝑘𝑖𝑛(𝐶1𝑀0)𝑃𝑠𝑘𝑖𝑛(𝐶1𝑀0)� + 1𝑉𝑠𝑘𝑖𝑛  𝑑𝐴𝐷𝑆(𝐶1𝑀0)𝑑𝑡  𝑋𝑑𝑒𝑟𝑚𝑎𝑙−𝑜𝑛−𝑜𝑓𝑓   
 
The equation is set up so that it can be used with and without dermal exposure, with Xdermal-on-off set 
to 1 and 0, respectively. The dermal exposure (ADS) is described by the following equation, where 
tdermalexptime is the time the rat or the human is exposed to tebuconzole, i.e. the time a product 
containing tebuconazole is estimated to be on the skin surface. This equation can be modified for 
specific exposure scenarios, in order to account for the time of the day the subject is exposed to the 
biocide product containing tebuconazole. 
 
𝑑𝐴𝐷𝑆(𝐶1𝑀0)
𝑑𝑡
 = 𝐼𝐹 𝑀𝑂𝐷(𝑇𝐼𝑀𝐸, 24) ≤  𝑡𝑑𝑒𝑟𝑚𝑎𝑙𝑒𝑥𝑝𝑡𝑖𝑚𝑒 𝑇𝐻𝐸𝑁 𝑑𝐴𝐷𝑆𝑐𝑜𝑛𝑡(𝐶1𝑀0)𝑑𝑡  𝐸𝐿𝑆𝐸 0 
 
The dermal absorption is calculated by Fick’s law, 
 
𝑑𝐴𝐷𝑆𝑐𝑜𝑛𝑡(𝐶1𝑀0)
𝑑𝑡
 =  𝐾𝑝  𝑆𝐴 � 𝐶𝑠𝑢𝑟𝑓𝑎𝑐𝑒(𝐶1𝑀0)  −  𝐶𝑠𝑘𝑖𝑛(𝐶1𝑀0)𝑃𝑠𝑘𝑖𝑛:𝑠𝑢𝑟𝑓𝑎𝑐𝑒(𝐶1𝑀0)� 
 
where Kp is the skin permeability rate constant in [dm/hr], SA is the exposed skin surface area in 
[dm2], Csurface is the concentration of compound in liquid mixture on the skin surface in [µmol/l] 
and Pskin:surface is the unitless skin:surface partition coefficient.   
 
According to the above equation, the exposure is calculated based on the concentration in the 
biocide liquid on the skin surface, the skin permeability and the skin:surface partition coefficient.  
The equation above simulates c0ntious absorption in a situation where a solution of a fixed 
concentration is present on the skin surface, assuming unlimited exposure within the simulation 
time.  
 
To simulate a situation where a solution of volume Vsurface(C1M0) and concentration Csurface,init(C1M0) is 
spilled on or administered to the skin surface, it is necessary to reduce the concentration of the 
compounds on the skin surface by removing the compound that has already been absorbed. As our 
PBTK model only considers the active compound, this is a practical mathematical way to administer 
the compound in the model. In reality, probably both the active compound and the solvent are 
absorbed  through the skin, and some of the solvent can evaporate as well. 
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𝐶𝑠𝑢𝑟𝑓𝑎𝑐𝑒(𝐶1𝑀0) =  𝐷𝑎𝑏𝑠(𝐶1𝑀𝑜)  � 𝐶𝑠𝑢𝑟𝑓𝑎𝑐𝑒,𝑖𝑛𝑖𝑡(𝐶1𝑀0) 𝑉𝑠𝑢𝑟𝑓𝑎𝑐𝑒(𝐶1𝑀0) −  𝐴𝐷𝑆(𝐶1𝑀0)�𝑉𝑠𝑢𝑟𝑓𝑎𝑐𝑒(𝐶1𝑀0)  
 
The fractional dermal absorption (Dabs) was added to this equation. In our simulations, all the 
compound that was administered on the skin surface was absorbed, and no equilibrium between the 
surface concentration and the skin concentration was obtained. If a lower value of Pskin:surface was 
used, the absorption rate would  be lower, but all the compound was absorbed. The same would 
happen if SA was smaller.  Thus, we added Dabs to the model, and thereby modified the Csurface term  
and reduced the concentration to equal the part of the solution that is absorbed.  Thus, we modified 
the surface concentration to control the amount of administered compound, which should be 
considered as practical solution.  
 
The above implementation was, however, not practical with respect to the simulations carried out in 
this work, which includes specific criteria based on application and product, including protection 
factors due to clothing and gloves. Therefore a new set of equations, with the dermal dose 
(𝐴𝐷𝑒𝑟𝑚𝑎𝑙𝑑𝑜𝑠𝑒(𝐶1𝑀0)) administered equally over the time period the exposure 
occurs (𝑡𝑑𝑒𝑟𝑚𝑎𝑙𝑒𝑥𝑝𝑡𝑖𝑚𝑒(𝐶1𝑀0)). This equation also includes the possibility to define the specific time 
interval during the day, by specifying the time of exposure start (𝑡𝑑𝑒𝑟𝑚𝑎𝑙𝑒𝑥𝑝𝑠𝑡𝑎𝑟𝑡(𝐶1𝑀0))  as well. All 
times are in hrs. It is possible to simulate exposure during two working weeks with a weekend break 
in between. 
 
𝑑𝐶𝑠𝑘𝑖𝑛(𝐶1𝑀0)
𝑑𝑡
=  𝑄𝑠𝑘𝑖𝑛
𝑉𝑠𝑘𝑖𝑛
� 𝐶𝐴(𝐶1𝑀0) −  𝐶𝑠𝑘𝑖𝑛(𝐶1𝑀0)𝑃𝑠𝑘𝑖𝑛(𝐶1𝑀0)� + 1𝑉𝑠𝑘𝑖𝑛  𝐴´𝐷𝑆(𝐶1𝑀0) 𝑋𝑑𝑒𝑟𝑚𝑎𝑙−𝑜𝑛−𝑜𝑓𝑓  
  𝐴´𝐷𝑆(𝐶1𝑀0) = 𝐼𝐹 𝑀𝑂𝐷(𝑇𝐼𝑀𝐸, 24) ≥  𝑡𝑑𝑒𝑟𝑚𝑎𝑙𝑒𝑥𝑝𝑠𝑡𝑎𝑟𝑡(𝐶1𝑀0) 𝐴𝑁𝐷 𝑀𝑂𝐷(𝑇𝐼𝑀𝐸, 24)
≤  (𝑡𝑑𝑒𝑟𝑚𝑎𝑙𝑒𝑥𝑝𝑠𝑡𝑎𝑟𝑡(𝐶1𝑀0) + 𝑡𝑑𝑒𝑟𝑚𝑎𝑙𝑒𝑥𝑝𝑡𝑖𝑚𝑒(𝐶1𝑀0)) 𝐴𝑁𝐷 (𝑇𝐼𝑀𝐸 ≥ 5 ∗ 24 𝑂𝑅 𝑇𝐼𝑀𝐸
≤ 7 ∗ 24) 𝑇𝐻𝐸𝑁 𝐴´𝑘𝑑𝑒𝑟𝑚𝑎𝑙(𝐶1𝑀0) 𝐸𝐿𝑆𝐸 0 
 
𝐴′𝑘𝑑𝑒𝑟𝑚𝑎𝑙(𝐶1𝑀0) = 𝐴𝐷𝑒𝑟𝑚𝑎𝑙𝑑𝑜𝑠𝑒(𝐶1𝑀0)  1𝑀𝑊𝐶1𝑀0  1𝑡𝑑𝑒𝑟𝑚𝑎𝑙𝑒𝑥𝑝𝑡𝑖𝑚𝑒(𝐶1𝑀0)  
 
𝐴𝐷𝑒𝑟𝑚𝑎𝑙𝑑𝑜𝑠𝑒(𝐶1𝑀0) is calculated based on specific exposure scenarios described in section 5.3.1.2 . The 
dermal dose is calculated from the estimated total exposure of a given formulation (product), 
protection factors due to clothes and gloves, and the estimated dermal absorption of the product. It 
has the unit [mg] in the model and not [mg/kg BW] which is used for the other exposure routes 
(oral bolus, dietary and iv).  
 
Equations for rapidly and slowly perfused tissue concentrations 
 
Tissues and organs not of specific interest in the model are often lumped together, and in such a 
way we can simulate to whole body without considering each organ specifically. The rapidly 
perfused (rperfused) tissue compartment, consist of the brain, hearth, kidney, lung and spleen. The 
concentration of the compound in the rperfused compartment is calculated by solving the following 
differential equation.  The variables correspond to the variables for liver compartment, where the 
blood flow (Qrperfused) and tissue volume (Vrperfused) are the combined blood flows and tissue volumes 
for all the tissues of the compartment, respectively. 
 
𝑑𝐶𝑟𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑(𝐶1𝑀0)
𝑑𝑡
=  𝑄𝑟𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑
𝑉𝑟𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑
� 𝐶𝐴(𝐶1𝑀0) −  𝐶𝑟𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑(𝐶1𝑀0)𝑃𝑟𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑(𝐶1𝑀0)� 
 
Similarly, the slowly perfused (sperfused) compartment contains muscle and bone.  
 
𝑑𝐶𝑠𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑(𝐶1𝑀0)
𝑑𝑡
=  𝑄𝑠𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑
𝑉𝑠𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑
� 𝐶𝐴(𝐶1𝑀0) −  𝐶𝑠𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑(𝐶1𝑀0)𝑃𝑠𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑(𝐶1𝑀0)� 
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A special compartment was made for adipose (fat) tissue was added to the model and described 
with a separate differential equation. As adipose tissue has very different properties compared to 
muscle and bone due to high content of neutral lipids, it was kept in a separate compartment, 
instead of including it in the slowly perfused compartment. 
 
𝑑𝐶𝑓𝑎𝑡(𝐶1𝑀0)
𝑑𝑡
=  𝑄𝑓𝑎𝑡
𝑉𝑓𝑎𝑡
� 𝐶𝐴(𝐶1𝑀0) −  𝐶𝑓𝑎𝑡(𝐶1𝑀0)𝑃𝑓𝑎𝑡(𝐶1𝑀0)� 
 
Equations for the blood compartments 
 
The concentration change in the blood is calculated as the difference in the free concentrations in 
the venous (CV) and the arterial blood (CA) multiplied by the cardiac output (QC) and divide by the 
whole blood volume (Vblood). 
 
𝑑𝐶𝑏𝑙𝑜𝑜𝑑(𝐶1𝑀0)
𝑑𝑡
=  𝑄𝐶
𝑉𝑏𝑙𝑜𝑜𝑑
� 𝐶𝑉(𝐶1𝑀0) −  𝐶𝐴(𝐶1𝑀0)�  
 
The free concentration of the compound in the venous blood (CV) is the sum of the venous blood 
leaving the different tissues and organs (CV,t = Ct/Pt), where t stands for tissue (liver, skin, fat, 
rperfused or sperfused). Not all tissues are accounted for in the model, and thus we only divide with 
of the sum of the blood flows of the tissues considered and not the cardiac output. Otherwise, mass 
would not be preserved.  
 
𝐶𝑉(𝐶1𝑀0) =
�𝑄𝑙𝑖𝑣𝑒𝑟  𝐶𝑉,𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0) + 𝑄𝑠𝑘𝑖𝑛 𝐶𝑉,𝑠𝑘𝑖𝑛(𝐶1𝑀0) + 𝑄𝑟𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑  𝐶𝑉,𝑟𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑(𝐶1𝑀0) +
𝑄𝑠𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑  𝐶𝑉,𝑠𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑(𝐶1𝑀0) + 𝑄𝑓𝑎𝑡 𝐶𝑉,𝑓𝑎𝑡(𝐶1𝑀0)�  / (𝑄𝑙𝑖𝑣𝑒𝑟 + 𝑄𝑠𝑘𝑖𝑛 + 𝑄𝑟𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑 + 𝑄𝑠𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑 + 𝑄𝑓𝑎𝑡) 
 
The equation can be extended to allow for intra venous (iv) administration, where Xiv-on-off variable 
is set  to one when the iv exposure route should be active and set to zero to keep it inactive.  
 
𝐶𝑉(𝐶1𝑀0) =
�𝑄𝑙𝑖𝑣𝑒𝑟  𝐶𝑉,𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0) + 𝑄𝑠𝑘𝑖𝑛 𝐶𝑉,𝑠𝑘𝑖𝑛(𝐶1𝑀0) + 𝑄𝑟𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑  𝐶𝑉,𝑟𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑(𝐶1𝑀0) +
𝑄𝑠𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑  𝐶𝑉,𝑠𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑(𝐶1𝑀0) + 𝑄𝑓𝑎𝑡 𝐶𝑉,𝑓𝑎𝑡(𝐶1𝑀0) + 𝐴𝐼𝑉𝑒𝑥𝑝(𝐶1𝑀0)′  𝑋𝑖𝑣−𝑜𝑛−𝑜𝑓𝑓�  / (𝑄𝑙𝑖𝑣𝑒𝑟 + 𝑄𝑠𝑘𝑖𝑛 +
𝑄𝑟𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑 + 𝑄𝑠𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑 + 𝑄𝑓𝑎𝑡) 
 
Where A´IVexp was calculated with the following equation, where AIVdose is the iv dose in [mg/kg BW] 
and A´IVexp and A´kiv have the unit [µmol/hr]. It is assumed that the iv dose in administered and 
distributed in the blood in 0ne minute.  The dose is scaled to be delivered in one minute, but having 
a unit of [µmol/hr] as a general implementation.  
 
𝐴𝐼𝑉𝑒𝑥𝑝(𝐶1𝑀0)′ = 𝐼𝐹 𝑇𝐼𝑀𝐸 ≤  1/60 𝑇𝐻𝐸𝑁 𝐴𝑘𝑖𝑣(𝐶1𝑀0)′  𝐸𝐿𝑆𝐸 0 
 
𝐴′𝑘𝑖𝑣(𝐶1𝑀0) = 𝐴𝐼𝑉𝑑𝑜𝑠𝑒(𝐶1𝑀0)  𝐵𝑊𝑀𝑊𝐶1𝑀0  60 𝑚𝑖𝑛/ℎ𝑟1 𝑚𝑖𝑛   
 
The compounds free concentration in the arterial blood is calculated as the whole blood 
concentration (free + bound) times the fraction unbound, as also described in section 3.1.2.1. 
   
𝐶𝐴(𝐶1𝑀0) = 𝐶𝑏𝑙𝑜𝑜𝑑(𝐶1𝑀0) 𝑓𝑢(𝐶1𝑀0) 
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Equations describing elimination of metabolites from the body 
 
The elimination in urine and faeces was modelled by first order kinetics. A specific compartment 
was constructed for this purpose. In the case of tebuconazole, practically all the tebuconazole was 
metabolites and thus it was only necessary to model the excretion of the metabolites. Moreover, we 
only considered the sum of all metabolites formed (labelled C1M1). The elimination rates for 
urinary and faecal excretion (labelled EU and EF respectively) are calculated with the following 
equations. 
𝑑𝐴𝐸𝑈(𝐶1𝑀1)
𝑑𝑡
= 𝐴𝐶1𝑀1 𝑘𝑒𝑢(𝐶1𝑀1) 
 
𝑑𝐴𝐸𝐹(𝐶1𝑀1)
𝑑𝑡
= 𝐴𝐶1𝑀1 𝑘𝑒𝑓(𝐶1𝑀1) 
  
Where keu and kef are the rate constants for urinary and faecal excretion in [hr-1], respectively, and 
AC1M1  is the total amount of metabolites in the body. The change of amount of metabolites at each 
time point is described by the following differential equations, and is the difference between the rate 
of formation of metabolites and the excretion rate for metabolites removed from the body.   
 
𝑑𝐴𝐶1𝑀1
𝑑𝑡
=  𝑑𝐴𝑀𝐿(𝐶1𝑀0)
𝑑𝑡
−  𝑑𝐴𝐸(𝐶1𝑀1)
𝑑𝑡
 
 
𝑑𝐴𝐸(𝐶1𝑀1)
𝑑𝑡
= 𝑑𝐴𝐸𝑈(𝐶1𝑀1)
𝑑𝑡
+ 𝑑𝐴𝐸𝐹(𝐶1𝑀1)
𝑑𝑡
 
 
The average concentration of metabolites in the body (Cbody) is calculated with the following 
equation, where VdSS  is the volume of distribution at steady state in the body in [l/kg]. 
 
𝐶𝑏𝑜𝑑𝑦(𝐶1𝑀1) = 𝐴𝐶1𝑀1𝑉𝑑(𝐶1𝑀1))𝑆𝑆  𝐵𝑊 
 
Mass balances for controlling that preservation of mass  
 
In addition we have set up mass balances to control that mass is preserved, i.e. that that no 
compound is lost during the simulation. The sum of the total amount of tebuconazole (AC1M0) and 
the combined amount of all metabolites (AC1M1) in the body, and the amount of compounds 
eliminated via faeces (AEF(C1M1))  and urine (AEU(C1M1)),  ATotal(C1), should be equal to the total amount 
of tebuconazole administered to the body in [µmol]. 
 
𝐴𝑇𝑜𝑡𝑎𝑙(𝐶1) = 𝐴𝐶1𝑀0 + 𝐴𝐶1𝑀1 + 𝐴𝐸𝑈(𝐶1𝑀1) + 𝐴𝐸𝐹(𝐶1𝑀1) =  𝐴𝐶1𝑀0 + 𝐴𝐶1𝑀1 + 𝐴𝐸(𝐶1𝑀1) 
 
AC1M0 is the portion of an oral bolus dose of tebuconazole  not yet absorbed and thus present in the 
GIT at a given time point, plus the combined amount tebuconazole in all compartments at the same 
time point. Compound administered by dietary exposure is sent directly to the liver, dermal dose is 
absorbed to the skin and an iv dose is added to the venous blood, and distributes from there.  AC1M1 
is the total amount of metabolites formed by metabolism of tebuconazole at a given time point, 
minus the amount of tebuconazole metabolites that excreted from the body at the same time point. 
(AC1M0 is labelled total_mass_C1M0 and AC1M1 is labelled total_mass_C1M1 in the graphs in the 
results section). 
 
𝐴𝐶1𝑀0 = 𝐴𝑂𝐿(𝐶1𝑀0) + 𝑉𝑙𝑖𝑣𝑒𝑟  𝐶𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0) + 𝑉𝑠𝑘𝑖𝑛 𝐶𝑠𝑘𝑖𝑛(𝐶1𝑀0) + 𝑉𝑟𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑  𝐶𝑟𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑(𝐶1𝑀0)+ 𝑉𝑠𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑  𝐶𝑠𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑(𝐶1𝑀0) +  𝑉𝑓𝑎𝑡  𝐶𝑓𝑎𝑡(𝐶1𝑀0) +  𝑉𝑏𝑙𝑜𝑜𝑑  𝐶𝑏𝑙𝑜𝑜𝑑(𝐶1𝑀0)  
 
𝐴𝐶1𝑀1 = 𝐴𝑀𝐿(𝐶1𝑀0) − 𝐴𝐸(𝐶1𝑀1)  
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A simple check of ATotal, is to sum up the amount of tebuconzole administered by different exposure 
routes for a given simulation on a daily bases, such that the combined exposure can be evaluated for 
a given day, summed up with exposure on all the prior day studies in the simulation. In the present 
implementation, the oral and the iv doses are only implemented as single bolus doses at time zero, 
whereas the oral dietary administration and the dermal exposure are implemented as repeated 
exposure on a daily basis.  NDermaldays is the number of days where repeated dermal exposure occurs, 
and correspondingly NOraldays is the number of days of repeated oral dietary exposure. 
 
𝐴𝑇𝑜𝑡𝑎𝑙𝑑𝑜𝑠𝑒 = 𝐵𝑊𝑀𝑊𝐶1𝑀0 �𝐴𝑂𝑟𝑎𝑙𝑑𝑜𝑠𝑒(𝐶1𝑀0)  + 𝐴𝑂𝑟𝑎𝑙𝑎𝑑𝑚(𝐶1𝑀0)   𝑁𝑂𝑟𝑎𝑙𝑑𝑎𝑦𝑠 +  𝐴𝑖𝑣𝑑𝑜𝑠𝑒(𝐶1𝑀0)�+ 1
𝑀𝑊𝐶1𝑀0
𝐴𝐷𝑒𝑟𝑚𝑎𝑙𝑑𝑜𝑠𝑒(𝐶1𝑀0) 𝑁𝐷𝑒𝑟𝑚𝑎𝑙𝑑𝑎𝑦𝑠  
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Appendix 3: Detailed mathematical description of the prochloraz model 
Equations for liver concentration, metabolism and oral exposure 
 
The concentration of the mother compound (labelled C1M0) in the liver (Cliver) is calculated by the 
following differential equation for change in the concentration over time in [µmol/l/hr].  
 
𝑑𝐶𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0)
𝑑𝑡
= 𝑄𝑙𝑖𝑣𝑒𝑟
𝑉𝑙𝑖𝑣𝑒𝑟
� 𝐶𝐴(𝐶1𝑀0) − 𝐶𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0)𝑃𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0)� + 1𝑉𝑙𝑖𝑣𝑒𝑟  �–𝑑𝐴𝑀𝐿(𝐶1𝑀0)𝑑𝑡  –𝑑𝐴𝑂𝐿(𝐶1𝑀0)𝑑𝑡 + 𝐴′𝑑𝑖𝑒𝑡𝑒𝑥𝑝(𝐶1𝑀0)�  
 
As described above, the concentration change depends on the difference in the concentration of free 
(unbound) prochloraz in arterial blood entering the liver and the concentration of free prochloraz in 
the venous blood leaving the liver, on the rate of metabolism in the liver, and the absorption rate of 
orally administered compound entering the liver via the portal vein. The input to the liver is 
modelled in the same way in the tebuconazole model. 
 
The liver part of prochloraz model is identical to the corresponding one for tebuconazole, with the 
exception a different set of equation was implemented for the metabolism. Experimental in vitro 
data for the intrinsic clearance (CLint) of prochloraz is available in the literature, but no Vmas and KM 
values.  At low prochloraz concentrations the following equation is used. 
 
𝑑𝐴𝑀𝐿(𝐶1𝑀0)
𝑑𝑡
= 𝐶𝐿𝑖𝑛𝑡(𝐶1𝑀0) 𝐶𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0)  𝑃𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0) 
 
At higher concentrations the metabolism of prochloraz was described by a combination of two 
reactions, using Michaelis-Menten kinetics. Formation of the first intermediate metabolite 
(metabolite 1) is described by one set of parameters and the remaining metabolic reaction scheme 
for depletion of metabolite 1 by another set of parameters. We make the preliminary assumption 
that the concentration of prochloraz and metabolite 1 in the liver is the same. The assumption is 
based on the hypothesis that most of the prochloraz entering the body metabolizes rather fast and 
undergoes ring opening to and then metabolizes further. 
 
𝑑𝐴𝑀𝐿(𝐶1𝑀0)
𝑑𝑡
= 𝑉max1(𝐶1𝑀0)  𝐶𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0) 𝑃𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0)⁄
𝐾𝑀1(𝐶1𝑀0) +  𝐶𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0) 𝑃𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0)⁄ ∗  𝑉max2(𝐶1𝑀0)  𝐶𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0) 𝑃𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0)⁄𝐾𝑀2(𝐶1𝑀0) + 𝐶𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0) 𝑃𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0)⁄    
 
Equations for rapidly and slowly perfused tissue and fat concentrations 
 
Tissues and organs not of specific interest in the model are often lumped together, with the rapidly 
perfused (rperfused) tissue compartment consisting of the brain, hearth, kidney, lung and spleen 
and the slowly perfused compartment consisting of muscle, bone and skin. Due to the special 
properties of adipose tissue and our experience with the tebuconazole model simulations, a special 
fat compartment was implemented. 
 
The concentration of the compound in the rperfused, sperfused and fat compartment is calculated 
by solving the following differential equation as described for the tebuconazole model, where all the 
variables and parameters are explained as well.   
 
𝑑𝐶𝑟𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑(𝐶1𝑀0)
𝑑𝑡
=  𝑄𝑟𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑
𝑉𝑟𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑
� 𝐶𝐴(𝐶1𝑀0) −  𝐶𝑟𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑(𝐶1𝑀0)𝑃𝑟𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑(𝐶1𝑀0)� 
 
𝑑𝐶𝑠𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑(𝐶1𝑀0)
𝑑𝑡
=  𝑄𝑠𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑
𝑉𝑠𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑
� 𝐶𝐴(𝐶1𝑀0) −  𝐶𝑠𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑(𝐶1𝑀0)𝑃𝑠𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑(𝐶1𝑀0)� 
. 
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𝑑𝐶𝑓𝑎𝑡(𝐶1𝑀0)
𝑑𝑡
=  𝑄𝑓𝑎𝑡
𝑉𝑓𝑎𝑡
� 𝐶𝐴(𝐶1𝑀0) −  𝐶𝑓𝑎𝑡(𝐶1𝑀0)𝑃𝑓𝑎𝑡(𝐶1𝑀0)� 
 
Equations for the blood compartments 
 
The concentration change in the blood is calculated based on the difference in the total 
concentrations (free and bound) in the venous and arterial blood as described for the tebuconazole 
model. 
 
𝑑𝐶𝑏𝑙𝑜𝑜𝑑(𝐶1𝑀0)
𝑑𝑡
=  𝑄𝐶
𝑉𝑏𝑙𝑜𝑜𝑑
� 𝐶𝑉(𝐶1𝑀0) −  𝐶𝐴(𝐶1𝑀0)�  
 
The free concentration of the compound in the venous blood is calculated as the sum of the venous 
blood leaving the different tissues and organs, where t stands for tissue (liver, rperfused, sperfused 
and fat). The sperfused compartment consists of muscle, bone and skin in the prochloraz model. 
The implementation of the iv and dermal exposure routes were left out in the present prochloraz 
model, but model can easily be modified to include those if need arises. 
 
𝐶𝑉(𝐶1𝑀0) = �𝑄𝑙𝑖𝑣𝑒𝑟  𝐶𝑉,𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0) + 𝑄𝑟𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑  𝐶𝑉,𝑟𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑(𝐶1𝑀0) + 𝑄𝑠𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑  𝐶𝑉,𝑠𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑(𝐶1𝑀0) + 𝑄𝑓𝑎𝑡 𝐶𝑉,𝑓𝑎𝑡(𝐶1𝑀0)�  / (𝑄𝑙𝑖𝑣𝑒𝑟 + 𝑄𝑟𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑 + 𝑄𝑠𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑 + 𝑄𝑓𝑎𝑡) 
 
The compounds free concentration in the arterial blood is calculated as the whole blood 
concentration (free + bound) times the fraction unbound. 
   
𝐶𝐴(𝐶1𝑀0) = 𝐶𝑏𝑙𝑜𝑜𝑑(𝐶1𝑀0) 𝑓𝑢(𝐶1𝑀0) 
 
Equations describing elimination of metabolites and prochloraz from the body 
 
The elimination in urine and faeces was modelling by first order kinetics. Like for tebuconazole a 
specific compartment was constructed for this purpose. Practically all the prochloraz was 
metabolites and thus it was only necessary to model the excretion of the metabolites when 
considering the portion of prochloraz absorbed from the GIT. The portion of prochloraz not 
absorbed is on the other hand excreted as prochloraz.  
 
In this model, we only considered the sum of all metabolites formed (labelled C1M1) and not the 
individual metabolites. The elimination rates for urinary and faecal excretion (labelled EU and EF 
respectively) were combined in the prochloraz model into a common term (labelled E). This was 
done because as according to our data, larger a fraction of the metabolites were eliminated via the 
urine at higher concentration, than at lower concentrations.  The excretion was thus calculated with 
the following equation, see section 3.1.2.5 for details. 
 
𝑑𝐴𝐸(𝐶1𝑀1)
𝑑𝑡
= 𝐴𝐶1𝑀1 𝑘𝑒(𝐶1𝑀1) 
 
The equation consists of the following subparts, which are not calculated specifically. 
 
𝑑𝐴𝐸(𝐶1𝑀1)
𝑑𝑡
= 𝑑𝐴𝐸𝑈(𝐶1𝑀1)
𝑑𝑡
+ 𝑑𝐴𝐸𝐹(𝐶1𝑀1)
𝑑𝑡
 
  
AC1M1, which is the total amount of metabolites in the body at each time point, is calculated with the 
following differential equation. The average concentration of metabolites in the body (Cbody)  is 
calculated as described  in section 3.1.2.5. 
 
Optimization of the cumulative risk assessment of pesticides and biocides using computational techniques: Pilot project 161 
 
𝑑𝐴𝐶1𝑀1
𝑑𝑡
=  𝑑𝐴𝑀𝐿(𝐶1𝑀0)
𝑑𝑡
−  𝑑𝐴𝐸(𝐶1𝑀1)
𝑑𝑡
 
 
For prohloraz that is not absorbed and eliminated as un-metabolized via faeces, we had to 
implement removal of the unabsorbed via faeces. In the case of oral dietary administration we 
remove the unabsorbed compound instantaneously, as it is of no practical purpose to consider it in 
the simulation. As we used a total excretion data for validation of the model and for adjusting the 
elimination rate constants, we needed a more realistic implementation in the case of a single oral 
dose. We proposed the following equation where we assumed that all the compound was excreted 
within 24 hrs. after administration of a single oral bolus dose. The linear excretion equation is just 
an approximation that is sufficient for the current purpose, as the data sets we used did not contain 
excretion data at time points under 24 hrs.  
 
𝑑𝐴𝐸,𝑂𝐵(𝐶1𝑀0)
𝑑𝑡
= 𝐼𝐹 𝑇𝐼𝑀𝐸 ≤  24 𝑇𝐻𝐸𝑁 (1 − 𝐹𝑎(𝐶1𝑀0)) 𝐴𝑂𝑟𝑎𝑙𝑑𝑜𝑠𝑒(𝐶1𝑀0)  𝐵𝑊𝑀𝑊𝐶1𝑀0  124ℎ𝑟  𝐸𝐿𝑆𝐸 0 
 
The corresponding portion of the unabsorbed compound from dietary exposure is calculated as 
equally excreted for a period of 24 hour, repeatedly.  
 
𝐴𝐸,𝐷𝑖𝑒𝑡(𝐶1𝑀0) = 𝐼𝐹 𝑀𝑂𝐷(𝑇𝐼𝑀𝐸, 24) ≤  24 𝑇𝐻𝐸𝑁 (1 − 𝐹𝑎(𝐶1𝑀0)) 𝐴𝑂𝑟𝑎𝑙𝑎𝑑𝑚(𝐶1𝑀0)  𝐵𝑊𝑀𝑊𝐶1𝑀0  𝑇𝐼𝑀𝐸24ℎ𝑟  𝐸𝐿𝑆𝐸 0 
 
And the total excretion of unabsorbed and not metabolised prochloraz is thus.  
 
𝐴𝐸(𝐶1𝑀0) =  𝐴𝐸,𝑂𝐵(𝐶1𝑀0)  + 𝐴𝐸,𝐷𝑖𝑒𝑡(𝐶1𝑀0)  
 
The combined excretion of prohloraz and its metabolites is thus calculated by addition together the 
contributions from the metaboltized and the original compound. This equation was of particular 
used for validation and adjusting the elimination rate constant based on experimental data. 
 
𝐴𝐸(𝐶1𝑡𝑜𝑡) =  𝐴𝐸(𝐶1𝑀1)  + 𝐴𝐸(𝐶1𝑀0) 
 
 
Mass balances for controlling that preservation of mass  
 
The mass balances to control that mass is preserved, i.e. that that no compound is lost during the 
simulation is similar to the corresponding equation for tebuconazole, with the exception that 
excretion of unabsorbed prochloraz (AEU(C1M0)) was added.  ATotal(C1), should be equal to the total 
amount of tebuconazole administered to the body in [µmol]. 
 
𝐴𝑇𝑜𝑡𝑎𝑙(𝐶1) =  𝐴𝐶1𝑀0 + 𝐴𝐶1𝑀1 + 𝐴𝐸(𝐶1𝑀1) + 𝐴𝐸(𝐶1𝑀0) 
 
AC1M0 is calculated with a similar equation as for tebuconazole, with the exception that the skin is 
part of the slowly perfused compartment, and AC1M1 is calculated in the same way as shown for the 
tebuconazole model. 
 
𝐴𝐶1𝑀0 = 𝐴𝑂𝐿(𝐶1𝑀0) + 𝑉𝑙𝑖𝑣𝑒𝑟  𝐶𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0) + 𝑉𝑟𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑  𝐶𝑟𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑(𝐶1𝑀0) + 𝑉𝑠𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑  𝐶𝑠𝑝𝑒𝑟𝑓𝑢𝑠𝑒𝑑(𝐶1𝑀0) +  𝑉𝑓𝑎𝑡  𝐶𝑓𝑎𝑡(𝐶1𝑀0) + 𝑉𝑏𝑙𝑜𝑜𝑑  𝐶𝑏𝑙𝑜𝑜𝑑(𝐶1𝑀0)  
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Appendix 4: Detailed mathematical description of the binary models 
The mathematical description of the binary model is made by combining the mathematical 
equations above for prochloraz. The Michaelis-Menten equation for each of the compound was 
modified to account for reversible inhibition. 
 
Thus the equation for R-tebuconazole (C1M0) with S-tebuconazole (C2M0) as inhibitor is as 
follows. 
 
𝑑𝐴𝑀𝐿(𝐶1𝑀0)
𝑑𝑡
= 𝑉max(𝐶1𝑀0)  𝐶𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0)𝑃𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0) 
𝐾𝑀(𝐶1𝑀0)  �1 + 𝐶𝑙𝑖𝑣𝑒𝑟(𝐶2𝑀0)𝐾𝐼(𝐶2𝑀0) 𝑃𝑙𝑖𝑣𝑒𝑟(𝐶2𝑀0)�  +  𝐶𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0)𝑃𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0) 
 
Correspondingly, the equation for tebuconazole with prochloraz as inhibitor is. 
 
𝑑𝐴𝑀𝐿(𝐶2𝑀0)
𝑑𝑡
= 𝑉max(𝐶2𝑀0)  𝐶𝑙𝑖𝑣𝑒𝑟(𝐶2𝑀0)𝑃𝑙𝑖𝑣𝑒𝑟(𝐶2𝑀0) 
𝐾𝑀(𝐶2𝑀0)  �1 + 𝐶𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0)𝐾𝐼(𝐶1𝑀0) 𝑃𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0)�  +  𝐶𝑙𝑖𝑣𝑒𝑟(𝐶2𝑀0)𝑃𝑙𝑖𝑣𝑒𝑟(𝐶2𝑀0) 
 
The variables are as described for the single compound model. KI(C2M0) is the inhibition constant for 
S-tebuconazole inhibiting R-tebuconzole, and KI(C1M0) is the inhibition constant for R-tebuconazole 
inhibiting S-tebuconazole. 
 
Thus equation for prochloraz (C1M0) with tebuconazole (C2M0) as inhibitor is as follows. We úse 
the Michelis Menten implementation for simulating the metabolism of procloraz. and not the 
intrinsic clearance one.  This was done to be able to implement the inhibition and explore the effect 
of inhibition at high exposure levels.  
 
The first part of the equation descripes the ring opening, which we concluded to be either CYP 1A or 
CYP 2E1 mediated, a reaction which is not likely to interfere with tebuconazole metabolism. The 
second part of the eqation is for the remaining metabolism of prochloraz, where similar reactions to 
the ones occouring when tebuczole is metabolised. Therefore we have implemented the inhibition 
term in the section equation.   
 
𝑑𝐴𝑀𝐿(𝐶1𝑀0)
𝑑𝑡
=  𝑉max1(𝐶1𝑀0)  𝐶𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0)𝑃𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0) 
�𝐾𝑀1(𝐶1𝑀0)   + 𝐶𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0)𝑃𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0)�   
𝑉max2(𝐶1𝑀0)  𝐶𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0)𝑃𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0) 
�𝐾𝑀2(𝐶1𝑀0)  �1 + 𝐶𝑙𝑖𝑣𝑒𝑟(𝐶2𝑀0)𝐾𝐼(𝐶2𝑀0) 𝑃𝑙𝑖𝑣𝑒𝑟(𝐶2𝑀0)�  +  𝐶𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0)𝑃𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0)� 
 
Correspondingly, the equation for tebuconazole with prochloraz as inhibitor is. 
 
𝑑𝐴𝑀𝐿(𝐶2𝑀0)
𝑑𝑡
= 𝑉max(𝐶2𝑀0)  𝐶𝑙𝑖𝑣𝑒𝑟(𝐶2𝑀0)𝑃𝑙𝑖𝑣𝑒𝑟(𝐶2𝑀0) 
𝐾𝑀(𝐶2𝑀0)  �1 + 𝐶𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0)𝐾𝐼(𝐶1𝑀0) 𝑃𝑙𝑖𝑣𝑒𝑟(𝐶1𝑀0)�  +  𝐶𝑙𝑖𝑣𝑒𝑟(𝐶2𝑀0)𝑃𝑙𝑖𝑣𝑒𝑟(𝐶2𝑀0) 
 
KI(C2M0) is the inhibition constant for tebuconazole inhibiting prochloraz, and KI(C1M0) is the 
inhibition constant for tebuconazole inhibiting prochloraz. 
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Then we added a few equations to be able to calculate the total concentration of the two active 
compounds in blood and the different tissues (t), and to calculate the total amount of active 
compounds and their metabolites, respectively.  
 
 
𝐶𝑡(𝑡𝑜𝑡) =  𝐶𝑡(𝐶1𝑀0)  + 𝐶𝑡(𝐶2𝑀0)  
 
𝐴𝐶1𝑀0,𝐶2𝑀0 =  𝐴𝐶1𝑀0  + 𝐴𝐶2𝑀0  
 
𝐴𝐶1𝑀1,𝐶2𝑀1 =  𝐴𝐶1𝑀1  + 𝐴𝐶2𝑀1 
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Appendix 5: List of the main variables used in the PBTK models 
BW:    body weight for rat (kg) 
A_C1_M1:   amount of metabolites of C1_M0 (µmol) 
A_C1_M1':   rate of change in amount of metabolites of C1_M0 (µmol/hr) 
ADS_C1_M0:   amount of C1_M0 absorbed via the skin (µmol) 
ADS_C1_M0':  rate of change in amount C1_M0 absorbed via the skin (µmol/hr) 
AML_C1_M0:   amount of free C1_M0 metabolised (µmol) 
AML_C1_M0':  rate of change in amount of free C1_M0 metabolised (µmol/hr) 
AOL_C1_M0:   amount of oral bolus dose of C1_M0 in GIT (µmol) 
AOL_C1_M0':  rate of change in amount of oral boles dose C1_M0 in GIT (µmol/hr) 
CA_C1_M0:   the free C1_M0 concentration in arterial blood (µmol/l) 
Cblood_C1_M0':   rate of change in mixed blood.  
Cblood_C1_M0:   C1_M0 concentration in blood (µmol/l) 
Cbody_C1_M1:   body concentration of C1_M0 metabolites (µmol/l) 
CLint_C1_M0:  intrinsic clearance of C1_M0 (ml/hr) 
Cliver_C1_M0:   concentration of C1_M0 in liver (µmol/l) 
Cliver_C1_M0':   rate of change in concentration of chlorpyrifos in liver (µmol/l/hr)  
Crperfused_C1_M0':  rate of change in C1_M0 concentration in rapid perfused (µmol/l/hr) 
Crperfused_C1_M0: C1_M0 concentration in rapidly perfused tissues (µmol/l) 
Cskin_C1_M0':   rate of change in C1_M0 concentration in skin (µmol/l/hr) 
Cskin_C1_M0:   C1_M0 concentration in skin (µmol/l) 
Csperfused_C1_M0':  rate of change in C1_M0 concentration in slowly perfused tissues 
(µmol/l/hr) 
Csperfused_C1_M0:  C1_M0 concentration in slowly perfused tissues (µmol/l) 
Csurface_C1_M0:  concentration of C1_M0 which the skin is exposed to (µmol/l) 
CV_C1_M0:   free C1_M0 concentration in venous blood (µmol/l) 
CVliver_C1_M0:   concentration of free C1_M0 in venous blood draining the liver (µmol/l) 
CVrperfused_C1_M0:  concentration of free C1_M0 in blood leaving rapid perfused tissues 
(µmol/l) 
CVskin_C1_M0:   concentration of free C1_M0 in blood leaving skin (µmol/l) 
CVsperfused_C1_M0: concentration of free C1_M0 in blood leaving slowly perfused tissues 
(µmol/l) 
Oraldose_C1_M0:  oral administration of C1_M0 (µmol/day)  
Dietexp_C1_M0:   dietary exposure of C1_M0 (µmol/hr) 
Excretion_C1_M1:  total excretion via faeces and urine of metabolites of C1_M0 (µmol) 
Excretion_C1_M1':     total rate of excretion via faeces and urine of metabolites of C1_M0 
(µmol/hr) 
Excretion_faeces_C1_M1:  excretion via faeces and urine of metabolites of C1_M0 (µmol) 
Excretion_faeces_C1_M1': rate of excretion via faeces and urine of metabolites of C1_M0 (µmol/hr) 
Excretion_urinary_C1_M1': rate of urinary excretion of metabolites of C1_M0 (µmol/hr) 
Excretion_urinary_C1_M1: urinary excretion of metabolites of C1_M0 (µmol) 
Fa_C1_M0:   Fractional absorption, unitless 
fu_C1_M0:   fraction unbound in plasma, unitless 
ka_C1_M0:   1. order absorption rate constant of C1_M0 (1/hr) 
ke_C1_M1:   1.order elimination constant for faeces and urine (1/hr) 
kfe_C1_M1:   1.order elimination constant for faeces (1/hr) 
KI_C1_M0, C2_M0: Inhibtion constant for compound C1_M0, inhibiting C2_M0  
KM_C1_M0:   Michaelis-Menten constant for metabolism of C1_M0 (µmol/l) 
kp_C1_M0:   skin permeability coefficient rate constant (dm/hr) 
kue_C1_M1:   1. order elimination constant for urine (1/hr) 
kzero_C1_M0:   zero-order uptake rate (µmol/hr)  
MW_C1_M0:   molecular weight for C1_M0 (mg/µmol) 
Oral_adm_C1_M0:  Dietary administeration of C1_M0 (mg/kg bw/day) 
Pblood_C1_M0:   blood:blood partition coefficient 
Pfat_C1_M0:   fat:blood partition coefficient 
Pliver_C1_M0:   liver:blood partition coefficient 
Prperfused_C1_M0:  rapidly perfused tissue:blood partition coefficient 
Pskin_C1_M0:   skin:blood partition coefficient  
Pskinsurface_C1_M0: skin:surface partition coefficient, unit less 
Psperfused_C1_M0:  slowly perfused tissue:blood partition coefficient  
QC:    cardiac output (l/hr) 
Qliver:    blood flow in liver (l/hr) 
Qp_fat:    blood flow in fat as percentage of cardiac output (%) 
Qp_liver:   blood flow in liver as percentage of cardiac output (%) 
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Qp_rperfused:   blood flow in rapidly perfused tissues as percentage of cardiac output 
(%) 
Qp_skin:   blood flow in skin as percentage of cardiac output (%) 
Qp_sperfused:   blood flow in slowly perfused tissues as percentage of cardiac output (%) 
Qfat:    blood flow in fat (l/hr) 
Qrperfused:   blood flow in rapidly perfused tissues (l/hr) 
Qskin:    blood flow in skin (l/hr) 
Qsperfused:   blood flow to slowly perfused tissues (l/hr) 
SA:    area of exposed skin (dm2)  
Varterial:   volume of arterial blood (l) 
Vblood:    volume of blood (l) 
Vfat:    volume of fat (l) 
Vd:    volume of distribution (l) 
Vliver:    volume of liver (l) 
Vmax_C1_M0:   maximum rate (velocity) for metabolism of C1_M0 (µmol/hr) 
VmaxC_C1_M0:   maximum rate for metabolism of C1_M0 per kg body weight (liver) 
(µmol/hr/kg) 
Vp_arterial:   volume of arterial blood as percentage of body weight (%) 
Vp_blood:   volume of blood percentage of body weight (%) 
Vp_fat:    volume of fat percentage of body weight (%) 
Vp_liver:   volume of liver percentage of body weight (%) 
Vp_rperfused:   volume of rapidly perfused tissues percentage of body weight (%) 
Vp_skin:   volume of skin percentage of body weight (%) 
Vp_sperfused:   volume of slowly perfused tissues percentage of body weight (%) 
Vp_venous:   volume of venous blood as percentage of body weight (%)  
Vrperfused:   volume of rapidly perfused tissue (l) 
Vskin:    volume of skin (l) 
Vsperfused:   volume of slowly perfused tissues (l) 
Vvenous:   volume of venous blood (l) 
TOTAL_C1_M0:   total mass of C1_M0 in blood, delivered to tissues or excreted (µmol) 
total_mass_C1_M0:  total mass of C1_M0 in body (µmol) 
total_mass_C1_M1:  total mass of metabolites of C1_M0 in body (µmol) 
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Appendix 6: Review on Metabolic Constants of Related Compounds 
Imidazoles and triazoles are known to be extensively metabolized in the liver by cytochrome P450s 
(CYPs) and other enzymes. Such compounds are also known to be potent inhibitors and inducers of 
CYP activity, and are at higher doses involved in substantial drug-drug interactions. Drug-drug 
interactions due to the inhibitory effects of ketaconazole, fluconazole, itraconazole have been 
extensively documented for a wide range of drugs in the literature. Increased CYP enzyme activity of 
some imidazoles and triazoles due to induction of CYP, for example mediated by PXR and CAR 
binding, is also well documented in the literature.  
 
The CYP metabolism of compounds from these classes is predominantly carried out by CYP 3A4, 
CYP 2C9 and   in humans, but other CYPs play a role as well (Gubbins, 2011; Dvorak, 2011). 
Metabolism in rats is carried out by other isoforms, as the three named isoforms in humans are not 
expressed in rats.  
Martignoni et al. reviewed species differences in expression of major drug-metabolizing CYPs  in 
human, rat, mouse, dog and monkey (Martignoni et al., 2006). Whereas in the CYP 1A, CYP 1B and 
CYP 2E families the same four isoforms are expressed in all five species, the number and type of 
isoforms expressed for CYP 2A, B, C, D and CYP 3A varies from one species to another. 
 
 
Triadimefon and triadimenol 
 
Crowell et al. measured metabolic constants for triadimefon depletion and triadimenol formation in 
hepatic micosomal metabolic assay for male and female SD rats, and male and female CD-1 mice 
(Crowell et al., 2010), and for triadimefon depletion in male human liver microsomes (Crowell et 
al., 2011). Gender differences were seen in rats for these processes, but not in mice. Species 
differences were also observed between rats, mice and human. 
 
The experimental Vmax and KM  values for triadimefon depletion in male rat and male human were 
used for triadimefon reduction in a PBTK model, and the corresponding parameters for triadimenol 
oxidation used in the same model were estimated to be half of values for  triadimefon reduction.  
 
Tridimefon depletion  Vmax [pmol min-1 mg-1 protein]  KM [µM]   
Rat liver microsomes-male (SD)  7452 ± 493   47 ± 8 
Rat liver microsomes-female (SD)  3771 ± 589   80 ± 25 
Mouse liver microsomes-male (CD-1) 2824 ± 261   45 ± 11 
Mouse liver microsomes-female (CD-1) 3957 ± 725   42 ± 20 
 
Triadimenol formation  Vmax [pmol min-1 mg-1 protein]  KM [µM] 
Rat liver microsomes-male (SD)  5703 ± 149   61 ±  4 
Rat liver microsomes-female (SD)  344 ±   15   78 ±  8 
Mouse liver microsomes-male (CD-1) 1052 ±   38   42 ± 20 
Mouse liver microsomes-female (CD-1) 1341 ±   52     6 ±  1 
 
      
Tridimefon reduction  VmaxC [µmol hr-1 kg-0.75]   KM [µM]   
Rat liver microsomes-male (SD)  556.4      47.3 
Human liver micorosomes   547.2    132.7 
 
Barton et al. published the apparent metabolic constants for triadimefon and myclobutanil by 
human and rat liver microsomes (Barton et al., 2006), measurements were carried out in pretreated 
rats in two dose groups, and in a control group. Relative liver weight and total CYP content was 
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significantly increased at in the highest dose group for both compounds. Half live in different rat 
and human CYP, and in rat and human male or female microsomes are given as well. 
 
 
Fluconazole and itraconazole 
  
Niwa et al. (Niwa et al., 2008a) published a review over metabolic constants in recombinant human 
CYP 3A4 and CYP 3A5 for a wide variety of drugs, including fluconazole and itraconazole. 
 
Compound      CYP  Vmax  [nmol   KM  
       min-1 nmol-1 protein]  [µM]   
Fluconazole 3-hydroxylation in supersomes CYP 3A4  19.3   106 
     CYP 3A5  3.85   49.3 
Fluconazole demethylation in supersomes CYP 3A4  0.55   35.6 
     CYP 3A5  0.217   43.8 
Itraconazole hydroxylation in supersomes CYP3 A4  0.27   0.0444 
 
 
Itraconazole 
 
Isoherranen et al. (Isoherranen et al., 2004) published metabolic constants for cDNA-expressed 
CYP 3A4 (supersomes)-mediated metabolism of itraconazole, and its metabolites hydroxy-
itraconazole and keto-itraconazole. Itraconazole undergoes hydroxylation to hydroxy-itraconazole, 
which is oxidized to keto-itraconazole. Keto-itraconazole then undergoes cleavage with the keto 
side-chain removed to form N-desalkyl-itraconazole. Kinetic parameters for CYP 3A4 inhibition of 
these compounds and their binding to CYP 3A4 are also listed in this paper. The detailed 
information on specific metabolic reaction in a specific CYP makes this information suitable for 
read-a-cross determination of missing metabolic constants for other triazoles and imidazoles. (The 
value for itraconazole reported in the review by Niwa et al. (Niwa et al., 2008b), is from this paper.) 
 
             CYP  Vmax  [nmol         KM 
        min-1 nmol-1 3A4]       [nM] 
Itraconazole hydroxylation in supersomes      CYP 3A4 0.27      44.4 ± 11.1 
Hydroxy-itraconazole oxydation in supersomes: CYP 3A4 0.543      71.7 ± 37.5 
Keto-itraconazole cleavage in supersomes        CYP 3A4 0.0869       17.9 ± 8.8 
 
 
Omeprazole 
 
Yamazaki et al.(Yamazaki et al., 1997) published metabolic constants for human recombinant CYP 
2C19 and 3A4 5-hydroxylation in insect liver microsomes.  
 
Sample     Vmax [nmol hr-1 nmol-1 P450] KM [µM]  
5-hydroxylation 
Human CYP 2C19 in insect liver microsomes  8.3   6.6 
Human CYP 3A4 in insect liver microsomes  2.4   60  
Sulfoxidation 
Human CYP 3A4 in insect liver mircosomes  18   140 
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Fipronil 
 
Metabolic constants were measured for fibronil, an insectide form the phenyl pyrazole family, in 
human and rat liver microsomes, as well as baculovirus-expressed CYP3A4 microsomes (Tang et al., 
2004).  The difference in fipronil metabolism was analyzed in 19 single donor human liver 
microsomes, showing significant inter-individual variations. Two individuals showed ultra-rapid 
metabolism of this compounds, one with over 40-fold faster metabolism than the most slowly 
metabolizing individual. Fipronil has significant structural similarities to prochloraz, however the 
CYP mediated metabolism of Fipronil involves oxidation of the sulfur to form a sulfonyl. 
 
Fipronil oxidation   Vmax [nmol min-1 mg-1 protein] KM [µM]   
Human liver microsomes    0.1074   27.2  
Rat liver microsomes    0.3904   19.9 
Baculovirus-expressed CYP 3A4 supersomes  12.7   17.4 
 
 
Bis-triazolylpropanol (DTP) in rat 
 
Bomont et al.  (Bomont et al., 1994) published paper on hepatic binding and clearance of DTP, and 
compared the interactions DTP and ketoconazole with CYPs . DTP undergoes CYP mediated N-
dealkylation to form a diol and a triazole, followed by oxidation of the diol to acid and conjugation 
of both the diol and the acid to form glucouronides. Vmax is calculated per standard rat body weight 
(SRW). 
 
Sample     Vmax [nmol hr-1 SRW-1]  KM [µM]   
Rat liver mircosomes (total concentration)  51.6   2.7  
Rat liver mircosomes (unbound concentration) 51.6   1.5   
 
 
Voriconazole 
 
Roffey et al.(Roffey et al., 2003)  reported in vivo metabolic constants in rats and dogs. 
 
      Vmax  [µg hr-1 ml-1]        KM  [µg/ml]  
In vivo male rats     1.2   2.4 
In vivo male/female dogs    0.11   0.27 
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Appendix 7: 2D structures of training set compounds for the developed 
QSAR models, showing ionizable atoms and predicted logD 
values at pH=7.0 and pH=7.4 (blood pH). 
Name 2D-structure with ionizable 
atoms 
logD 
pH=7.0 
logD 
pH=7.4 
Comment 
Albendazole  3.1 3.1 NH in the imidazole 
ring partly ionized to  
NH2+ (2-1%) 
 
Anastrozole  0.97 0.97  
Aripiprazole  5.2 5.4 N (dark blue) partly 
ionized to NH+ 
(82-65%) 
 
Cefmetazole  -2.7 -2.7 Carboxyl acid fully 
 Ionized 
 
 
Clomethiazole  1.6 1.6  
 
 
 
Fluconazole  0.50 0.50  
 
 
 
Fosfluconazole  -5.5 -5.6 Phosphate group  
ionized (both OH) 
(net charge -2) 
 
Genaconazole  0.97 0.97  
 
 
 
Itraconazole  4.2 4.29 N partly ionized to 
 NH+ (23-11%) 
 
 
Ketoconazole  3.3 3.4 N partly ionized to 
 NH+ (43-23%) 
 
 
Lansoprazole  1.8 1.8  
 
 
170 Optimization of the cumulative risk assessment of pesticides and biocides using computational techniques: Pilot project 
 
Letrozole  1.9 1.9  
 
Mebendazole  2.8 2.8  
 
 
 
Methimazole  -0.3 -0.3  
 
 
 
Metronidazole  0.0 -0.01 Compound ionized  
as shown  
(net charge 0) 
 
Omeprazole  2.2 2.2 NH partly ionized to 
N- (3-7%) 
 
 
Pantoprazole  1.7 1.7 NH partly ionized to  
N- (4-10%) 
 
 
Rabeprazole  1.8 1.8 NH partly ionized to  
N- (0-1%) 
 
 
Sulfisoxazole  -0.3 -0.55 NH ionized to N- 
(99-100%) 
 
 
Sulfamethoxazole 
 
0.0 -0.32 NH ionized to N-  
(94-97%) 
 
Tinidazole 
 
-0.3 -0.27  
 
 
Voriconazole 
 
0.9 0.93  
 
 
Flumazenil 
 
0.67 0.67  
 
 
 
Clotrimazole  5.4 5.4 N ionized to NH+ 
(12-5%) 
 
 
Astemizole 
 
4.1 4.4 N ionized to NH+  
Net charge  
+2 (9-4%), +1 (89-
92%) 
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Appendix 8: Overview over blood and tissue concentration and excretion 
data 
The data sets with excretion, as well as blood and tissue concentration data are listed below. 
 
Excretion data for tebuconazole and predominantly for the metabolites from DAR 
(European Commission, 2007b) and JMPR (2010) 
 
Table A8.1. Mean cumulative excretion from single bolus dose experiments in male rat at two 
different doses, 5 test animals in each dose group. The same data set is found both in DAR and 
JMPR. Mean 0.81% of the dose was left in the body for the low and high dose group. 
 
Dose   2 mg/kg bw  = 1.62 µmol 20 mg/kg bw  = 16.2 µmol 
  time (h) total excretion total excretion total excretion total excretion 
  [hr] [% of adm dose] [µmol] [% of adm dose] [µmol] 
Urine 4 3.2 0.052 1.2 0.19 
  8 6.6 0.107 3.4 0.55 
  24 13.9 0.226 11.7 1.90 
  32 14.9 0.242 12.6 2.05 
  48 15.9 0.258 13.9 2.26 
  56 16.1 0.262 14.1 2.29 
  72 16.3 0.265 14.4 2.34 
Faeces 24 71.1 1.15 61.3 9.96 
  48 79.9 1.30 70.8 11.50 
  56 81.3 1.32 71.1 11.55 
  72 82.1 1.33 72.1 11.71 
urine+faeces 24 85.0 1.38 73.0 11.86 
  48 95.8 1.56 84.7 13.76 
  56 97.4 1.58 85.2 13.84 
  72 98.4 1.60 86.5 14.05 
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Table A8.2. Cumulative excretion data from DAR (European Commission, 2007b), iv bolus dose 
experiments in male rhesus monkeys. 
 
IV bolus dose of tebuconazole in vivo in rhesus monkey. DAR B.6.12.7     
Actual dose [µg]: 240 
 
BW_m [kg]: 6.2 
 
  
  [µmol]: 0.780 
    
  
        Urine pan /   Normalized Normalized 
Time Urine Faeces Cage rinse Cage wash Total excr. Total excr. Total excr. 
[hr] [% of dose] [% of dose] [% of dose] [% of dose] [% of dose] [% of dose] [µmol] 
4 39.49 0.04 8.07 0.00 47.6 45.2 0.353 
8 53.89 0.07 13.04 0.00 67.0 63.6 0.496 
12 56.14 0.07 15.56 0.00 71.8 68.2 0.531 
24 66.52 8.28 19.83 0.00 94.6 89.9 0.701 
48 70.92 9.03 22.00 0.00 102.0 96.8 0.755 
72 71.66 9.66 22.59 0.00 103.9 98.7 0.770 
96 71.96 9.71 22.67 0.00 104.3 99.1 0.773 
120 72.02 9.71 23.23 0.00 105.0 99.7 0.777 
144 72.02 9.71 23.47 0.09 105.3 100.0 0.780 
 
 
Table A8.3. Cumulative excretion data from DAR, (European Commission, 2007b) dermal dose 
experiments in male rhesus monkeys. 
 
Dermal dose of tebuconazole in vivo in rhesus monkey. DAR B.6.12.7     
Actual dose [µg] 261 
 
SA [cm2]: 24  [µg/cm2]: 10.9 
 
[µmol]: 0.848 
    
  
            Normalized Normalized 
Time Urine Faeces Cage rinse Urine pan Total excr. Total excr. Total excr. 
[hr] [% of dose] [% of dose] [% of dose] [% of dose] [% of dose] [% of dose] [µmol] 
4 0.20       0.20 0.19 0.0016 
8 2.44 0.02     2.46 2.38 0.0201 
12 3.27 0.02 0.38   3.67 3.54 0.0301 
24 4.36 1.18 0.49   6.03 5.82 0.0494 
48 4.36 1.50 0.49 0.47 6.82 6.59 0.0558 
72 4.36 1.53 0.49 0.47 6.85 6.62 0.0561 
96 4.36 1.58 0.49 0.47 6.90 6.66 0.0565 
120 4.36 1.63 0.49 0.47 6.95 6.71 0.0569 
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Table A8.4. Cumulative excretion data from DAR (European Commission, 2007b), dermal dose 
experiments in male rhesus monkeys. 
 
Dermal dose of tebuconazole in vivo in rhesus monkey. DAR B.6.12.7     
Actual dose [µg] 132 
 
SA [cm2]: 24  [µg/cm2]: 5.5 
 
[µmol]: 0.429 
    
  
                
Time Urine Faeces Cage rinse Urine pan Total excr.   Total excr. 
[hr] [% of dose] [% of dose] [% of dose] [% of dose] [% of dose]   [µmol] 
4 0.69     0.27 0.96   0.0041 
8 2.54     1.01 3.55   0.0152 
12 3.71   0.37 1.01 5.09   0.0218 
24 6.87 0.11 0.85 1.01 8.84   0.0379 
48 7.75 1.18 0.85 1.01 10.79   0.0463 
72 8.25 1.23 0.85 1.01 11.34   0.0486 
96 8.25 1.23 0.85 1.01 11.34   0.0486 
120 8.25 1.26 0.98 1.01 11.50   0.0493 
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Blood and tissue concentration data for tebuconazole in rabbit from Zhu et al. (2007) 
 
Table A8.5. Data for R- and S- tebuconazole after administration of an iv bolus dose of 30 mg/kg 
BW of racemic mixture of tebuconazole, BW of animals 2-2.25 kg. Each time point corresponds to 
one animal. 
 
S(+) form   R(-)form   S(+) + R(-)   
Time conc. time conc. time total conc. 
[min] [µmol/l] [min] [µmol/l] [min] [µmol/l] 
BRAIN concentration-time curve       
14.7 32.7 14.7 38.1 15 70.8 
29.4 70.2 29.4 83.5 30 153.7 
59.82 53.3 59.82 66 60 119.3 
119.4 15.1 119.4 30.3 120 45.4 
358.8 2.42 358.8 2.42 360 4.84 
HEART concentration-time curve       
14.46 38.8 14.46 47.4 15 86.2 
30.18 56 30.18 66.6 30 122.6 
60.6 42.9 60.6 51.5 60 94.4 
119.4 18.2 119.4 28.3 120 46.5 
238.8 13.6 240 21.2 240 34.8 
  
 
480.6 2.02 480 2.02 
KIDNEY concentration-time curve       
14.46 38.6 14.46 42.3 15 80.9 
30.24 67.4 30.24 84.6 30 152 
59.88 55.2 59.88 68.7 60 123.9 
120 13.5 120.6 23.3 120 36.8 
239.4 11 240 20.2 240 31.2 
LIVER concentration-time curve       
15.72 42.5 15.72 55.8 15 98.3 
28.86 80.6 30.18 99.4 30 180 
60.6 86.4 60.6 106 60 192.4 
119.4 27.5 119.4 40.8 120 68.3 
238.8 20.5 240 27.2 240 47.7 
477.6 2.15 478.8 2.86 480 5.01 
LUNG concentration-time curve       
14.76 925 16.08 989 15 1914 
30.84 381 30.84 466 30 847 
60.6 162 61.8 226 60 388 
120.6 70.6 121.8 106 120 176.6 
240 28.3 240 42.4 240 70.7 
480 35.3 481.2 42.4 480 77.7 
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S(+) form   R(-)form   S(+) + R(-)   
time conc. time conc. time total conc. 
[min] [µmol/l] [min] [µmol/l] [min] [µmol/l] 
SPLEEN concentration-time curve       
15.12 48.1 15.72 52.9 15 101 
29.52 101 30.18 112 30 213 
59.7 55.4 60.6 80.2 60 135.6 
120 12.8 120.6 24.1 120 36.9 
240 16 240 27.3 240 43.3 
FAT concentration-time curve       
13.14 50.5 14.46 47.7 15 98.2 
28.92 73 28.92 63.2 30 136.2 
59.22 194 59.22 170 60 364 
239.4 171 239.4 171 240 342 
480 4.21 480 11.2 480 15.41 
MUSCLE concentration-time curve       
14.76 3.25 14.76 4.67 15 7.92 
30.18 5.08 30.18 5.89 30 10.97 
59.76 12.7 60.6 15.5 60 28.2 
120 8.33 120 13.9 120 22.23 
240 4.47 240.6 7.61 240 12.08 
PLASMA concentration-time curve       
6 36.1 4.026 24.5 5 60.6 
14.04 31.5 14.1 21.7 15 53.2 
32.1 25.2 30.18 18.5 30 43.7 
60 16.5 58.38 13.2 60 29.7 
120.6 7.07 118.8 7.46 120 14.53 
237 1.31 239.4 2.89 240 4.2 
479.4 0.193 481.2 1.68 480 1.873 
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Excretion data for prochoraz and predominantly for metabolites from DAR 
(European Commission, 2010e) 
 
Table A8.6. Collection of data from single dose groups using oral bolus dose administration to rat, 
measured at different time points. 
 
Dose: 10 mg/kg BW = 6.64 µmol       Scaled to 
  
        
  98% recov. 
male time urine bile feaces 
cage 
wash bile+feaces 
tot. 
excr. tissues  total tot. excr. 
N 
animals [hr] [%] [%] [%] [%] [%] [%] [%] [%]   
5 24 14.8 47.3 14.3 1.2 61.6 77.6 11.9 89.5   
1 48 37.7   47.9 0.0 47.9 85.6 5.1 90.7   
5 168 45.0   40.9 7.2 40.9 93.1 0.4 93.5   
  [hr] [µmol] [µmol] [µmol] [µmol] [µmol] [µmol] [µmol] [µmol] [µmol] 
5 24 0.98 3.14 0.95 0.08 4.09 5.15 0.79 5.94 5.71 
1 48 2.50   3.18 0.00 3.18 5.68 0.34 6.02 6.17 
5 168 2.99   2.71 0.48 2.71 6.18 0.03 6.21 6.48 
female time urine bile feaces 
cage 
wash bile+feaces 
tot. 
excr. tissues  total tot. excr. 
N 
animals [hr] [%] [%] [%] [%] [%] [%] [%] [%]   
5 24 6.4 52.1 9.7 0.5 61.8 68.7 15.2 83.9   
5 168 29.2   59.5 5.6 59.5 94.3 0.5 94.8   
  [hr] [µmol] [µmol] [µmol] [µmol] [µmol] [µmol] [µmol] [µmol] [µmol] 
5 24 0.42 3.46 0.64 0.03 4.10 4.56 1.01 5.57 5.50 
5 168 1.94   3.95 0.37 3.95 6.26 0.03 6.29 6.47 
           Dose: 100 mg/kg BW = 66.4 µmol       Scaled to 
  
        
  98% recov. 
male time urine bile feaces 
cage 
wash bile+feaces 
tot. 
excr. tissues  total tot. excr. 
N 
animals [hr] [%] [%] [%] [%] [%] [%] [%] [%]   
1 48 51.2   28.8 0.0 28.8 80.0 4.0 84.0   
5 168 54.0   37.2 10.0 37.2 101.2 0.5 101.7   
  [hr] [µmol] [µmol] [µmol] [µmol] [µmol] [µmol] [µmol] [µmol] [µmol] 
1 48 34.0   19.1 0.0 19.1 53.1 2.7 55.7 62.4 
5 168 35.8   24.7 6.6 24.7 67.2 0.3 67.5 64.7 
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Table A8.7. Accumulated excretion for 4 male rats in a multiple dose experiment using oral bolus 
dose administration is shown below.  0.23% of the dose was found in tissues (0.10% skin, 0.07% 
liver, 0.04% gut content and 0.02% blood cells) and 0.18% in carcass 168 hrs after administration 
of labelled dose.  
 
Multiple dose. 14 unlabeled 100 mg/kg/day and   
1 labeled 100 mg/kg/day on day 15          = 66.4 µmol/day 
  
    
  
time urine faeces cage wash total total 
[hr] [% dose] [% dose] [% dose] [% dose] [µmol] 
6 9.43         
12 21.13         
24 49.81 13.75   63.56 42.2 
48 65.21 21.57   86.78 57.6 
72 69.56 23.5   93.06 61.8 
96 70.64 23.79   94.43 62.7 
120 71.27 23.94   95.21 63.2 
144 71.65 24.02   95.67 63.5 
168 71.89 24.08 0.84 96.81 64.2 
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Whole blood concentration of prochloraz and metabolites from DAR (European 
Commission, 2010e)  
 
Table A8.8. Total radioactivity measured as ng equivalent/ ml, mean from 5 male and 5 female 
animals at each time point after oral bolus dose administration to rats. 
 
Dose 10 mg/kg bw             
Gender male       female       
Time Cblood  +/- Cblood  +/- Cblood  +/- Cblood  +/- 
[hr ] [ng/mL] [ng/mL] [µmol/l] [µmol/l] [ng/mL] [ng/mL] [µmol/l] [µmol/l] 
0.25 559 304 1.48 0.81 341 64.9 0.91 0.17 
0.5 1290 405 3.42 1.08 586 104 1.56 0.28 
1 2270 674 6.03 1.79 897 137 2.38 0.36 
2 4610 1360 12.24 3.61 1560 170 4.14 0.45 
3 6680 1970 17.73 5.23 2200 513 5.84 1.36 
4 8490 2550 22.54 6.77 2820 871 7.49 2.31 
6 10600 2730 28.14 7.25 3320 1390 8.81 3.69 
8 10400 3430 27.61 9.11 2820 1080 7.49 2.87 
12 8210 3040 21.79 8.07 2310 868 6.13 2.30 
24 3700 1660 9.82 4.41 970 374 2.57 0.99 
48 572 352 1.52 0.93 311 107 0.83 0.28 
96 134 38.8 0.36 0.10 114 43.5 0.30 0.12 
120 100 54.1 0.27 0.14 84.2 37.6 0.22 0.10 
168 49.8 11.3 0.13 0.03 46.4 19.7 0.12 0.05 
 
Dose 100 mg/kg bw             
Gender male 
   
female 
  
  
Time Cblood  +/- Cblood  +/- Cblood  +/- Cblood  +/- 
[hr ] [ng/mL] [ng/mL] [µmol/l] [µmol/l] [ng/mL] [ng/mL] [µmol/l] [µmol/l] 
0.25 4840 932 12.85 2.47 1599 431 4.24 1.14 
0.5 10000 2080 26.55 5.52 3120 271 8.28 0.72 
1 18900 3650 50.17 9.69 4480 376 11.89 1.00 
2 34300 4740 91.05 12.58 6700 696 17.79 1.85 
3 46700 5110 123.97 13.57 10200 1490 27.08 3.96 
4 56600 7060 150.25 18.74 13300 1820 35.31 4.83 
6 72700 4180 192.99 11.10 20800 3990 55.22 10.59 
8 76800 7930 203.88 21.05 26900 5730 71.41 15.21 
12 85500 14000 226.97 37.16 31100 8680 82.56 23.04 
24 52700 7940 139.90 21.08 19400 5560 51.50 14.76 
48 6850 1620 18.18 4.30 4470 878 11.87 2.33 
96 1300 293 3.45 0.78 1510 511 4.01 1.36 
120 1020 481 2.71 1.28 917 179 2.43 0.48 
168 387 105 1.03 0.28 581 239 1.54 0.63 
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Appendix 9: Supplementary information for dietary and dermal exposures 
scenarios  
The dietary exposure scenarios are based on finding of pesticides residues in commodities on the 
sold on the Danish marked, based on samples taken by the pesticide control unit of theDanish 
Veterinary and Food Administration. The yearly reports from 2009 and 2011, show that 
tebuconazole and prochloraz residues were only found in fruit and vegetables(Jensen et al., 2010; 
Jensen et al., 2011; Jensen et al., 2012), see Tables A5.1 and A5.2.   
 
The dermal exposure scenarios used in this reported have been based on exposure assessments 
made by the Danish EPA. Data for solvent based tebuconzole biocide formulations used for 
industrial pre-treatment of wood and for professional brush application are given in Table A5.3. 
Data for an oil-water based tebuconazole pesticide formulation, used for spraying on fields for 
agricultural use are listed in Table A5.2. Assessment for the pesticide product has been made with 
and without gloves for protection of hands. Protection due to the use of gloves was not applied in 
the exposure assessment of the biocide products. 
 
Table A9.1. Number of  samples taken (#samples) and  samples positively detected with tebuconazole residues 
(#pos.)  in the years 2009-2011. The data were taken from reports over finding of pesticide residues in food by 
the pesticide monitoring program and DTU (Jensen et al., 2010; Jensen et al., 2011; Jensen et al., 2012). 
 
  2011 2010 2009 
  #samples  #pos. #samples #pos. #samples  #pos. 
Abrikos      5 1 1 1 
Blomme  45 3   
 
46 2 
Citron    
 
51 1     
Courgette    
 
7 1     
Fersken  18 2 26 8 21 3 
Grapefrugt  53 2   
 
    
Gulerod    
 
  
 
17 1 
Kirsebær    
 
5 1     
Kiwi  50 1   
 
    
Lime    
 
5 1     
Melon  44 1   
 
    
Nektarin  33 4 27 6 31 7 
Papaya    
 
  
 
18 1 
Peberfrugt  56 2 52 1     
Salat    
 
30 1     
Tomat  29 3 29 1 39 1 
Vindrue  52 4 66 2 84 3 
Ærter m. bælg  15 5 6 2 5 1 
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Table A9.2. Number of samples taken (#samples) and samples positively detected with prochloraz residues 
(#pos.)  in the years 2009-2011. The data were taken from reports over finding of pesticide residues in food by 
the pesticide monitoring program and DTU (Jensen et al., 2010; Jensen et al., 2011; Jensen et al., 2012). 
 
  2011 2010 2009 
  #prøver  #pos #prøver  #pos #prøver  #pos 
Abrikos      5 1 1 1 
Blomme  45 3   
 
46 2 
Citron    
 
51 1     
Courgette    
 
7 1     
Fersken  18 2 26 8 21 3 
Grapefrugt  53 2   
 
    
Gulerod    
 
  
 
17 1 
Kirsebær    
 
5 1     
Kiwi  50 1   
 
    
Lime    
 
5 1     
Melon  44 1   
 
    
Nektarin  33 4 27 6 31 7 
Papaya    
 
  
 
18 1 
Peberfrugt  56 2 52 1     
Salat    
 
30 1     
Tomat  29 3 29 1 39 1 
Vindrue  52 4 66 2 84 3 
Ærter m. bælg  15 5 6 2 5 1 
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Table A9.3.  Exposure assessments for industrial timber pre-treatment and professional brush application using 
solvent based formulation, calculated from values provide by the Danish EPA.  Indicative value for potential 
body and hand exposure, duration of exposure, penetration through clothing and gloves, have been estimated as 
part of the Danish EPAs risk assessment of biocide products base on data from (Garrod et al., 1999; Garrod and 
et al., 2000). Active substance concentration of 0.5 % (w/w) is typical concentration of such concentration of 
biocide products on the Danish marked. 
 
Type of treatment   Industrial timber Professional 
    pre-treatment brush application 
Formulation   Solvent based Solvent based 
  Unit IPBC IPBC 
Active substance % (w/w)   0,5 0,5 
Potential body exposure       
Indicative value  [mg/min] 3,8 1,12 
Duration [min] 240 180 
Potential dermal deposit [mg] 912 201,6 
Clothing type   Coated overalls Light clothing 
Clothing penetration [%] 10 50 
Actual dermal deposit [product] [mg] 91,2 100,8 
Hand exposure       
Indicative value  [mg/min] 1,17 9,14 
Duration [min] 240 180 
Potential dermal deposit [mg] 281 1645 
Migation by gloves [%] 100 100 
Actual dermal deposit [product] [mg] 281 1645 
Total dermal exposure       
Total dermal deposit [mg] 372 1746 
Acitve substance [mg] 1,86 8,73 
Dermal absorption [%] 15,7 15,7 
Systemic exposure via dermal route [mg] 0,292 1,37 
Systemic exposure via dermal route [µmol] 0,949 4,45 
 
 
 
 
 
 
 
 
  
182 Optimization of the cumulative risk assessment of pesticides and biocides using computational techniques: Pilot project 
 
Table A9.4.  Exposure assessment for Mystic 250 EC (Tebuconazole), downwards spraying of pesticide solution 
by tractor operated equipment (In Danish). The exposure is calculated by a model the Danish EPA has used for 
their risk assessment of the product, without and with protection of hands by gloves (2012). The concentrated 
product is formulated as an oil-water emulsion. This product can be considered as a typical pesticide product for 
agricultural use. The red boxes show the dermal exposure only (shown both in mg /day and µmol/day), and 
these are the exposure scenarios used in this report, assuming that 20 has are sprayed per day. 
 
Mystic 250 EC (Tebuconazole) Flydende traktor udbringning nedadrettet 
       Grønne felter udfyldes, resten beregnes automatisk. 
    
       
       AOEL   
0,033 
     AOEL i mg/dag per person 
(person på 70 kg) 
2,31 
     Dosering l/ha 
1 
     Aktivstofmængde g/l 
250 
     Aktivstof mængde kg/dag 
5 
Beregnet udfra et areal på 20 
ha 
     
      Uden værnemidler 
       
Eksponeringscenarie: flydende formulering ved traktor udbringning 
Procedure 
Inhalativ 
eksponering 
Hoved 
eksponering 
Dermal 
eksponering 
hænder 
Krops 
eksponering 
Total 
eksponering % AOEL  
Blanding og påfyldning 0,003 - 12,000 - 12,003 
961 udsprøjtning i markafgrøder 0,005 0,300 1,900 8,000 10,205 
       Dermal absorption ufortyndet 
12 
     Dermal absorption fortyndet 
20 
      
      
Korrigering for dermal absorption 
     
Procedure 
Dermal 
eksponering  
     
Blanding og påfyldning 1,44 
     
Udsprøjtning 2,04 
     
   
Dermal exposure only (inhalative exposure 
substracted) 
Total eksponering inkl. 
Inhalation 3,488 
 
3,480 mg/day 11,31 µmol/day 
Procent af AOEL 151 
 
151 %     
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       Med værnemidler 
       Med handskefaktor på 60 % ved udsprøjtning og 90 % ved opblanding 
Procedure 
Inhalativ 
eksponering 
Hoved 
eksponering 
Dermal 
eksponering 
hænder 
Krops 
eksponering 
Total 
eksponering % AOEL  
Blanding og påfyldning 0,003 - 1,200 - 1,203 
445 udsprøjtning i markafgrøder 0,005 0,300 0,760 8,000 9,065 
       Dermal absorption ufortyndet 12 
     Dermal absorption fortyndet 20 
      
      Korrigering for dermal absorption 
     
Procedure 
Dermal 
eksponering  
     
Blanding og påfyldning 0,144 
     
udsprøjtning 1,812 
     
   
Dermal exposure only (inhalative exposure 
substracted) 
Total eksponering inkl. inhalation 1,964 
 
1,956 mg/day 6,35 µmol/day 
Procent af AOEL 85 
 
85 %     
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Optimization of the cumulative risk assessment of pesticides and biocides using 
computational techniques: Pilot project 
This pilot project is intended as the first step in developing a computational strategy to assist in refining 
methods for higher tier cumulative and aggregate risk assessment of exposure to mixture of pesticides 
and biocides.  For this purpose, physiologically based toxicokinetic (PBTK) models were developed for 
two compounds, tebuconazole and prochloraz, and a binary mixture of these compounds in two species, 
rat and human. PBTK models can be used to estimate the concentration levels (internal doses) of toxic 
substances and their metabolites in blood and tissue, by a collection of differential equations, and 
parameters describing species physiology and ADME (absorption, distribution, metabolism and 
elimination) characteristics of the chemicals. Sufficient data were found to determine the parameters 
needed for the PBTK model development.  The PBTK models were validated on plasma and tissue 
concentration level data of tebuconazole in rabbit, and in most cases the predictions were seen to be 
within a factor of two compared to the experimental data. Also simple blood concentration 
measurements for both compounds from a mixture study in rat, and other data were used to validate and 
evaluate the models.  Exposure scenarios were constructed based on findings of pesticide residues in 
food of ordinary consumers, and assessment of dermal exposure of professional workers. PBTK 
simulations were carried using these scenarios. 
 
 
